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ABSTRACT
Paget’s disease of the vulva and breast are rare diseases. Unlike Paget’s disease of the 
breast, where the consensus is that the great majority of cases are associated with an 
in-situ or invasive ductal carcinoma, only approximately 10-30% of cases of Paget’s 
disease of the vulva have an invasive adenocarcinoma present. It is believed that the 
Paget cells in Paget’s disease of the breast are derived from the underlying in-situ or 
invasive breast carcinoma, and these cells migrate up through the ducts onto the 
nipple epidermis. The histogenesis underlying vulval Paget’s disease is unclear. 
Paget’s disease of the vulva may become secondarily invasive even in the absence of 
an underlying malignancy.
The aim of the study was to identify abnormalities present in Paget’s diseases of the 
vulva and the breast and to investigate whether there are any differences in molecular 
markers in the Paget cells of those cases with invasive disease compared to those 
cases without invasive disease. Such an analysis may identify some of the molecular 
pathways underlying both vulval and breast Paget’s disease, as well as generating 
potential markers for clinical prognosis.
Archival paraffin wax-embedded sections of Paget’s disease of the vulva or breast 
were used. Immunohistochemical analysis was performed to analyse markers 
involved in the cell cycle (p53, pRb, cyclin D l, Ki67), in angiogenesis (e.g. VEGF, 
PD-ECGF/TP, MVD) and cell adhesion molecules (e.g. plakoglobin, E-cadherin, P- 
catenin). Sections that were immunopositive for the tumour marker p53 were 
microdissected, the DNA extracted, amplified and sequenced. In situ hybridisation 
was also used to determine the presence of mRNA of the adhesion molecules in the
2
tissue sections. A national register for Paget’s disease of the vulva was established 
requesting that clinicians who have patients with Paget’s disease of the vulva should 
enrol them.
Results suggest E-cadherin, plakoglobin and pRb and p53 may have a role to play in 
the pathogenesis of Paget’s disease of the vulva and pRb, plakoglobin, VEGF and 
PD-ECGF/TP in Paget’s disease of the breast. Wide local excison was the preferred 
treatment option for patients registered in the PDV database. The information from 
the Paget’s register and the results obtained from the thesis may increase the 
understanding of Paget’s disease of the vulva and breast.
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CHAPTER 1 GENERAL INTRODUCTION
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1.1 Who was Sir James Paget?
Sir James Paget was bom in Great Yarmouth in 1814. After gaining his medical 
qualification at St. Bartholomew’s Hospital, he was retained as a curator of the 
museum at the Royal College of Surgeons. In 1847 he became Assistant Surgeon at 
St. Bartholomew’s Hospital and in 1858 was appointed as Surgeon to Queen 
Victoria. It was during his years at St. Bartholomew’s Hospital that he described two 
different diseases which both bear his name today: Paget’s disease of the breast and 
Paget’s disease of the bone. In 1874 he published a report entitled “On Disease of the 
Mammary Areola preceding Cancer of the Mammary Gland”. In this, he describes 
cases of Paget’s disease of the nipple (Paget, 1874). This lesion is characterised by 
the presence of large cells, with abundant, pale cytoplasm and large nuclei with 
prominent nucleoli, in the surface epithelium of the nipple. These cells are generally 
referred to as Paget cells, although Treves et al. (1954) questioned this practice since 
Paget did not actually describe the histological features or the cellular morphology of 
the lesion. Similar conditions involving Paget cells located outside the mammary 
gland have been termed extramammary Paget’s disease, the most common locations 
being the vulva and perianal region. Crocker in 1889 described the first case of 
extramammary Paget’s disease. He reported lesions on the scrotum and penis, with 
clinical features similar to those described by Paget ( Olson et al., 1991). Other 
affected sites include the axilla, eyelids, groin, buttock, thigh and the external ear 
canal (Whorton et. al. 1955; Fligiel et al., 1975; Chanda et al., 1985; Watanabe et al., 
1993). Paget’s disease of the bone is a completely different and unrelated condition, 
which Sir James Paget described in 1876 and which is characterised by abnormal 
remodelling and deformity of the bones. It has distinguishing clinical and radiological
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appearances and there has been evidence to suggest that a virus may be involved in 
its aetiology.
1.2 Paget’s disease of the vulva (PDV)
Paget’s disease of the vulva is a rare intraepithelial in situ carcinoma that comprises 
approximately 1% of all vulval neoplasms (Curtin et al., 1990). It was W. Dubreuilh, 
Professor of Dermatology at Bordeaux University, who described the first case of 
Paget’s disease in the vulva. In his paper he describes a 51-year old woman who 
presented with a 3-year history of an itchy, painful pimple on the clitoris which had 
been gradually increasing in size (Dubreuilh, 1901). On inspection there was a red 
indurated eroded lesion on the labium majorum. Within this were areas of white 
islands of hyperkeratosis. The red scaly lesions with hyperkeratosis are classical 
features of PDV. Figure 1.1 demonstrate clinical presentation of PDV.
Figurel.l Photograph of PDV (xlOO)
26
1.3 Development of the vulva
1.3.1 Development of the external genitalia
The transverse septum divides the primitive cloaca into an anterior urogenital portion 
and a posterior rectal portion. The urogenital portion of the cloacal membrane breaks 
down shortly after division is complete forming the urogenital sinus which develops 
into three portions. There is an external phallic part, a deeper narrow pelvic part 
between it and the region of the Mullerian tubercle, and a vesicourethral part 
connected superiorly to the allantois. Externally in this region the genital tubercle 
forms a conical projection around the anterior part of the cloacal membrane. Two 
pairs of swellings - a medial pair (the genital folds) and a lateral pair (genital 
swellings) - are then formed by the proliferation of mesoderm around the end of the 
urogenital sinus. Development up to this time (10 weeks’gestation) is the same in the 
male and the female. Differentiation then occurs. The genital tubercle enlarges only 
slightly and becomes the clitoris. The genital folds become the labia minora and the 
genital swellings enlarge to become the labia majora. The bladder and urethra form 
from the vesicourethral portion of the urogenital sinus and the vestibule from the 
pelvic and phallic portions.
1.3.2 Vulval skin
The epidermis of the vulval skin and its appendages, hair, sebaceous and sweat 
glands, are developed from the ectoderm. The dermis is developed from the 
mesoderm. The epidermis is established at about the 8th day of gestation when the 
ectoderm differentiates within the developing embryo. Three cell types invade the 
developing epidermis during the first six months of intra-uterine life. Melanocytes, 
derived from the neural crest, and Langerhans cells, derived from the mesoderm, are
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present at the end of the 3rd month while Merkel cells, the origin of which is 
uncertain, are present by the 6th month. Hair follicles begin to form during the 3rd 
month of gestation and sebaceous glands by the 4th month; differentiation of the 
primordial cells into sebum producing cells also proceeds rapidly. Eccrine sweat 
glands appear during the 3rd month of pre-natal life and apocrine glands develop after 
6 months.
The intrinsic components of the dermis originate from the mesoderm during the 2nd 
month of embryonic life. The major cellular component is the fibroblast which 
synthesises and secretes the amorphous and structural connective tissue matrix to 
support the epidermal appendages and other component tissues.
1.4 Anatomy of the vulva
The vulva lies mainly within the urogenital triangle. The urogenital triangle 
constitutes the anterior section of the perineum; the posterior anal triangle being the 
posterior section. The perineum is derived from the body wall ectoderm, the hindgut 
endoderm and the intervening mesoderm. It forms part of the pelvic outlet caudal to 
the pelvic diaphragm.
The vulva consists of the mons pubis, the labia majora and minora, the vestibule of 
the vagina, the hymen, the greater vestibule glands of Bartholin, the clitoris with its 
prepuce and frenulum, the bulbs of the vestibule and the external urethral orifice 
(Figure 1.2.).
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1.4.1 Mons pubis
Overlying the symphysis pubis, the mons pubis becomes recognisable at puberty with 
the deposition of subcutaneous fat and the appearance of pubic hair.
1.4.2 Labia maiora
The labia majora originate from the mons pubis anteriorly and merge with the 
perineal body posteriorly. On inspection they consist of two cutaneous folds which 
form the lateral boundaries of the pudendal cleft. After puberty the deposition of 
subcutaneous fat within the labia majora produces a greater degree of prominence 
and the presence of pigmentation and hair on their lateral surfaces establish them as 
well defined structures. The medial surfaces of the labia majora are hairless and 
contain numerous sebaceous glands which may be in contact with each other or 
separated by the protrusion of the labia minora.
1.4.3 Labia minora
The labia minora are two thin folds of hairless skin, devoid of subcutaneous fat, 
which are situated between the labia majora on either side of the vaginal and urethral 
openings. The labia minora are separated from the labia majora by interlabial 
furrows. Anteriorly, the labia minora divide into lateral and medial parts. The lateral 
parts unite anteriorly to the clitoris, in a fold of skin overhanging the glans to form 
the prepuce of the clitoris. The medial parts unite on the under surface of the clitoris 
to form its frenulum. Posteriorly, the labia minora fuse to form a transverse fold, the 
frenulum of the labia, or fourchette, behind the vaginal opening. Being devoid of
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adipose tissue the labia minora are composed mainly of elastic fibres and blood 
vessels and possess a rich innervation.
1.4.4 The vestibule
The cleft between the labia minora is termed the vestibule of the vagina and it 
extends from the clitoris to the fourchette. The urethra and the openings of the 
vagina, the ducts of Bartholin’s glands and the minor vestibular glands are all found 
within the vestibule. The junction of the vestibule with the vagina is identified by the 
presence of the hymen or its remnants.
1.4.5 Bartholin’s glands
Deeply situated within the posterior parts of the labia majora are the Bartholin’s 
glands. The glandular secretion is clear, mucoid and alkaline and is increased during 
sexual arousal. The main duct of each Bartholin’s gland opens at the lateral margin 
of the vagina just behind the mid-point and superficial to the hymen ring. The 
glands and their ducts can be a site of infection or cyst formation.
1.4.6 Minor vestibular glands
These glands are tubular structures; their acini are lined with columnar epithelium 
and their ducts with transitional squamous epithelium. They are found mainly in the 
posterior part of the vulva. The opening of the ducts can be seen with the naked eye.
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1.4.7 The clitoris
The clitoris is situated in the midline at the apex of the vulval cleft. It is covered with 
stratified squamous epithelium that is thinly keratinised. No sebaceous, apocrine or 
sweat glands are present. It consists of erectile tissue and is the homologue of the 
penis. The bulbs of the vestibule, also composed of erectile tissue, participate in the 
formation of the clitoris. The external urethral orifice lies between the vagina and the 
clitoris.
1.4.8 Blood supply of the vulva
The arterial blood supply of the perineum is from branches of the internal iliac and 
femoral arteries. The superficial external pudendal artery, a branch of the femoral 
artery, pierces the deep fascia of the thigh anteriorly, to overlie the round ligament of 
the uterus. It runs medially to supply the mons pubis and labia of the vulva. The deep 
external pudendal artery, also a branch of the femoral artery, pierces the deep fascia 
of the thigh medially to enter the labia of the vulva. The venous drainage of the 
perineum is similarly arranged and eventually reaches the femoral and internal iliac 
veins.
1.4.9 Lymphatic drainage of the vulva
The regional lymph nodes of the perineum are situated in the groin at the base of the 
femoral triangle. These superficial lymph nodes subsequently drain to deep nodes in 
the pelvis and ultimately to para-aortic nodes on the posterior abdominal wall.
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1.4.10 Nerve supply to the vulva
Innervation to the perineum is by the ilioinguinal nerve (LI) and the genital branch 
(L2) of the genito-femoral nerve (LI, 2). These supply the anterior part of the 
perineum. The lateral aspect of the perineum is supplied by the perineal branch (SI) 
of the posterior cutaneous nerve of the thigh (SI, 2, 3). The remainder of the 
cutaneous innervations is supplied by the pudendal nerve (S2, 3, 4) and the perineal 
branch of the 4th sacral nerve.
Mons pubis 
Clitoris
Urethra
Skene's (>land
labium  minorus
Vestibule
I^abium majorus
llvm en
Bartholin duct opening
Posterior fourchette
Perineum
Figure 1.2 Diagram of the vulva.
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1.5 Histology of the vulva
1.5.1 Epidermis
A stratified squamous epithelium, the epidermis varies in thickness in different 
regions of the body. In stained vertical sections its lower border, at the dermal- 
epidermal junction, presents an undulating appearance due to the epidermal or rete 
ridges.
Histologically, the epidermis of the vulva is described in four layers.
1. A basal layer, or stratum germinativum, the lower border of which rests on 
the basal lamina.
2. A spinous or prickle cell layer which forms the bulk of the epidermis.
3. A granular layer.
4. A homy layer or stratum comeum.
There is progressive differentiation of the keratinocytes through the various layers to 
form the tough, protective, outer surface of the skin. Immediately above the basal 
layer are the larger polygonal cells of the spinous layer. The cells of this layer are less 
basophilic than those of the basal layer. As the keratinocytes ascend through the 
epidermis they become flatter and broader, deeply staining keratohyalin granules 
appear in their cytoplasm and a granular layer is established. Above the granular 
layer an abrupt change occurs with the cells becoming anucleate to form the keratin 
o f the homy layer.
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1.5.2 Dermis
The dermis is divided into papillary and reticular layers. The papillary dermis 
projects upwards between the rete ridges and is composed of fine collagen fibres and 
elastic fibres which support the vascular and lymphatic channels as well as the nerve 
terminals. The reticular dermis lies below the papillary dermis and is composed of 
coarse collagen fibres lying parallel with the epidermal surface. The vascular and 
lymphatic plexuses which drain the papillary dermis lie within the reticular dermis, 
which also contains the nerve fibres associated with the papillary nerve terminals.
1.6 Clinical presentation of PDV
PDV is an intraepithelial lesion which usually appears in post-menopausal Caucasian
women with a mean age of 64 years. Often the presenting symptoms are pruritus and
soreness and it is not uncommon for the symptoms to have been present for some
time before the patient first presents clinically. The condition appears as
erythematous scaly patches with islands of hyperkeratosis, most commonly on the
labia majora (Figure 1.1), but it can also involve the perineum and the perianal
region. The diagnosis is made by biopsy and there is a distinctive histological
appearance with pathognomonic ‘Paget’ cells. On the basis of histological
examination, Wilkinson and Brown (2002) proposed a classification for PDV:
1 a. Intraepithelial neoplasia.
1 b. Intraepithelial neoplasia and stromal invasion.
lc. Underlying adenocarcinoma of skin appendage or a subcutaneous vulval gland. 
2a. Secondary to anal or rectal adenocarcinoma.
2b. Secondary to urothelial neoplasia.
2c. Secondary to adenocarcinoma of other site.
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1.7 Histopathology of PDV
Paget cells can be distinguished by their large vesicular nuclei often located centrally 
(Figure 1.3). Pronounced nuclear atypia and pleomorphism are usually present. 
Mitotic figures may be frequent. The basophilic or amphophilic finely granular 
cytoplasm is abundant and vacuolated, and often contains mucin. The cells tend to 
form nests or aggregates within the epidermis, most commonly in the basal layers. 
Two types of Paget cells have been documented (Goldblum and Hart, 1997). Classic 
type (type A) cells are characterised by vesicular nuclei with prominent nucleoli and 
abundant clear or amphophilic cytoplasm (Figure 1.3i). The signet ring type (type B) 
is characterised by an eccentrically displaced nucleus due to large cytoplasmic mucin 
droplets (Figure 1.3ii). Such cells may also be present in the sweat gland ducts, 
which have led some to suggest that the Paget cells are derived from a local apocrine 
gland neoplasm (Parker et al., 2000). In the literature very few studies (Goldblum and 
Hart, 1997; Helwig et al., 1963; Lee et al. 1977) have documented the different types 
of Paget cells present in their study. In the majority of cases type A Paget cells 
predominated. There was no correlation between type A and type B Paget cells and 
PDV with and without invasive disease in these studies.
In the current study, the majority of Paget cells were classic type A. There was no 
difference in the staining pattern of the antigens between the two subtypes of Paget 
cells.
The Paget cells contain neutral and acid mucopolysaccharides and carcino- 
embryonic antigen (CEA) has been identified (Olson et al, 1991). Other markers have 
also been identified in Paget cells which will be described later in section 1.13.
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pFigure 1.3 H&E staining of PDV (x200). 
Arrows point to Paget cells.
i  « S < 9 .
Figure 1.3i Photomicrograph of type A Paget cells (x400). 
Arrows point to Paget cells.
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Figure 1.3ii Photomicrograph of type B Paget cells in the basal layer of the epidermis 
(x400).
1.8 Electron microscopy of Paget cells
There are few ultrastructural studies on PDV (Demopoulous, 1971; Lagios et al., 
1984; Ordonez et al., 1984, 1987). Electron microscopy has shown that the large 
Paget cells contain numerous cytoplasmic organelles, including free ribosomes, 
smooth and rough endoplasmic reticulum, lysosomes, numerous enlarged 
mitochondria and Golgi membranes (Sagami, 1963; Sagebiel, 1969). The plasma 
membrane shows microvilli and desmosomal attachments, but fewer than those seen 
between keratinocytes. The keratinocyes close to the Paget cells have fewer 
desmosomes than usual. No desmosomal attachments are seen between Paget cells 
and melanocytes (Sagami, 1963; Lagios et al., 1984). Abnormal cells with 
characteristics of both keratinocytes and Paget cells have also been demonstrated 
(Sagami, 1963; Sagebiel, 1969; Lagios etal., 1984). These apparently intermediate 
cells have been designated pre-Paget cells (Lagios et al, 1984) and such observations 
support the concept of an in situ origin of Paget cells.
37
1.9 Differential histological diagnosis of PDV
‘Pagetoid spread’, is a term used to describe any condition where cells are distributed 
singly and in small groups throughout an epithelial layer. This term has been derived 
from the distinctive histological pattern of the epidermal infiltration of Paget cells. A 
variety of intraepithelial lesions may assume a ‘Pagetoid appearance’. These include 
superficially spreading malignant melanoma, Bowen’s disease, mycosis fungoides, 
Langerhans cell histiocytosis and Spitz naevus. Toker cells are normal epidermal 
cells that resemble Paget cells, found in 10% of normal nipples. Diagnostic problems 
arise, particularly if  the biopsy is taken from degenerating areas, when only a few 
atypical cells are present, and when the cells contain melanin pigment.
Morphologically, these situations raise the possibility of a melanocytic lesion and 
dysplastic squamous changes. In most cases, with the help of immunostains and 
careful morphological examination, the correct diagnosis can be made.
1.10 Histogenesis of PDV
Many studies have sought to address the histogenesis of extramammary Paget’s 
disease with various theories having been put forward. A tendency for Paget cells to 
be located within apocrine gland-bearing areas has led some authors to believe that 
their origins are from apocrine ducts (Mazoujian et al., 1984; Nagle et al, 1985;
Olson et al, 1991). Boehm and Morris (1971) identified them as being of apocrine 
type on the evidence of their blue staining reaction with colloid iron. The presence of 
apocrine epithelial antigen (Kariniemi et al., 1984) and gross cystic disease fluid 
protein (Mazoujian et al, 1984) concurred with this hypothesis. These suggestions do
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not explain the presence of Paget cells in areas without apocrine glands and others 
have found no evidence of apocrine differentiation (Tsukada et al., 1975) but have 
suggested that the cells are of eccrine sweat gland type (Webb and Beswick, 1983). 
Some have concluded that Paget cells represent an aberrant differentiation from 
pluripotential epidermal stem cells (Medennica and Sahihi, 1972; Frederich and 
Wilkinson, 1982; Guamer et al., 1989; Urabe et al., 1990).
The migration of Paget cells from an underlying carcinoma has been widely accepted 
as the origin of mammary Paget’s disease. This led Koss et al. (1968) to suggest that 
extramammary Paget’s disease was similar and that PDV was always associated with 
an underlying carcinoma. However, several studies have consistently shown that this 
is not so in the majority o f cases. Boehm and Morris (1972) reviewed 100 cases of 
PDV reported in the literature and found that only 28 had been described with an 
underlying carcinoma. Chanda (1985) reviewed details on 197 published cases of 
extramammary Paget’s disease of which 150 were women and 47 were men. 
Twenty-four percent had an underlying cutaneous or adnexal carcinoma and 29% of 
the cases were said to be associated with an associated internal malignancy. What is 
not clear from the review is whether the underlying cutaneous carcinoma was an 
invasion of Paget cells from the overlying epithelial disease or vice versa i.e an 
invasion of the epidermis from the underlying tumour, or was a separate carcinoma 
derived from a different clone of cells, thus unrelated to the intraepithelial Paget’s 
disease. Defegu et al. (1986) found the overall incidence of associated malignancy 
for extramammary Paget’s disease was 15% with vulval cancer constituting 33% of 
these. One theory that has been put forward is that extramammary Paget’s disease 
arises as a primary intraepidermal neoplasm in most cases, with the Paget cells either
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originating from the intraepidermal cells of the apocrine gland ducts or from 
pluripotent keratinocyte stem cells (Lloyd et al, 2000). Others have suggested that 
the Paget cells migrate upwards along the ducts from an adnexal carcinoma (Hastrup 
et al., 1988). Invasive disease can develop from this in situ disease (Goldblum and 
Hart, 1997) and this may have been a confounding issue in the consideration of the 
association with an underlying malignancy.
1.11 Management of PDV
Excluding invasion of PDV or a deeper underlying malignancy is the first essential 
step in the management and treatment of Paget’s disease of the vulva. The need to 
exclude invasive disease warrants excision of the lesion. Previously, radical 
vulvectomy was the preferred treatment but others have recommended more 
conservative surgery. A simple vulvectomy at a depth of at least 5mm of 
subcutaneous tissue has been recommended as the optimal treatment for 
intraepithelial Paget’s disease by Feuer et al. (1990). Bergen et al. (1989) performed 
skinning vulvectomy with split-thickness skin grafts to treat some of their patients 
with intraepithelial Paget’s disease of the vulva. Others have advocated a wide local 
excision with sufficient depth of underlying dermis to detect invasion (MacLean, 
2000).
Histologically, the extent of the disease is often greater than the clinically apparent 
lesion with residual disease present after excision. Obtaining frozen sections at the 
time of surgery has been advocated to ensure adequate surgical clearance (Stacy et 
al., 1986). Gunn and Gallager (1980) demonstrated that even this may not be
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successful owing to the irregularity and multifocal nature of the disease and they 
noted that local recurrence is frequent unless a wide local excision is performed.
Some have advocated other methods of treatment. Burrows et al. (1995) treated their 
five patients who had extramammary Paget’s disease (two cases involving the vulva) 
with radiotherapy. Ewing et al., (1991) treated six cases with CO2 laser and others 
have used chemotherapy (Yamazaki et al., 1999; Voigt et al., 1992; Watanabe et 
al.2002). Parker et al. (2000) compared and evaluated the initial treatments of 76 
patients in a retrospective study. They found that patients who had a wide local 
excision had a better prognosis than patients treated with simple vulvectomy, radical 
vulvectomy, radiotherapy or chemotherapy. Chapter 6 of this thesis will discuss this 
further.
1.12 Prognosis of PDV
In general the prognosis of PDV depends on whether there is dermal invasion or an 
underlying adnexal adenocarcinoma present. Similarly, disease location and type of 
treatment are also important prognostic factors. In his review, Chanda (1985) 
demonstrated a 46% higher mortality rate in those patients who had PDV with an 
associated underlying cutaneous adnexal adenocarcinoma compared to those without 
a carcinoma. In their retrospective study of 76 patients with Paget’s disease of the 
vulva, Parker et al. (2000) also found that patients with Paget’s disease and 
underlying adenocarcinoma (n=13), patients with a coexisting cancer (n=8), and 
those with invasive Paget’s disease (n=9) had a poorer prognosis than those with 
purely intraepithelial Paget’s disease (n=46). They also suggested that the location of 
the Paget’s disease is important for the prognosis; those patients with clitoral
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involvement had a worse outcome compared to those with lesions located at other 
sites in the vulva. Approximately a quarter to over half of all patients with PDV will 
have recurrence of the disease (Fanning et al., 1998; Zollo et al., 2000).
1.13 Literature review
One of the aims of this study was to investigate the expression of various molecular 
markers in Paget’s disease of the vulva and to identify any differences in the 
expression of these markers between those with pure intraepithelial Paget’s disease 
and those cases with invasive adenocarcinoma. Such an analysis might identify 
potential markers of clinical prognosis. The paucity of literature regarding the 
molecular pathology and the expression of molecular markers in PDV is in part due 
to the rarity of this disease. Most studies that have been performed have involved 
small numbers of cases. A summary of various studies performed in the literature is 
shown in Table 1.1.
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Table 1.1 Review of expression of antigen markers in Extramammary Paget’s
disease
Authors Study Results
Kariniemi et. al. 
(1984)
Expression of CEA and AEA 
in 7 cases of MPD and 12 
cases of EMPD
All cases of EMPD +ve 
for CEA and AEA
Kariniemi et al. 
(1985)
Cytokeratin expression in 
Paget cells
7 cases of EMPD 
positive for PKKi and 
RGE53
Olso et al. (1991) Immunohistochemical features 
of Paget’s disease of the vulva 
with and without 
adenocarcinoma
No significant difference 
in the expression of 
GCDFP-15 ,EMA,
CEA, B72.3, S-100 and 
oestrogen receptor 
between the two 
groups.
Diaz de Leon et. 
al.(2000)
Oestrogen, progesterone and 
androgen expression in 28 
cases of EMPD.
Androgen receptor 
expression in 15/28 
cases of EMPD (23 
vulval cases) Oestrogen 
and progesterone not 
expressed
Brummer et al. 
(2004)
Her-2/neu expression in Paget 
disease of the vulva and the 
female breast
8 of 10 cases of PDV
Alo et al., (2005) Fatty acid synthase expression 
in Paget’s disease of the vulva
20 cases. Increased 
expression with 
increased aggressiveness
1.14 Paget’s disease of the vulva database
PDV is an uncommon disease and individual clinical experience is therefore limited. 
In 1997 the British Society for the Study of Vulval Disease (BSSVD) established a 
national register asking all clinicians who had patients with PDV to enrol them. This 
register has been publicised via the Royal College of Obstetricians and
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Gynaecologists, the British Association of Dermatologists and the British 
Gynaecological Cancer Society. Members of the Department of Obstetrics and 
Gynaecology at the Royal Free and University College Medical School (Hampstead 
Campus) have continued to contact clinicians and collect information on cases 
throughout the country. Registration and follow-up forms have been devised and 
sent to clinicians so that information on the management and clinical outcome on 
cases of PDV can be gained; this will increase our understanding of this rare but 
important disease. This is discussed further in chapter 6 of this thesis.
1.15 Paget’s disease of the breast (PDB)
Described in 1874 by Sir James Paget, less than 4% of all breast carcinomas are 
associated with PDB (Ashikari et al.,1970; Ascensao et al.,1985; Chaudary et al., 
1986; Osther et al., 1990). The lesion is characterised by the presence of large, pale, 
intraepidermal neoplastic (Paget) cells within the nipple epithelium. As stated 
earlier, Sir James Paget did not actually describe the histological features or cellular 
morphology of the lesion. He did not regard the nipple lesion per se as neoplastic, 
but stated that ‘a superficial disease induces in the structures beneath it, in the course 
of many months, such degeneracy as makes them apt to become the seats of cancer’ 
(Paget, 1874). This view was no longer tenable after the first microscopic studies 
clearly defined the Paget cells as neoplastic. One of the earliest clinical descriptions 
of PDB has been attributed to John of Ardene (Graham, 1939) who recorded the 
development of a sore in the nipple of a priest in 1307, within two years the 
cancerous change extended into the underlying breast and was associated with 
changes in the overlying skin. In 1841, Velpeau described the dermatitis-like 
changes of the nipple and areola that preceded cancer of the breast in women.
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However, it was Sir James Paget who has been credited with recognition of the lesion 
as a clinical entity. Jacobaeus (1904) provided a histological description of three 
cases of Paget’s disease and advanced the concept that Paget’s disease reflects an 
epidermotropic extension of an underlying adenocarcinoma into the surface 
epithelium. His findings were later supported by Muir (1927,1929) and Ingis (1936).
1.16 The breast
Mammary glands are modified sweat glands with the specialised function of 
providing nutrients for the newborn infant. Located on the anterior chest wall, they 
serve as target organs for a variety of hormones (McManus and Welsch, 1984).
These hormones have an active or a passive role in the physiology of mammary 
glands. Hormones that actively influence breast physiology are prolactin, oestrogen 
and progesterone. Oestrogen promotes the growth and development of the duct 
system, and progesterone stimulates lobular development. For oestrogen and 
progesterone to exert their effect, prolactin must be present (Reyniak, 1979). 
Oestrogen initiates mammary epithelial stem cell division, but prolactin, insulin, and 
growth hormone are necessary for the process to continue. A variety of other 
hormones, including human placental lactogen and thyroxine, influence DNA 
synthesis in the ductal epithelial cells (McManus and Welch, 1984). The various 
hormones act in concert to promote morphological and functional development of the 
breast through the establishment of the duct system and production of milk. These 
dynamic processes of mammogenesis and galactopoiesis commence during fetal life, 
continue throughout puberty and the reproductive years, and end following 
menopause.
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1.17 Development of the breast
1.17.1 Fetal mammary development
The primitive milk streak (milk line) appears in the human embryo during the 5th 
week of gestation (Hamilton et al., 1968) as two ventral bands of slightly thickened 
ectoderm. The pair of milk lines extends from the axilla to the groin. Shortly after 
its formation, most of the band regresses except for a small segment that remains in 
the thoracic-pectoral region where it forms the mammary ridge. By the 7th to 8th 
week of gestation, the mammary anlagen have been established as a thickening of the 
milk line. This is followed by the development of the nipple. The smooth muscle of 
the nipple and areola form through differentiation of the mesenchymal cells in the 
chest wall between the 12th and 16th weeks of gestation. Sex differences become 
apparent toward the end of the 1st trimester under the influence of oestrogen and 
testosterone. During the 3rd trimester placental hormones initiate canalisation of the 
epithelial strips; this process continues from the 20th to the 32nd week of gestation.
The development of the mammary lobules between the 32nd and 40th weeks 
results in an increase in the mammary tissue. Meanwhile, the pigmented nipple- 
areola complex develops. At birth, the mammary ducts open into a small shallow 
depression, referred to as the mammary pit. Shortly thereafter, evagination of the 
mammary pit results in the formation of protuberant nipples (Tavassoli, 1999).
1.17.2 Postnatal stage
A transient mammary hyperplasia is observed in some newborn infants as a result of 
transplacental transfer of the maternal hormones. A colostrum-like fluid may appear 
in the nipple of newborn males or females up to a week postpartum. The hyperplastic
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breast tissue characterised by ducts distended with secretory material involutes by the 
3rd to 4th postpartum week. During childhood, some branching of the primary duct 
system occurs, but significant changes do not become apparent until puberty. The 
changes taking place during puberty and adolescence result from a surge of hormonal 
activity by the pituitary gland and ovaries. The ovarian follicles secrete oestrogenic 
hormones, which stimulate further growth and branching of the duct system 
simultaneously with proliferation of the periductal stroma. Along with progesterone, 
the oestrogen secretion results in the development of the lobular units. The adult 
breast assumes its final protuberant appearance with pigmented nipple and areola 
about 3-4 years following the initial surge of the hormonal activity.
1.17.3 Nipple-areola complex
The nipple, rich in sensory nerve endings, is located in the centre of the complex 
surrounded by the areola and elevated above it over the 4th intercostal space. The 
initial development of the primitive nipples, which appear as a narrow crest of 
ectodermal cells, precedes that of the mammary gland (Hughes, 1950). The nipple 
nodule is composed o f bundles of smooth muscle and elastic tissue traversed by 
lactiferous ducts, which have their orifice at the tip of the nipple. Stratified squamous 
epithelium covers the nipple and areola. Clear cells may be present in the surface 
epithelium. These cells lack intracytoplasmic mucin, have normal nuclei, fail to react 
to CEA antibodies and should not be mistaken for Paget’s cells. Toker, (1970) 
described a glandular type of clear cells ini 2% of nipples in autopsy cases. These 
“Toker cells” have abundant clear cytoplasm, large nuclei and easily identifiable 
nucleoli. Sebaceous and apocrine glands are present in the nipple and areola, but hair 
follicles are found only in the areola. The areola surface is punctuated by rounded
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elevations known as ‘tubercles of Montgomery’ which comprise the openings of the 
ducts of large sebaceous glands known as ‘glands of Montgomery’.
1.17.4. Structure of the adult duct system
The breast consists of 15-20 segments or lobes (Cowie, 1974). Each lobe is drained 
by a collecting duct, but the segments are ill-defined and not identified on either 
gross or microscopic inspection. The lactiferous (collecting) ducts converge on the 
nipple, with the majority opening at the nipple. Between the ages of 13 and 15 years, 
the ducts elongate and the lobules are formed by lateral and dichotomous branching 
(Monaghan, 1990). The different parts of the duct system are given specific 
designations to help communicate the site of a lesion. Also referred to as the terminal 
duct-lobular unit, a small portion of the terminal duct together with the acini 
constitutes the lobule. Lobules are only fully developed and functional during 
lactation.
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Figure 1.4 Diagram of the breast.
Ref www.cancer.org.au.
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1.18. Anatomy of the breast
1.18.1 Microscopic anatomy
The duct and lobule system constitutes the functional component of the breast 
although the fibroadipose tissue surrounding the duct system accounts for the major 
bulk of the organ. Except for a small segment of the collecting ducts at the nipple 
orifice where squamous epithelium lines the duct, the entire duct system is lined by 
two cell layers: the inner epithelial cell layer along the luminal surface and a 
surrounding interrupted layer of myoepithelial cells. The long axis of the inner 
epithelial cells is perpendicular to that of the myoepithelial cells. These cell layers 
are surrounded by a basal lamina. A stem cell population is dispersed throughout the 
duct system with the highest concentration in the lobules. Proliferation of these cells 
results in the expansion of the duct system during gestation and lactation and possibly 
during pathological proliferative and neoplastic processes. The intralobular stroma is 
loose and more cellular than the interlobular stroma. A thin rim of similarly loose 
stroma surrounds the entire duct system, but it is most conspicuous in the lobules 
where the compact cluster of ductules is present. This is believed to be a specialised, 
more hormone-sensitive component of the mammary stroma.
1.18.2 Anatomic relations
The superficial pectoral fascia envelops the breast and the undersurface of the breast 
lies over the deep pectoral fascia, which covers pectoralis major muscle. Fibrous 
bands (Cooper’s accessory ligaments) connect the fascial layers and represent the 
natural means of supporting the breast.
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1.18.3 Blood supply of the breast
The internal thoracic (mammary), the posterior intercostals as well as the highest 
thoracic, lateral thoracic, and pectoral branches of the thoracoacromial (multiple 
branches of the axillary artery) arteries provide the major blood supply to the breast. 
The posterior intercostal arteries and several other branches of the axillary artery, 
including the highest thoracic and pectoral branches of the thoracoacromial, also 
contribute to the blood supply. The anterior perforating branches of the internal 
mammary artery supply 60% of the breast (the medial and central parts), whereas the 
upper outer quadrant is supplied by the lateral thoracic artery. However, variations in 
the blood supply and patterns of circulation are common.
The three groups of veins that drain the breast are the intercostal veins, the axillary 
veins and the internal (thoracic) mammary vein perforators. Tumour embolisation 
through the venous channels plays a major supplementary role in the spread of breast 
carcinoma to the lungs, brain, liver, bone and other distant tissues.
1.18.4 Lymphatic drainage from the breast
75-97% of lymph from the breast flows to the axillary nodes and 3-25% 
to the internal mammary nodes (Hultom et al., 1955; Hultom et al 1974). A very 
limited drainage passes to the posterior intercostal lymph nodes located close to the 
articulation o f the ribs and vertebrae. The lymphatic drainage serves as the major 
route for dissemination of mammary carcinoma. Based on a correlation of the 
location o f carcinomas and the distribution of lymph node metastases, it appears that 
a preferential flow via certain pathways exists depending on where the primary
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carcinoma is located in the breast. In general, tumours located in the upper outer 
quadrant metastasise mainly to the axillary nodes whereas only those located in the 
central or medial region of the breast may metastasise to the internal mammary chain. 
Only tumours in the upper outer and upper central part of the breast show metastases 
to Rotter’s nodes, which are located between the pectoralis major and pectoralis 
minor muscles, and the axillary nodes.
1.18.5. Nerve supply to the breast
The overlying skin of the breast is supplied by the cutaneous branch of the intercostal 
nerves T4 -T6. Sympathetic fibres supply the blood vessels and glands, but the 
control of lactation is hormonal.
1.19. Clinical Presentation of PDB
PDB presents as a well demarcated, slightly indurated erythematous scaling or 
crusted area on the nipple or areola. It is rare before the 4th decade and is most
tVi tlifrequent in the 5 and 6 decades (Colcock et al., 1954; Rissanen et al., 1969; Paone et 
al.,1981). The early changes may be minimal, perhaps a small, crusted and 
intermittently moist area on the nipple (Figure 1.5.i) giving a brownish stain on 
clothing, or producing an itching, pricking or burning sensations. The lesion always 
appears first on the nipple, subsequently spreading to the areola and seldom involving 
the surrounding skin. Less often, a serous or blood-stained discharge from the nipple 
is the presenting symptom. This is often prominent in later the stages, when 
ulceration and erosion of the nipple tend to occur (Figure 1.5.ii). Nipple retraction 
may be seen, but this is not characteristic, and is most often caused by adhesions to 
an underlying tumour. Studies have shown three different clinical patterns at
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inspection and palpation: 1) nipple changes only, 2) nipple changes and an 
underlying palpable tumour in the breast and 3) breast tumour only (subclinical 
Paget’s disease o f the nipple) when Paget’s disease of the nipple is an incidental 
histological finding in a mastectomy specimen (Ashikari et al., 1970; Kister et al., 
1970; Chaudary et al., 1986). In most series about half the patients with clinical 
Paget’s disease o f the nipple had a palpable breast tumour, and in the other half the 
clinical features were confined to the nipple (Ashikari et al., 1970; Kister et al., 1970; 
Paone et al., 1981; Ascensao et al., 1985; Johnson et al., 1987). Paget’s disease of 
the breast is generally unilateral, but bilateral lesions have been reported (Anderson, 
1979). Paget’s disease is seen in both the female and male breast (Archibald, 1922; 
Crichlow and Czemobilsky, 1969; Fine, 1986; Desai et al., 1996). It has also been 
reported in ectopic breast tissue (Kao et al., 1986) and in supernumerary nipples 
(Martin et al., 1994). The observed incidence of subclinical Paget’s disease of the 
nipple depends on the thoroughness of histological examination of mastectomy 
specimens, and consequently the figures vary greatly in different series. In most 
studies Paget’s disease of the nipple was present in about one-fifth of breasts with 
palpable tumour (Rissanen et al., 1969; Ashikari et al., 1970; Kister et al., 1970; 
Ascensao et al., 1985). In such cases the associated breast tumour was not 
necessarily immediately adjacent to the nipple (Kister et al., 1970; Bussolati et al., 
1975). The commonest presentation is Paget’s disease associated with a non-invasive 
intraductal carcinoma. This may be limited to the ducts just beneath the nipple, or it 
may be more extensive in its distribution within the breast. Cases of PDB associated 
with ductal carcinoma in-situ (DCIS) alone usually have no palpable tumour within 
the breast, and the presence of a palpable mass in the context of Paget’s disease 
should raise the suspicion of invasive carcinoma (Ashikari et al., 1970; Jones et al.,
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1985; Chaudary et al., 1986). Cases of Paget’s disease with no palpable mass 
account for 50% of all presentations. A palpable tumour is almost always present in 
the invasive carcinoma component of Paget’s disease and, in 1/2 -2/3 of patients at 
this stage, axillary lymph node metastases are identified at the time of presentation 
(Ashikari et al., 1970; Ascenao et al., 1985; Chaudary et al., 1986; Eusebio et al., 
1992). Among the histological subtypes of intraductal carcinoma, Paget’s disease 
appears to be most commonly associated with the solid/comedo form (Stockdale et 
al., 1989; Eusebio and Deckers, 1992). This subtype is considered to be the most 
biologically aggressive, with a higher nuclear grade and greater number of mitoses 
(Martin et al., 1994).
Figure 1.5.i. Early changes in PDB (xlOO).
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Figure 1.5.ii Ulceration and erosion of the nipple in PDB (xlOO).
1.20. Histopathology of PDB
The epidermis is thickened with papillomatosis, enlargement of the interpapillary 
ridges and hyperkeratosis or parakeratosis on the surface. Within the epidermis, the 
Paget cells are dispersed between the prickle cells (keratinocytes). They vary in 
number and, when profuse, the Malpighian layers may be disrupted. There is usually 
a chronic inflammatory reaction in the upper dermis. In the later stages the epidermis 
may be atrophic or eroded. The Paget cell’s cytoplasm is usually periodic acid-Schiff 
(PAS)-positive and diastase resistant (Crawley, 1957) which indicates the presence of 
neutral polysaccharides and supports the glandular origin of the cells. They are 
disposed singly among the keratinocytes or in clusters which, if basal in situation, 
may mimic a malignant melanoma. The Paget cells may also extend down the ducts 
of appendages. An underlying breast carcinoma is not always seen on biopsy, as it 
may be more deeply situated. Careful examination usually reveals an intraductal 
carcinoma within the lactiferous ducts, usually situated distally from the nipple, but 
sometimes in the terminal ducts, and often appearing to spread between the two
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layers of epithelial and myoepithelial cells of the duct. The carcinoma in-situ cells 
accumulate within and distend the ducts and spread in both directions. A number of 
ducts are usually involved. At a later stage the carcinoma becomes invasive and 
behaves like any other breast carcinoma, e.g. infiltrating ductal carcinoma of the 
breast. Figure 1.6 demonstrates H&E staining of PDB.
Figure 1.6 H&E stain of PDB (x200).
1.21. Histogenesis
Over the years, a variety of explanations have been offered about the nature of PDB 
cells. Orr and Paris (1962) suggested that PDB cells represented altered melanocytes. 
Derived in part from the presence of melanin pigment seen within some Paget cells, 
this viewpoint has been refuted since the cells fail to show a positive reaction to S- 
100 protein or the melanoma marker HMB45, but do show a positive reaction to low 
molecular-weight cytokeratin subclasses. Although the Paget cells in the nipple and 
the underlying carcinoma cells have been found to express similar markers in many
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studies, a few cases have shown discordance, e.g. between the expression of CEA 
and gross cystic disease fluid protein (GCDFP)-15 at the two sites (Cohen et al.,
1993). Furthermore, at the ultrastructural level, Paget cells of the breast show 
microvilli along the plasma membrane, intracellular and extracellular lumen 
formation, and desmosomal attachment to adjacent keratinocytes and other Paget 
cells (Sagebiel et al., 1969; Satiani et al., 1977; Jahn et al.1995), whereas well 
developed desmosomal junctions are almost never identified in melanocytic cells 
(Sagebiel et al.,1969). It is now accepted that PDB cells are capable of phagocytosing 
melanin (Culberson et al.,1956; Peison et al., 1985). Two other theories that have 
been put forward to account for the origin of PDB are : 1) the epidermotropic theory, 
which postulates that Paget cells are ductal carcinoma cells that have migrated along 
the basal membrane of the underlying ducts to the epidermis of the nipple (Lloyd et 
al., 2000) and 2) the concept of in situ transformation, which regards the Paget cells 
as malignant keratinocytes appearing in situ and thus considers Paget’s disease of the 
nipple to be an independent in situ carcinoma (Willis, 1960; Paone et al.,1981; Lagios 
et al., 1984). This transformation theory is favoured for extramammary Paget’s 
disease (Sitakalin et al., 1985) but could also account for the cases of PDB in which 
no underlying carcinoma can be identified in the mastectomy specimen, despite 
extensive sampling. The presence of cells with morphological features intermediate 
between Paget cells and keratinocytes, as well as the occasional “dyskeratotic” 
appearance of Paget cells as they migrate into the stratum comeum, support this 
possibility. Sagami (1963) and Sagebiel (1969) independently provided substantial 
evidence in support of an in situ transformation in the development of PDB. Both 
demonstrated desmosomal junctions between Paget cells and adjacent keratinocytes. 
Sagebiel’s description of keratinocytes that exhibit a paucity of desmosomes and
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separation of tonofibrils by a clear peripheral zone of cytoplasm adjacent to Paget 
cells may reflect early stages of transformation of keratinocytes to Paget cells at the 
ultrastructural level. On the other hand, Muir (1927,1929) presented strong 
histological evidence for an intraepithelial extension of cancer cells (Paget cells) 
from an underlying intraductal carcinoma in the upper extremity of a lactiferous duct 
to the subpapillary epidermis, forming the background for the epidermotropic theory 
(Ingis, 1946, 1952; Toker, 1961,1967; Ordonez et al., 1987; Ostheretal., 1990). 
Most immunohistochemical studies which have revealed that the Paget cells express 
antigens closely resembling cells of mammary origin, have tended to favour the 
epidermotropic theory, while the theory of in situ transformation has found support 
mainly in ultrastructural studies. However, it is possible that both theories may be 
correct and there may be more than one mechanism involved. Further studies are 
needed to solve this enigma.
1.22. Immunohistochemical investigations of PDB
Immunofluorescence and immunoperoxidase techniques have demonstrated positive 
staining of PDB cells for casein, CEA, cytokeratin 7, epithelial membrane antigens, 
milk fat globules and lectins (Bussolati and Pich, 1975; Kariniemi et al., 1984, 1985; 
Kirkham et al., 1985; Mariani-Constantini et al., 1985; Cohen et al.,1993 (Table 1.2).
These results suggest that the Paget cells express antigens typical of glandular 
epithelia, which fit in well with the epidermotropic theory. Only a few investigators, 
however, compared the Paget lesions with the underlying tumour (Tani and Skoog, 
1988; Cohen et al., 1993). This relationship is essential as a basis for a discussion of 
histogenesis. The epidermotropic theory, moreover, takes no account of the
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observations o f some cases of PDB without an underlying carcinoma (Muir, 1939; 
Ashikari et al., 1984; Lagios et al., 1984). Although the immunohistochemical data 
strongly suggest a mammary origin of the Paget cells, a possible alternative 
explanation o f these data, based on the in situ transformation theory, is that the basal 
epidermal cells of the nipple, in response to unknown stimuli, acquire properties 
typical of apocrine and mammary ducts. This alternative could explain the findings 
of casein-containing basally located epidermal cells lacking the characteristic 
morphology of Paget cells (Bussolati and Pich, 1975). These cells may have been 
pre-Paget cells. Such a concept was supported by observations on the replication of 
Paget cells (Pierard-Franchimont and Pierard, 1984), showing proliferation of the 
cells to be topographically controlled within the epidermis.
Table 1.2 Review of expression of antigen markers in mammary Paget’s
disease
Authors Study Results
Kariniemi et. al. 
(1984)
Expression of CEA and AEA 
in 7 cases of MPD
5/7 of MPD +ve for CEA.and 
6/7 of MPD +ve for AEA.
Kariniemi et al. 
(1985)
Cytokeratin expression in 
Paget cells
Six cases of MPD positive for 
PKKi and RGE53
Cohen et al.(1993) Mammary Paget’s disease and 
associated carcinoma. An 
immunohistochemical study
18/20+ve for cytokeratin (MAK- 
6), 6/20 +ve for keratin, 20/20 
+ve for epithelial membrane 
antigens, 9/20+ve for GCDFP- 
15, 7/20 +ve for CEA, 7/20+ve 
for SI00 protein,
1/20+ve for K-casein and a- 
lactalbumin,
1/19+ve for oestrogen receptor, 
1/25+ve for progesterone 
receptor
Brummer et al. 
(2004)
Her-2/neu expression in Paget 
disease of the vulva and the 
female breast
5 of 5 of PDB positive
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1.23. Classification of PDB
On the basis of histological examination, clinical PDB may be classified into four 
stages (Lagios et al., 1984): Stage 0 - PDB confined to the epidermis, without an 
underlying lesion; Stage 1- PDB associated with DCIS limited to the ducts just 
beneath the nipple; Stage 2 - PDB accompanied by more extensive DCIS; Stage 3 - 
PDB accompanied by invasive ductal carcinoma. The existence of stage 0 is still 
debatable but there are reports of Paget’s disease of the breast without an underlying 
carcinoma (Muir et al., 1939; Ashikari et al., 1970; Haagensen, 1970; my own 
personal observations described in Chapter 2, Page 84). In stages 1 and 2 there is 
usually no palpable tumour. These two stages comprise up to 50% of all cases 
(Colcock and Sommers, 1954; Culberson and Horn, 1956; Maier et al., 1969; 
Ashikari et al., 1970; Kister and Haagensen, 1970; Page et al., 1982; Ascensao et al., 
1985). A palpable tumour is always present in stage 3, and in 1/2- 2/3 of patients 
with this stage there are axillary lymph node metastases (Maier et al., 1969; Ashikari 
et al., 1970; Kister and Haagensen, 1970; Paone and Barker, 1981; Ascensao et 
al.,1985).
1.24. Management of PDB
Until recently, mastectomy had been considered standard therapy for PDB regardless 
of the presence or absence of a palpable underlying mass (Mendez-Femandez et al., 
1980; Lichter and Lippman, 1981; Anelli et al., 1995). In a small number of cases, 
efforts have focused on a more limited excision of the nipple-areola complex, with or 
without radiation, and more limited surgical procedures (Plowman et al., 1986; 
Peterse et al., 1988; Menzies et al., 1989; Stockdale et al., 1989; Bulens et al., 1990; 
El-Sharkawi and Waters, 1992; Eusebio and Deckers, 1992; Anelli et al., 1995;
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Pierce et al., 1996; Banerjee et al., 1997). The presence of a clinically palpable mass 
has been used as a discriminating factor in the selection of a surgical approach. For 
women presenting with a palpable lesion, treatment generally consists of some form 
of mastectomy (Colcock et al., 1954; Maier et al., 1969; Rissanen and Holsti, 1969). 
Reported experience with breast-conserving management of Paget’s disease of the 
breast is very limited. The method of wide local excision of the nipple-areola 
complex followed by axillary node dissection in cases with small or micro invasive 
carcinoma, with or without radiation therapy, or with radiation therapy alone, has 
been used in a few patients (Rissanen and Holsti, 1969; Bulens et al., 1990; El- 
Sharkawi and Waters, 1992; Anelli et al., 1995; Pierce et al., 1996). The subjects for 
conservative therapy have been women without a palpable mass, those with lesions 
confined to the nipple without an underlying breast carcinoma, those with only a 
minimal intraductal carcinoma in the lactiferous ducts and all those reluctant to have 
mastectomy. It is difficult to verify that an underlying carcinoma is absent without a 
mastectomy, but if this could be accomplished with clinical and mammographic 
studies, conservative treatment would be an option for women with limited lesions. 
The relatively good results that have been obtained in the small number of reported 
cases of conservative surgery (Lagios et al., 1984; du Toit et al., 1988; Lichter and 
Lippman, 1988) are encouraging, but follow-up periods in most studies are short and 
the precise extent of the in situ carcinoma, the size of invasive carcinoma (if any), 
and the status of the surgical margins are either not well defined or not well 
documented. Local recurrence rates in PDB have varied from 0%-40% (Paone and 
Barker, 1981; Bulens et al., 1990; El-Sharkawi and Waters, 1992).
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A combination of wide local excision of the lesion within the nipple-areola complex 
along with radiation therapy may be preferable so as to minimise chances of local 
recurrence.
1.25. Prognosis of PDB
The prognosis of the disease depends on whether there is an underlying carcinoma, 
the tumour size, and the status of the axillary lymph nodes. Patients with a palpable 
mass at presentation have a worse prognosis than those without a mass. Ashikari et 
al. (1970) reported that patients without a palpable mass and negative axillary nodes 
had a 5-year survival rate of 97%, which dropped to 95% at 10 years. Axillary lymph 
node metastases were found in 13% of women without an underlying palpable mass. 
The overall survival rate for those without an underlying palpable mass was 92% at 
five years and 87% at 10 years. In contrast, the 5-year survival rate for the 113 
patients with a palpable mass was 40% at five years and 38% at 10 years. For patients 
with a palpable mass but negative nodes, the 5-year survival rate was 73%. This 
study clearly demonstrates the influence of tumour size and axillary node metastases 
on prognosis and survival; unfortunately, it is unclear whether the survival rates are 
actuarial or absolute. Salvadori et al. (1976) provided actuarial survival rates for 41 
patients who presented without a palpable mass. The 5-year survival rate for these 
patients was 92%, dropping to 82% at 10 years with a median survival time of 16.4 
years. Of these, 34 had a histological assessment of the lymph nodes and none had 
evidence of nodal involvement. Of 50 women who had a palpable mass, the survival 
rate was 38% at five years dropping to 22% at 10 years. Forty-eight of these patients 
had histological assessment of their lymph nodes and, of these, 42 (84%) had positive 
nodes. Among men, the 5-year survival rates are consistently worse (Lancer and
61
Moschella, 1982; Haagensen, 1986) at around 20% (Lancer and Moschella, 1982). 
This more aggressive behaviour has been attributed to the more advanced stage of the 
disease at presentation. Understandably, there are no reports of conservative 
treatment among men.
1.26. Hypothesis
PDB is frequently, though not exclusively, associated with an underlying ductal 
tumour. It is currently believed that such breast Paget cells are derived from this 
tumour and that they migrate up through the ducts into the nipple epidermis. In PDV, 
however, only about 10-30% of cases are associated with an invasive 
adenocarcinoma which may pre-exist or develop secondarily to the Paget’s disease. 
This disease is thought to occur as a primary intraepidermal neoplasm which may 
then undergo subsequent steps of malignant progression with invasion. There are 
currently no markers to suggest which cases will progress to invasive disease.
Paget’s disease of the breast and vulva may therefore have a different molecular 
pathology, which is reflected in their different clinical presentation. In addition, such 
differences in molecular pathology may reveal specific markers valuable in 
identifying those cases of PDV which could progress to malignancy.
The hypothesis which will be examined in this thesis will attempt to answer the 
following questions:
1. Is there a difference in the molecular pathology between PDV and PDB?
2. Are there differences in the molecular pathology when PDV is associated 
with or without an underlying invasive adenocarcinoma?
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3. Are there biological molecular markers that can determine the progression of 
intraepidermal PDV to invasive PDV?
4. If there are differences in the molecular pathology between intraepidermal 
and invasive PDV are these reflected in different clinicopathological 
presentation?
1.27. Aims of the project
Specifically, the following areas of molecular carcinogenesis have been chosen to 
examine the hypothesis, since abnormalities in such pathways are very important in 
the malignant progression of several different tumour types, including vulval and 
breast carcinoma:
- cell proliferation, cell cycle control and oncogene expression
- angiogenic factors
- cell adhesion factors
In addition, a database was constructed (for the first time in the UK), to correlate 
clinicopathological parameters of PDV with invasion and prognosis, and to consider 
treatment options including surgical vs. non-surgical.
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2.1 INTRODUCTION
Several studies have shown that there is an important association between genetic 
changes in oncogenes and tumour suppressor genes (TSGs) and the development of 
most human cancers. Some of the aberrant genes, and their respective proteins, have 
been suggested to be useful as markers of malignancy. In this chapter the expression 
of the oncoprotein c-erbB-2(HER2/Neu% the tumour suppressor proteins p53 and 
pRfKplOS^^RBl) and the cell cycle- related proteins cyclin D1 
(CCND1/PRAD1/Bcl-1) and Ki67 will be examined to determine whether they can 
be used as prognostic markers in PDV and PDB and their role in malignant 
progression of these diseases.
2.1.1 Cancer Progression
Transformation of a normal cell to the neoplastic state involves the derangement of 
its genetic programme controlling growth and differentiation. Willis (1952) described 
cancer progression as “growth of which exceeds, and is uncoordinated, with that of 
normal tissue and persists in the same excessive manner after cessation of the stimuli 
which evoke change”
As with other diseases, both genetic and environmental factors are implicated in the 
aetiology of human cancers. Cancers are heterogeneous conditions. Malignant cells 
require independence from mitogenic signals, they may no longer require cellular 
adhesion, or cell type-specific cytokines and may proliferate faster and lose the 
ability to undergo apoptosis. The process of carcinogenesis is believed to be a 
stepwise accumulation of genetic abnormalities. The exact nature of the 
abnormalities for each tumour is not well understood; however, early cytogenetic 
studies showed that many human solid tumours exhibited a reproducible loss of
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genetic material at defined chromosomal loci. These losses are specific for a given 
tumour type and may differ between tumours. The absence of functional genes at 
these loci seems to be related to tumour development and, moreover, both alleles 
were sometimes lost (by deletion or gross chromosomal rearrangement). Hanahan 
and Weinberg (2000) have described six hallmarks essential for carcinogenesis 
(Figure 2.1).
Evasion of  
apoptosis
Growth signal 
autonom y
Evasion o f growth 
inhibitory signals
Invasion &
Angiogenesis m etastasis
Unlimted replicative 
potential
Figure 2.1 The six hallmarks of cancer.
Reprinted from Cell vol 100, Hanahan and Weinberg. 
The Hallmarks of cancer, Page 57, copyright 2000, with 
permission from Elsevier.
2.1.2 Oncogenes
Oncogenes, derived from the Greek word “oncos” meaning tumour, are mutated 
forms of proto-oncogenes, whose functions are to encourage and promote the normal 
growth and division of cells. Proto-oncogenes encode cellular proteins, e.g. growth
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factors, growth factor receptors, intracellular signalling proteins, cell cycle- 
associated proteins and nuclear transcription factors, all of which relay signals to the 
cell’s nucleus, stimulating growth. When proto- oncogenes change genetically to 
become carcinogenic oncogenes the result is excessive cell multiplication, as part of 
the stepwise progression to the development of cancer.
The activation of a proto-oncogene to express its oncogenic potential can occur in 
several ways: point mutation; chromosomal rearrangement; gene amplification, viral 
insertion and deletion. Oncogenes act in a dominant manner, i.e. only one mutant 
allele is required to change cellular behaviour, as compared to TSGs that act in a 
recessive manner, i.e. both alleles of the gene must be inactivated to change cellular 
behaviour. There are now over 100 known oncogenes including HER2/ErbB-2/Neu 
and CCDl/PRADl/Bcl-1. These are discussed in subsequent sections.
2.1.2.i. HER 2/ErbB-2/Neu
The HER2 oncogene codes for a plasma membrane protein, c-ErbB-2. It belongs to 
the Epidermal Growth Factor Receptor (EGFR) family. It was first described in rat 
neuroglioblastoma cells induced by treatment with a carcinogen (Schechter et al., 
1985). HER2 is 80% homologous to EGFR and 80% itself. The gene is located at 
17q21- q22 (Fukushige et al., 1986). C-ErbB-2 is widely distributed. This 
transmembrane protein is a receptor-like tyrosine kinase which is phosphorylated on 
the intracellular tyrosine kinase domain by a ligand-receptor interaction. This 
phosphorylation leads to signal transduction by phosphorylating second 
messengers, inducing RAS-GTP. Studies have shown that over expression of c- 
ErbB-2 is associated with breast, stomach, ovarian and bladder cancers (Hupp et al., 
1995; Wang & Prives 1995; Zauberman et al., 1995). Oncogenic transformation of 
the protein by truncation/ point mutation leads to phosphorylation and permanent
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activation. Kunz et al., (1995) have described remission in 11% of patients with c- 
ErbB-2 over expressing metastatic breast cancer using a monoclonal anti- HER2 
antibody. Herceptin, a monoclonal antibody that binds the extracellular domain of c- 
ErbB-2 has been used for the treatment of metastatic breast cancer whose tumours 
overexpress c-ErbB-2. Herceptin functions through a combination of action including 
enhanced receptor degradation, inhibition of angiogenesis and recruitment of immune 
cells, resulting in antibody-dependent cellular cytotoxicity.
2.1.3. Tumour suppressor genes (TSGs)
That cancer may be genetically determined has been recognised for many years 
(Broca, 1866) and, consistent with this, it has also been clear that some types of 
cancers cluster in families however, inherited cancers only contribute to -5%  to all 
cancers. Through observations of the genetic epidemiology of the rare childhood 
cancer, retinoblastoma, Knudson suggested that a heterozygous_child might inherit a 
(recessive) mutation of one allele of a tumour-predisposing gene at birth (an 
inherited first genetic “hit”). Such individuals will go on to develop cancer if the 
mutation is made homozygous by subsequent damage to the remaining intact allele 
(the second somatic genetic “hit”; Knudson, 1971). Knudson’s proposal of a class of 
cellular genes that regulate cell growth by counteracting the action of growth 
promoting genes was novel. It was subsequently proposed that these latter genes, 
which are active at embryogenesis for proliferation (“transforming” oncogenes), are 
suppressed at differentiation “suppressor” genes (Comings, 1973). Therefore, 
Knudson named a proposed new class of gene as TSGs. Cancer-causing mutations in 
TSGs can formally be regarded as being recessive at the molecular level because both 
copies of the gene must be defective.
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TSGs encode proteins that normally function to inhibit cell growth, cell division and 
to prevent cancer. Examples include the BRCA1 gene, which is mutated in inherited 
breast and ovarian cancers, the retinoblastoma gene, RBI and P53/TP53, which is 
altered in approximately 50% of solid human sporadic cancers (Hollstein et. al.,
1991) and in the Li- Fraumeni Syndrome, which predisposes patients to multiple 
primary cancers at an early age.
The interaction between oncogenes and TSG’s can be clearly demonstrated in the 
molecular events that are implicated in colorectal cancer progression. (Fearon, 1997) 
Hereditary colorectal cancer develops by means of defined stages that go from 
lesions in the crypt of the colon through adenomas to manifest cancer. They are 
characterised by the accumulation of multiple mutations in tumour suppressor genes 
and oncogenes that affect the balance between cell proliferation and apoptosis.
2.1.4. The cell cycle
The major task of the cell cycle (Figure 2.2) is to ensure that DNA is replicated once 
during synthesis (S) phase and that identical chromosomal copies are distributed 
equally to two daughter cells during mitosis (M) phase (Heichman and Roberts,
1994). There are four main phases: G l, S, G2 and M. S is the DNA synthesis phase 
and M is the cell division phase (Figure 2.2). These two phases are separated by the 
gap phases Gl and G2. M phase can be divided into three further phases: prophase, 
metaphase and anaphase. G l, S, and G2 comprise the interphase. Cells can enter a 
non-proliferative phase from G l, called GO phase, resting phase or quiescence. Cells 
enter the cycle and execute DNA synthesis in response to external factors. During the 
first phase of the cycle, G l, cells are responsive to these mitogenic stimuli and are 
dependant on them in order to reach a critical restriction point, termed ‘R’, at the end
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of Gl (Pardee, 1989). Beyond R, cell cycle transition becomes autonomous. 
Transition through the cycle is regulated by the activities of cyclin dependent kinases 
and their inhibitors. A cyclin dependent kinase (CDK) is active as a serine/threonine 
kinase if it associates with a cyclin protein and becomes activated by it. This then 
results in the phosphorylation of the target proteins. This cyclin/CDK mechanism 
provides multiple levels of control. Cyclin proteins are only present during particular 
phases of the cell cycle. This is the result of the specific induction and elimination of 
such proteins at certain points. The development o f human cancer represents the 
uncoordinated and unlimited growth of the cell. This is believed to be the result of a 
step wise accumulation of genetic abnormalities (Fearon, 1997). These genetic 
abnormalities are partly due to the aberrations of cell cycle regulators (Malkonen
1995)
Gl G l
S
Figure 2.2 Diagram of the cell cycle.
2.1.5. Cyclin D1 
The cvclins
The cyclin D1 gene was isolated as the PRADH CCND1 oncogene located on 
chromosome 1 l q l 3, clonally rearranged and over-expressed in parathyroid adenomas
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(Motokura et al, 1991); it is also identical with the BCL1 oncogene which is 
translocated and over-expressed in a significant subset of B-cell neoplasms 
(Rosenberg et al., 1991; Withers et al., 1991). Three different cyclin Ds have been 
identified (cyclins D1-D3); their distribution is cell type specific, with cyclin D1 
being expressed in most epithelial and fibroblast cells and cyclin D3 in lymphoid 
cells (Sherr, 1995). The association o f individual cyclins with their cognate cyclin 
dependent kinases (CDKs), together with additional regulation of CDKs by 
phosphorylation and by inhibitor proteins (CKIs), results in a regulated complex that 
drives the events of the cell cycle (Morgan, 1995). The expression of CKIs may be 
induced by stimuli such as contact inhibition, extracellular anti-mitogenic factors like 
tumour growth factor p, and cell cycle checkpoints like the p53 DNA damage 
checkpoints (Saneverino et al., 2003). The cyclins D1-D3 functions as rate limiting 
controllers of Gl progression through the cell cycle. While levels of the CDKs 
remain relatively constant throughout the cell cycle, the presence of the cyclins 
varies; this is the result of specific induction and elimination of these proteins at 
various stages of the cell cycle. Cyclin D1 also plays a role in cell proliferation 
through the activation of the CDKs. Induction of cyclins starts when cells enter the 
cell cycle from a quiescent state; it requires growth factors and adherence of cells to 
extracellular matrix components such as collagen and fibronectin. Binding of growth 
factors to receptors, either at the surface of the cells (e.g. EGFR) or in the cytoplasm 
(in the case of steroids), triggers a cascade of events which links the ligand signal to 
binding the nucleus, resulting in the activation of transcription factors. Cyclin D1 
protein associates with cdk4 or cdk6, and this complex is then positively regulated by 
cyclin activating kinase and cdc25 and negatively by CKIs. The final target of an 
activated cyclin D: cdk4 or cdk6 kinase complex is the pRb (Weinberger 1995).
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Abnormal cyclin D1 expression has been found in several tumours including breast, 
vulval and prostate cancers. It has also been found to be amplified in breast cancers 
(Theillet et. al, 1990).
2.1.6. RBI
RBI is located at 13ql4 and codes for the retinoblastoma protein pRb (piOS1*31)
The main roles of pRb are to act as a signal transducer connecting the cell cycle clock 
with the transcriptional machinery. pRb exerts most of its effects in the first two- 
thirds of the Gl phase of the cell cycle. Through the preceding hours of G l, pRb is 
found in a hypophosphorylated form. The bulk of pRb prepared from cells during the 
last several hours of Gl is, in contrast, hyperphosphorylated. pRb maintains this 
hyperphosphorylated configuration throughout the remainder of the cell cycle, losing 
its multiple phosphate groups only upon emergence from mitosis. Several lines of 
evidence indicate that this phosphorylation causes the inactivation of the growth 
inhibitory functions of pRb. Firstly, oncoproteins made by three classes of DNA 
tumour viruses eliminate pRb function by binding and sequestering 
hypophosphorylated pRb, ignoring hyperphosphorylated forms. Secondly, the 
hypophosphorylated form binds and controls a number of other cellular proteins, e.g. 
E2F transcription factor; the hyperphosphorylated form appears to have lost the 
ability to interact with these proteins. Thirdly, conditions that cause pRb 
phosphorylation favour cell proliferation (Cobrinik et al., 1992). Cyclins of the D 
class (Dl, D2 and D3) are most prominently implicated in the phosphorylation of 
pRb. These cyclins serve as regulators o f the Cdk4 and Cdk6 kinases. 
pRb binds to the transcription factor E2F to form a complex that blocks transcription 
in a way that is dependent on the cell cycle. Binding is disrupted by viral
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oncoproteins (e.g. adenovirus E1A, simian virus T antigen, HPV16/18/E7) or by 
phosphorylation of pRb by Cdk4, and Cdk6 with Cyclin D1 complexes and CDK2 
and Cyclin E (Weinberg, 1995). Hyperphosphorylated pRb dissociates from E2F 
allowing activation of S-phase genes. The balance between levels of active pRb and 
E2F proteins is important for regulation of cell-cycle progression. More than 20 other 
pRb-binding proteins have been identified, suggesting that pRb might play a variety 
of roles in the regulation of cell proliferation, in addition to its best understood role 
with E2F (Taya ,1997).
Loss of pRb immunostaining by deletion or mutations of the RBI gene has been 
demonstrated in a variety of tumours e.g., breast cancers (Sherbet et al., (2003), 
ovarian cancers (Gras et al., 2001), lymphomas (Rassidakis et al., 2004), and it has 
also been demonstrated to be an independent predictor of survival in bladder cancer 
(Agerbaek et al., 2003).
2.1.7. P53/TPS3
The P53/TP53 gene located at 17p 13.1 codes for the p53 protein and was initially 
identified through its association with the papovavirus SV40 (Lane and Crawford, 
1979; McCormick and Harlow, 1980). p53 is detectable at the plasma membrane 
during mitosis in normal and malignant cells and is distributed widely throughout the 
tissues.
Similar to the paradigm of the retinoblastoma gene, (RBI) the nature of P53 was 
recognised through the phenotype produced by the loss of function. A connection 
between the p53 protein and cell death, while consistent with the recessive (tumour 
suppressor) phenotype was directly demonstrated in complementing studies 
examining the effects of either adding or removing P53 from the armamentarium of
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the cell. Yonish-Rouach et. al.1991; Lowe et al., 1993 published results regarding 
loss and gain of p53 function, and provided strong evidence that P53 is a regulator of 
apoptosis. While the relationship between P53 and apoptosis had been recognised, 
numerous other reports demonstrated an important role for P53 in regulating cell 
cycle dynamics. The wild type (wt) P53 gene acts as a TSG negatively regulating 
cell growth and division. P53, a DNA binding transcription factor, also functions as a 
checkpoint regulator.
Loss of wt p53 function results in the loss of the G1 checkpoint and hence shortening 
of the time available for DNA repair before replication. The end result is a 
demonstrable genomic instability, with chromosomal aberrations accumulating at an 
increased rate. Such a loss of DNA fidelity is a potential mechanism for the increased 
plasticity of cancer cells and could thereby endow p53 loss with prognostic 
significance. Accordingly, p53 has been named the “guardian of the genome”. 
Somatic mutations at the P53 locus, usually point mutations which inactivate its TSG 
activity are the most common genetic change in human cancers and occur in 50%, 
including cancer of the breast, colon, pancreas, and bladder. (Dong, et al, 2003; 
Khaled et al. 2003; Tachibana et al. 2004).
Several studies have examined whether p53 aberrations may have a prognostic value 
in human malignancy. Abnormalities in p53 have been observed in as many as 50% 
of human cancers and can occur through both gene deletions and a variety of gene 
mutational events (Hollstein et al.1994; Malkin et al., 2001). An abundance of 
evidence suggests that p53 may play a significant role in both tumourigenesis and in 
anticancer treatment response. In animals with tumours lacking p53, loss of p53 
disrupts an important apoptosis pathway, which results in refractoriness of these 
tumours to a wide assortment of standard antineoplastic therapies, including radiation
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and chemotherapy (Lowe et al, 1993, 1994). Through its disruption of an apoptosis 
pathway, the loss of p53 function may confer a tumour with far reaching resistance to 
radiation therapy and a broad spectrum of anticancer drugs (Fisher, 1994). 
Correspondingly, the ability of reintroduced p53 to restore apoptotic death to p53 
deficient cells further confirms p53 as a potentially important regulator of treatment 
response.
Accumulation of p53 protein can be detected immunohistochemically. The basis of 
the commonly used immunohistochemical stain is that p53 protein levels are 
regulated through protein degradation events. Normally, p53 protein is virtually 
undetectable by antibody-mediated staining. However, mutant (mt) p53 usually 
resists protein degradation for an increased length of time, leading to the appearance 
of immunohistochemical (IHC) p53 overexpression. There is a strong correlation 
between IHC p53 positivity and p53 mutations (mt p53) in some carcinomas 
(Bodmer et al., 1992; Maestro et al., 1992). However, p53 positivity does not always 
imply there is a mutation present in the gene as other factors can cause an increase in 
the half-life o f the protein, e.g. a regulatory defect or stabilisation by other proteins 
such as Mdm-2.
DNA damage 
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Figure 2.3 Some molecular events o f the cell cycle.
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2.1.8. Ki67
The gene encoding Ki67 is located at 10q25. Characterisation of the Ki67 antibody 
revealed that it was reactive with a nuclear structure present exclusively in 
proliferating cells. A detailed cell cycle analysis revealed that the antigen was present 
in the nuclei of cells in G l, S and G2 phases of the cell cycle as well as in M. 
Quiescent or resting cells in the GO phase did not express Ki67 (Gerdes et al., 1984). 
The cellular distribution of the Ki67 protein is not constant but is subject to dramatic 
changes during the cell cycle.
Because the Ki67 antigen is present in all proliferating cells (normal and tumour 
cells), it soon became evident that its presence is an excellent marker to determine the 
growth fraction of a given cell population (Thomas and Gerdes, 2000). For this 
reason, antibodies against the Ki67 protein have been increasingly used as diagnostic 
tools in different types of neoplasms. Ki67 expression has been shown in certain 
diseases, e.g. Barrett’s oesophagus, to indicate increased proliferation in an early 
stage of neoplastic progression (Barrett et al., 1999). In the case of multiple 
myeloma it can be shown that Ki67 correlates with the course of the disease and, 
furthermore, it is a useful marker in distinguishing multiple myeloma from 
monoclonal gammopathy of unknown significance (Drach et al., 1992; Miguel- 
Garcia et al., 1995).
Ki67 has been found to correlate with poor survival in ovarian cancer (Anttila et al., 
1998) and is a poor prognostic indicator for breast cancer (Giovanni et al., 1999).
The proliferating cell nuclear antigen (PCNA) has also been used as a marker of 
proliferation (Schwarting, 1993; Kubbutat et al., 1994). However, it has been shown 
not to be a reliable marker of proliferating cells as the PCNA antibody stains
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quiescent cells, and PCNA not only has a role in DNA replication but also has a role 
in DNA repair (Thomas and Gerdes, 2000).
2.1.9. The Immunohistochemistry Technique
The process of staining tissue with antibodies on sections is referred to as 
immunohistochemistry (IHC); it is an essential adjunct of modem diagnostic 
pathology. Immunohistochemistry has several advantages in that there is preservation 
of tissue architecture and cell morphology, and also there is direct visualisation of 
cell localisation. In the majority of cases, pathological tissue samples are fixed in 
formaldehyde and embedded in paraffin wax for examination of microscopic 
morphology. A major limitation of routinely processed tissues for IHC is that many 
potentially interesting antigens are altered during tissue fixation and processing. As 
an alternative, sections of snap-frozen tissues can be used to detect most of these 
antigens. Nevertheless, paraffin wax-sections offer well preserved tissue architecture 
and cytomorphology superior to that obtained in frozen sections and thus allow more 
accurate antigen localisation. Also, due to the rarity of PDV and PDB, obtaining 
tissue for analysis was very difficult and required a multicentre approach involving 
many hospitals to gain a sufficient numbers of cases. Paraffin wax-embedded 
samples therefore represented an invaluable resource of human tissues in a number of 
different hospitals accessible for retrospective studies going back two decades. Thus, 
for this research, the use of paraffin wax- sections was the preferred choice for IHC 
analysis.
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2.1.9.i. Theory of fixation
Formaldehyde is the most commonly used fixative in histopathology. The 
commercially available solution contains 35-40% gas by weight; (“Formalin”) which 
reacts with basic amino acids to form methylene bridges. Two buffers were used in 
this study. At the Royal Free, 10% formol saline was used. 10% neutral buffered 
formaldehyde was used at the Royal London Hospital.
The use of neutral buffered formalin and formol saline almost completely stops the 
formation of formalin pigment which occurs with non-buffered acid formaldehyde 
solutions, and also fixes tissues more rapidly.
2.1.9.ii Antibodies
Antibodies belong to a group of proteins called immunoglobulins (Igs) .They 
comprise five major classes; immunoglobulin G (IgG), IgA, IgM, IgD and IgE. Each 
immunoglobulin is composed of two identical heavy (H) chains and two identical 
light (L) chains. The H chains differ in antigenic and structural properties and 
determine the class and subclass of the molecule. The classes have been designated 
gamma (IgG), alpha (IgA), mu (IgM), delta (IgD) and epsilon IgE. Of the five 
classes, IgG and IgM are the most frequently utilised antibodies in IHC.
2.1.9.iii. Polyclonal antibodies
The antibodies available to detect tissue antigens can be either polyclonal antisera or 
monoclonal antibodies. Polyclonal antibodies are produced by different cells and, in 
consequence, are immunochemically dissimilar; they react with various epitopes on 
the antigen against which they are raised. By far the most frequently used animal
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used for the production of polyclonal antibodies is the rabbit. The popularity of 
rabbits for the production of polyclonal antibodies is attributable primarily to the 
rabbit’s easy maintenance. Rabbits offer other advantages also: human antibodies to 
rabbit serum proteins are rare, whereas those to ruminants, such as goat, are more 
common.
2.1.9.iv. Monoclonal antibodies
Monoclonal antibodies are produced from hybridoma clones of plasma cells and 
myeloma cells. Antibodies from a given clone are immunohistochemically identical 
and react with a specific epitope on the antigen against which they are raised. Mice 
are currently used almost exclusively for the production of monoclonal antibodies. 
There are numerous advantages of monoclonal antibodies in IHC over their 
polyclonal counterparts; these include high homogeneity, absence of non-specific 
antibody binding, ease of characterisation and lack of batch-to-batch variability. 
However, some pitfalls in the use of monoclonal antibodies should also be noted. 
Firstly, the methods for the screening o f useful clones and for quality control must be 
identical to the methods for which the monoclonal antibodies were raised. Often, 
monoclonal antibodies are characterised using frozen tissue, for example, when the 
intended research is on formalin-fixed specimens. Secondly, the targeted epitope 
must survive fixation. In some cases an antigen may be shown to survive formalin 
fixation (by use of polyclonal antibodies) but the particular epitope with which the 
monoclonal antibody interacts does not. Similarly, reactivity of an epitope after 
optimal fixation does not necessarily assure survival under suboptimal fixation 
conditions. Thirdly, the targeted epitope must be unique to a given antigen. One of 
the greatest benefits that comes with the use of monoclonal antibodies, namely
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specificity, will be lost if the antibody is directed against an epitope shared by two or 
more antigens. The cross reactivity of polyclonal antisera can be absorbed out, but 
the cross-reactivity of a monoclonal antibody cannot.
2.1.9.V. Antigen retrieval for immunohistochemical reactions
Alterations to antigens in paraffin wax-embedded tissues are related to a variety of 
changes in the three- dimensional structure of proteins resulting from cross-linking 
by formaldehyde and, to a lesser extent, from heating and dehydration during paraffin 
wax-embedding. As a consequence, epitopes may be destroyed, denatured or masked, 
which may diminish or abrogate their detection.
2.1.9.vi Heat-induced epitope retrieval (HIER)
The development of HIER procedures has been the critical breakthrough in paraffin 
section immunohistochemistry (Shi et al., 1991; Cattoretti et al., 1993; Norton et al.,
1994). HIER methods substantially increase the sensitivity of reactions of antibodies 
directed to paraffin-resistant antigens, especially those located in the nucleus. 
Moreover, some antibodies that have never before reacted in paraffin sections show 
specific staining following HIER pre-treatment.
There are several variations of HIER. Many laboratories have attempted to improve 
the original method by altering the buffer solutions as well as the source and mode of 
heating. Currently, the most popular HIER technologies use pressure cookers, 
microwave ovens or autoclaves as the heat source and low-molarity buffers with acid 
or alkaline pH (Cattoretti et al., 1993; Bankflavi et al.1994; Beckstead et al., 1994; 
Norton et al., 1994; Miller et al., 1995). The exact mechanism by which HIER works 
is unknown. It is thought to reverse the masking effects of formaldehyde fixation and
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routine tissue processing. Hydrolytic-proteolytic cleavage of formaldehyde-related 
crosslinks, unfolding of inner epitopes, as well as the extraction of calcium ions from 
co-ordination complexes with proteins are among the hypothesised mechanisms 
(Morgan et al., 1994; Taylor et al., 1996; Morgan et al., 1997).
Experimental data suggest that the pH and molarity of the retrieval buffers are among 
the most important factors for efficacy (Shi et al., 1991; Cattoretti et al., 1993; 
Morgan et al., 1994; Shi et al., 1995; Taylor et al., 1996; Morgan et al., 1997). Citrate 
buffer (sodium citrate-citric acid) at pH 6.0 is a very popular retrieval medium and 
has been used at molarities between 0.01 and 0.1 M (Shi et al., 1991; Cattoretti et al., 
1993). Successful protocols can be established by varying key conditions in the 
antigen retrieval process. The use of different temperatures can markedly enhance the 
retrieval of the antigen. The process is optimised by trial and error of different 
temperature regimes.
2.1.9.vii Protease digestion
Protease induced epitope retrieval (PIER) was introduced by Huang (1975) and it was 
the first method to counteract the antigen masking effects of formalin fixation. It was 
the most commonly used antigen retrieval method before the advent of heat based 
methods. A wide variety of enzymes has been used for this purpose including 
proteinase K, trypsin, DNAse and pepsin. The beneficial effects of the PIER 
mechanism is related to cleavage of the molecular cross-linking by the proteolytic 
enzyme, allowing the epitope to return to its normal configuration, enabling more 
effective binding of the antibody. However, the cleavage is non-specific and some 
antigens might be negatively affected by this treatment (Battifora et al., 1986).
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2.1.9.viii. Antigen detection
The use of enzymes linked to Ig to identify specific substances emerged with the 
work by Nakane and Pierce, who labelled an Ig with the peroxidase enzyme rather 
than with a fluorescent compound (Nakane and Pierce, 1966). The labelled antibody 
binds the antigen and the attached enzyme catalyses the oxidative reaction. This 
direct-labelled technique was the forerunner of numerous other methods that bring 
enzymes and antibodies together to allow the enzyme action to identify the location 
of the antigen through the antibody intermediary. Along with the direct-labelled 
methods, the indirect-labelled methods were developed, providing amplification and 
universality. By using a labelled secondary antibody, any number of primary 
antibodies can be used (to which the secondary antibody binds; Farr et al., 1981). 
This allows great freedom in selecting antigens to study and antibodies with which to 
study them. All that is needed is secondary “anti-antibody” reagent with an enzyme 
attached. The important aspect of this technique is the increased amplification of the 
signal obtained.
2.1.9.ix Enzymes used for antigen detection
Two enzymes frequently used for antigen detection are alkaline phosphatase and 
horseradish peroxidase. The peroxidase enzyme has been used over many years in 
IHC assays. Peroxidase has an oxidative function when used in conjunction with a 
source of oxygen. The peroxidase enzyme found in the horseradish plant has been 
widely used since it is easily obtained and it is antigenically different from all 
mammalian forms of the enzyme. The oxidative function of this enzyme allows for 
the use of chromogens which, when oxidised, not only change colour but precipitate 
in such a manner as to render permanent detection.
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In the experiments described in this work horseradish peroxidase was used as part of 
the streptavidin-biotin complex method.
2.1.9.x The streptavidin-biotin complex (SBC) method 
The streptavidin-biotin complex method (Figure 2.4) involves, at the core, the 
vitamin biotin and the protein streptavidin, which bind together irreversibly (1 0 19 M 
dissociation constant). By establishing a biotin link, through streptavidin, between the 
horseradish peroxidase enzyme and a secondary antibody reagent, enzyme 
localisation can be achieved at the site of primary antibody interaction with the 
specimen. The streptavidin and the biotinylated peroxidase are mixed together at the 
appropriate concentrations at RT for 30 min. to form the streptavidin-biotin complex. 
Originally the the glycoprotein avidin was used to conjugate with biotin, however, 
avidin may bind non-specifically to negatively charged structures such as the nucleus, 
and secondly, as it is a glycoprotein, it can react with molecules such as lectins. 
Because of these disadvantages avidin was replaced with streptavidin.
SBC
Biotinyiated 
rabbit anti-mouse I
Peroxidase streptavidin 
b io tin  complex
Mouse monoclonal 
primary antibody
Figure 2.4 Streptavidin-biotin complex immunolabelling method.
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2.1.9.xi Chromogenic substrates
In addition to many enzyme systems available there are, with each, a series of 
chromogenic substrate solutions that can be used to create different colours to 
identify the location of the antigen. For the peroxidase system, there are numerous 
oxidisable compounds that precipitate as a permanent colour. The most common, and 
the one which was used in this work, was 3, 3-diaminobenzidine tetrahydrochloride 
(DAB). This compound precipitates to a brown colour when in solution with 
peroxidase and hydrogen peroxide. The signal can be intensified with the use of 
imidazole. This material is also insoluble in alcohol and xylene, and therefore the 
tissue may be routinely dehydrated and cleared without loss of chromogen
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2.2. METHODS
2.2.1. Sample collection and preparation
LREC approval was obtained for the use of archival vulval and breast tissue.
Tissue specimens
Seventy-two cases of PDV and 38 cases of PDB were retrieved from the 
Histopathology Department at the Royal Free Hospital and from collaborators as 
listed in the Acknowledgements. The archival cases had all been formalin fixed and 
paraffin wax- embedded (see Appendix I). These cases were diagnosed and treated 
between 1984 and 2000. Ten cases of PDV were associated with invasive 
adenocarcinoma. Of the 38 cases of PDB, six had an underlying invasive carcinoma; 
14 had DCIS alone and six had both DCIS and invasive carcinoma. Twelve cases of 
PDB had no DCIS or underlying carcinoma despite exhaustive sampling by the 
referring hospital pathologist, and review by Dr Julie Crow (JCC), Consultant 
Histopathologist at the Royal Free Hospital. Eleven cases of underlying breast ductal 
carcinoma were also available for the study. A pathologist from each referring 
histopathology department originally diagnosed all cases. JCC reviewed all of the 
haematoxylin and eosin (H&E) stained slides of the cases to confirm the original 
diagnosis. The number of PDV and PDB cases available for IHC for some markers 
were fewer than 72 and 38 respectively due to the limited amount of archival tissue. 
Wax-embedded sections of Paget’s tissue, 5pm thick, were cut using a microtome 
and mounted on 3-aminopropyltriethoxysilane (APES; see Appendix I)-coated glass 
slides to aid adherence. Slides were stored at 4°C if there were not used immediately
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as there has been reports of loss of antigen when left at room temperature (Prioleau 
and Schnitt, 1995; Jacobs et al., 1996).
2.2.2. Optimisation of the immunohistochemical protocol 
Immunohistochemistry was optimised to ensure reduction of non-specific 
background staining, using suitable positive controls for each respective antibody. 
Optimising of antibody dilutions was performed for all primary antibodies, starting 
with the recommended manufacturer’s dilution and then using a range either side. 
Incubation time was also optimised for all antibodies, along with incubation 
temperature, allowing for specific staining with the lowest concentration of antibody 
but still providing intense specific staining. Various antigen retrieval steps e.g none, 
microwaving, pressure cooking and protease digestion were also optimised using 
various concentrations and incubation times.
A known positive control was used in each staining procedure to ensure optimal 
quality of reagents and methods, and to ensure that the staining was successful. The 
same control specimen was used for each run for a given antigen to assess the 
intensity of the stain. Negative controls (same specimen as positive control) were 
also included in each staining run. In the negative controls the primary antibody was 
omitted and replaced by phosphate buffered saline (PBS) in one reaction, and the 
secondary antibody replaced by PBS in another.
2.2.3. Immunohistochemical staining of PDV and PDB sections with t>53.
Ki67, Cyclin D l. pRb and c-erBb2 antibodies
Immunohistochemical staining was performed using the streptavidin-biotin
preroxidase method. Tissue sections were deparaffinised in xylene (3x5 min) and
then rehydrated in different percentages of ethanol up to distilled water (3x5 min).
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3% hydrogen peroxide (lOmin) was placed on the sections to block endogeneous 
peroxidase. They were then washed in Tris-buffered saline (TBS) or PBS for 2x5 
min. Optimum antigen retrieval was performed by microwaving the slides in warmed 
lOmM citrate (see Appendix I) buffer for 10 min and leaving to cool to room 
temperature for 30 min. The slides were then washed in TBS (Ki67) or PBS (2x5 
minutes). Non- specific binding was blocked by incubating the slides with either 
normal rabbit serum (NRS), normal goat serum (NGS) or normal horse serum (Table 
2.2). The sections were then incubated with the primary antibody. Washes were with 
either TBS or PBS depending on the antibody. All incubations took place in a 
humidity chamber. Table 2.1 describes the clone, working dilution, method of 
antigen retrieval, incubation time and positive controls used. This was followed by 
the incubation with the secondary antibody. Incubation times were 45 min. Table 2.2 
describes method of non specific binding and secondary antibodies used for each 
antigen. Following incubation with their respective primary and secondary 
antibodies, all sections were then incubated with streptavidin-biotin-horseradish 
peroxidase complex (Dako), diluted 1:200 in TBS, for 30 min.
Antibody binding was visualised with a solution containing the chromogen DAB for 
8-12min and then terminated with tap water. The sections were then counterstained 
with Mayer’s haematoxylin. Finally, the slides were dehydrated in methanol, cleared 
in xylene to allow the refractive index to be 1. They were then mounted in Depex and 
a coverslip added. They were then viewed under a light microscope at various 
magnifications. For each case of PDV and PDB there was a separate H &E stain. 
When assessing the immunostains of each antigen, the H& E section was viewed at 
the same time to identify the Paget cells. The results were analysed by four
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independent observers [JCC, myself (PEE), Dr Kerstin Rolfe (KJR) and Ann 
ChristineWong Te Fong (ACWTF)].
Sections were scored positive for p53, Cyclin D1 and c-erBb2 if >10% of the Paget 
cell nuclei were stained brown. This value was chosen to indicate a firm cut-off point 
in the antigens immunohistochemical staining above potential background levels. 
Furthermore, such p53-positive levels enabled mutational analysis to be performed 
on dissected specimens (Chapter 3). The full scoring system is indicated in Tables
2.3 and 2.4. Staining intensity was also noted for all markers. Ki67 staining was 
expressed as a percentage of positive Paget cell nuclei to the nearest 5% (Ki67 
staining index). The total staining index for all samples in each clinical group was 
then divided by the number of samples. The result obtained was the ‘mean Ki67 
staining index’ for each group.
When performing double marker expression, two markers were assessed on two 
sections of the same case, each stained with a separate antibody, and not using two 
different stains on the same section.
Due to the limited amount of specimens, sections were stained on two separate 
occasions. They were also scored three times by different individuals to ensure 
reproducibility. There was <5% variation between sections and observers.
Due to the lack of archival material of PDV only cases of PDB were examined for the 
presence of the c-erbB-2 antigen.
2.2.4 Statistical analysis
The Fisher’s exact test was applied for p53, pRb, and cyclin D1 and c-erbB-2 
analysis (since samples were either positive or negative for these proteins). It was 
also used to assess double marker expression in PDV. The Wilcoxon Rank-Sum test
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applied for Ki67 analysis as it was a continuous variable. A p value <0.05 was 
considered significant.
Table 2.1 Antibodies used for IHC
Antigen Source Clone W orking
dilution*
Antigen
retrieval
Incubation 
time and 
temp.
Positive
control
P53 Dako
M7001
D 07 1:100 Microwave lh R.T Ovarian
carcinoma
Ki67 Immunotech.
IM0505
MIB-1 1:25 Microwave l'/zhR.T Tonsils
Cyclin D1
Novocastra
NCL-
CYCLIN D1
DCS-6 1:20 Microwave Overnight
R.T
Breast
carcinoma
PRb Novocastra
NCL-RB
1F8 1:20 Microwave Overnight
R.T
Breast
carcinoma
c-erbB-2 Dako Polyclonal 1:100 Microwave 1 'Ah R.T Breast
carcinoma
* In PBS-BSA, :0.1%
Table 2.2 Non specific binding and secondary antibody used
Primary antibody Solution used to block non­
specific binding
Secondary antibody
P53 NRS 1:10 PBS-BSA lOmin Biotinylated rabbit anti-mouse 
serum 1:200 in 0.1% PBS-BSA
Ki67 NGS 1: 10 PBS lOmin Biotinylated Goat anti­
rabbit/mouse 1:200 in 0.1% 
PBS-BSA
Cyclin D1 NRS 1:5 PBS-BSA lOmin Biotinylated rabbit anti-mouse 
1:400 in 10% NHS
PRb NGS 1:100 PBS-BSA lOmin Biotinylated goat anti-rabbit 
mouse 1:100 in 10% NHS
c-erbB-2 Normal horse serum 1:100 TBS 
20min
Biotinylated horse anti­
rabbit/mouse in 10% NHS
NHS -normal human serum
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Table 2.3 Scoring of primary antibodies used in IHC. Staining was nuclear and
counted as positive.
Antigen % Paget Cells staining Score
Cyclin D l, p53 <10% Normal
>10% Abnormal
PRb <1% Abnormal
>1% Normal
Ki67 Staining scored to the nearest 5% (Ki67 staining index) 
and the mean taken for each clinical group
c-erbB-2 >10% of Paget cells expressing c-erbB-2 and 
membranous staining of the Paget cells was considered 
to be positive.
Table 2.4 Scoring system for p53, cyclin D1 and c-erbB-2
% of Paget cell 
nuclei stained Score
< 10% 0
11-24% 1
25-49% 2
50-74% 3
> 75% 4
2.3 RESULTS
2.3.1. p53 and Ki67 expression in PDV and PDB 
p53
Fifteen cases (29%) of PDV expressed p53 with scores ranging from 1-4, as 
identified by Table 2.4. Four of these cases were associated with an invasive 
adenocarcinoma of which three had a score of 2 and the remaining one had a score of
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4. In PDB, five cases (13%) were positive for p53 with a score range of 1-4. Of the 
five cases two had an associated DCIS with scores of 1 and 2; two cases which had 
both DCIS and invasive carcinoma had scores of 3 and 4, and the remaining case 
which had no underlying DCIS or invasive carcinoma, had a score of 3. In all cases, 
the intensity of the staining was strong. These results are summarised in Table 2.5. 
There was no significant difference between those cases of PDV with or without 
invasive disease or underlying carcinoma. Similarly, there was no significant 
difference in the expression of p53 between cases of PDB associated with DCIS, 
invasive carcinoma, both DCIS and invasive carcinoma and those without. Figures 
2.5 and 2.7 demonstrate p53 expression in PDV and PDB. In both cases the intensity 
of the staining was strong.
Ki67
The mean Ki67 staining index for PDV was 17% and for PDB it was 11%. The mean 
Ki67 staining index for the vulval cases without invasion was 16% and for those with 
invasion it was 19% (Table 2.5). The four cases with invasion that were positive had 
proliferation rates of 5, 5, 50 and 75% respectively and for those cases without 
invasion, the proliferation rates were between 5 and 40%.There was no statistical 
difference in the Ki67 staining index between PDV cases with and without invasive 
disease in PDV. Similiarly, there was no difference between cases of PDB with 
DCIS, with invasive carcinoma, both DCIS and invasive carcinoma and without. 
Figures 2.6 and 2.8 demonstrate Ki67 expression in PDV and PDB respecctively. In 
both cases the intensity of the staining was strong.
The expression of both p53 and Ki67 was examined in PDV to assess whether there 
was any correlation between the markers (Tables 2.6). There appeared to be no 
correlation in the expression of p53 and Ki67.
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Figure 2.5 p53 expression in PDV (x 40) with a score of 4.
Figure 2.6 Ki67 expression in PDV (x 40) with a Ki67 staining index of 40%.
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Figure 2.7 p53 expression in PDB (x 40) with a score of 4.
Figure 2.8 Ki67 expression in PDB (xlOO) with a Ki67 staining index of 40%.
2.3.2. Cyclin D1 and pRb expression in PDV and PDB 
Cyclin D1
Forty-one cases (59%) of PDV stained positive for cyclin D1. Thirty-six of these 
(61%) of PDV without invasive disease expressed this protein. The range of score 
was between 1 and 4. The intensity of staining was mild to moderate. This was 
compared to 5 /10 (50%) cases of invasive PDV which were positive for cyclin D1.
The range of scores was between 1 and 3 and the intensity of staining was also mild 
to moderate. Figures 2.9 and 2.10 demonstrate cyclin D1 expression in PDV with a 
score of 3. The staining intensity was moderate. There was no significant difference 
between those cases of PDV with invasive disease and those cases without.
In PDB, three of 34 cases (8%) expressed cyclin D1 with a score of between 1 and 4. 
Two cases had DCIS alone and the third case had both DCIS and invasive disease. 
Again, the intensity of staining was also mild to moderate. The results are 
summarised in Table 2.5. Figure 2.11 demonstrate Cyclin D1 expression in PDB.
pRb
Thirty-two of seventy-two (44%) cases of PDV had abnormal expression of pRb. 
Twenty-five of sixty two (40%) cases of PDV without invasive disease were negative 
for the protein. This was compared to seven cases (70%) of PDV with invasive 
disease that was negative for pRb. The expression of both pRb and cyclin D1 was 
assessed in each PDV case (Table 2.2). There was a significant difference p= 0.048 
between those cases of PDV with invasive disease and those cases without invasive 
disease expressing both proteins (Table 2.6). Twenty four of thirty-six PDB cases 
(67%) did not express the protein pRb. These included nine cases of DCIS, six cases 
with invasive disease and one case with DCIS and invasive disease. The intensity of 
staining in all cases was mild to moderate. In most cases epithelial cells adjacent to 
the stained Paget cells were also positive for the pRb. The results are summarised in 
Table 2.5. Figures 2.12 and 2.13 demonstrate pRb expression in PDV and PDB.
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Figure 2.9. Cyclin D1 expression in PDV (x 50) with a score
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Figure 2.10 Cyclin D1 expression in PDV (xlOO) with a score of 4.
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Figure 2.11 Cyclin D1 expression in PDB (x 200) with a score of 2.
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Figure 2.12 pRb expression in PDV(xlOO).
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Figure 2.13 pRb expression in PDB (x 200) with a score of 3.
2.3.3. C-erbB-2 expression in PDB
Twenty-five of 38 cases (66%) of PDB were positive for c-erbB-2 expression with a 
score between 2-4. The 25 cases included nine DCIS, two cases with DCIS and 
invasive carcinoma and two cases of invasive carcinoma alone. In all cases the 
staining was in the plasma membrane and the intensity was strong. In 11 cases the 
underlying ductal carcinoma was available for assessment. In all cases the PDB 
results correlated with the epidermal sections of the underlying carcinoma. Similar 
scores were obtained. Figures 2.14 and 2.15 demonstrate c-erbB-2 expression in 
PDB. The expression of c-erbB-2 in combination with other markers was also 
assessed in each PDB case (Table 2.7). No correlation was found between the 
different proteins.
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Figure 2.14 C-erbB-2 expression in PDB(x 200) with a score of 4.
Figure 2.15. C-erbB-2 expression in PDB(xlOO) with a score of 4.
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Table 2.5 Immunoreactivity for p53, Ki67, cyclin D l, pRb and c-erbB-2 
expression in PDV and PDB cases
Antibody Location Without invasive 
Disease
With invasive 
disease
All cases
p53 Vulva
Breast
26% (11/42) 40% (4/10) p=0.62 29% (15/52) 
13% (5/37)
Ki67 Vulva
Breast
*16±22% *19±28% 17 ±23% 
11 ± 19%
Cyclin Dl Vulva
Breast
61% (36/59) 50%(5/10) p=0.75 59% (41/69) 
8% (3/34)
pRb Vulva
Breast
40% (25/62) 70% (7/10) p=0.16 44% (32/72) 
67% (24/36)
c-erbB-2 Breast 66% (25/38)
+DCIS occurs only in PDB. 
* mean ±SD
Table 2.6 Double marker expression in PDV
Proteins Non invasive PDV Invasive PDV
p53 + Ki67 + 8/52(15%) 2/10(20%)
P53- Ki67 + 11/52(21%) 2/10(20%)
Cyclin D1+ pRb+ 21/62(34%) 0/10(0%)
Cyclin D+ pRb- 16/62(26%) 5/10(50%)
Both negative 10/62(16%) 2/10(20%)
Cyclin Dl - pRb + 8/62(13%) 2/10(20%)
+ positive - negative
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Table 2.7 Double marker expression in PDB
Proteins PDB only 
(n = ll)
PDB+DCIS
(n=15)
PDB+DCIS+invasive 
(carcinoma n=3)
PDB+invasive
carcinoma
(n=8)
C-erbB-2 + 
+Ki67
1/11(9%) 1/15(6%) 1/3(33%) 1/8(12%)
C-erbB-2 + 
Ki67-
2/11(18%) 1/15(6%) 0/3(0%) 0/8 (0%)
C-erbB-2
+pRb+
2/11(18%) 2/15(13%) 1/3(33%) 1/8(12%)
C-erbB-2
+pRb-
7/11(64%) 6/15(40%) 0/3(0%) 3/8(37%)
Both
negative
1/11(9%) 2/15(13%) 2/3(67%) 3/8(37%)
C-erbB-2 -  
pRb+
0/11(0%) 1/15(6%) 3/3(100%) 1/8(12%)
2.4. DISCUSSION
2.4.1 p 53 and Ki67 expression in PDV 
p53
Reports of the immunohistochemical detection of p53 in PDV have shown positivity 
ranging from 0-80% (Table 2.8A). A study conducted by Takata et al.(1997) 
demonstrated p53 expression in three of their 14 cases of extramammary 
intraepithelial Paget cases, which included two cases of PDV, neither of which were 
positive. In the three cases that were positive, <5% of the cells were immunopositive 
for p53. Others (Scheistroen et al., 1997) noted only 12% of their PDV cases to be 
positive for p53. The converse was found in the report by Crawford et a l, (1999). 
Their study demonstrated p53 positivity in 16 of 20 cases (80%) of PDV cases. The 
variable results demonstrated could be due to the diversity of different antibodies 
used and different methodologies in the immunohistochemistry. Examples include 
the use of p53 clone Bp53-12, (Kobe) in the Nakamura study, NCL-CM1 p53 clone 
(Novacastra) and DOl p53 clone (Scandinavian Diagnostic Services) in the
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Scheistroen study; the incubation of the p53 antibody overnight at 4°C in the Takata 
study and no apparent antigen retrieval in the Kanitakis study. Similarly, the lack of a 
standardised immunohistochemical criterion to classify a section as positive may 
have played a part. The use of paraffin wax -embedded archival tissue to detect the 
p53 protein also has its limitations. Alteration of the p53 protein during tissue 
fixation processing and the limited choice of antibodies available for use on paraffin- 
embedded archival tissue may all contribute to the diverse results seen in the 
literature. In this current study a section was scored positive only if  >10% of Paget 
cells had positive nuclear staining. Although Crawford et al.,(1999) used the same 
p53 antibody (clone D07, Dako) no details were given with respect to incubation 
times, and antibody concentrations or what criteria were used to classify a section as 
p53 positive.
p53 protein expression has also been examined in other epithelial skin lesions (Ro et 
al., 1993). It was not detected in benign skin disease such as seborrhoeic keratoses or 
keratoacanthomas, but 56% of squamous cell carcinomas and 42% of basal cell 
carcinomas were positive for p53. Dysplastic skin lesions were also positive (27%). 
The authors suggested that p53 may be involved in the progression towards invasive 
malignancy in human squamous skin lesions. Our group has shown that the p53 
protein is over expressed in 69% (47/68) cases of vulval squamous cell carcinoma. 
Rolfe et al., (2003; unpublished data) and we have also demonstrated p53 over 
expression in vulval intraepithelial neoplasia and lichen sclerosus adjacent to vulval 
cancer, but p53 was not expressed in adjacent normal vulva to the vulval squamous 
cell carcinoma. Furthermore, it was not expressed in histologically normal vulval 
biopsies (Rolfe et al., unpublished data).
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In this study, it has been demonstrated that 29% of PDV cases over expressed p53. 
p53 may therefore have a role to play in PDV progression. In addition, in some 
cases, p53 over expression may be associated with progression of PDV towards 
invasive carcinoma, since more samples were p53 positive in PDV cases associated 
with an invasive carcinoma compared to PDV cases without invasive disease, 
although this did not reach statistical significance.
Table 2.8A p53 expression in extramammary Paget’s disease
Study No positive for p53 No of PDV
Kanitakis et al (1993) 0/5 (0%) 0/2 (0%)
Takata etal (1997) 3/14 (21%) 0/2 (0%)
Wieneke et al (1994) 6/12 (50%) 0/3 (0%)
Scheistroen et al (1997) 4/34 (12%) 4/34 (12%)
Nakamura etal (1995) 11/28 (39%) 2/10 (20%)
Crawford et al (1999) 16/20 (80%) 16/20 (80%)
Zhang et al., (2003) 4/14 (28%) 4/14 (28%)
Ki67
There have been no previous studies that have examined Ki67 expression in PDV. 
However, several studies have sought to investigate whether Ki67 could be used as a 
marker of premalignant progression in CIN (Kruse et al., 2004; 2005) and Lichen 
Sclerosus (Rolfe et al., 2001). These studies have demonstrated an increase in Ki67 
expression as the dysplasia increases. It has also been shown to correlate with the 
degree of dysplasia in Barretts oesophagus (Hong et al. 1995) and in ulcerative colitis
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(Andersen et al., 1998). Hendricks et al. (1994) demonstrated that the pattern of Ki67 
immunostaining might have prognostic significance in vulval squamous cell 
carcinoma. In addition to common prognostic factors, patients with a localised Ki67 
labelling pattern tended to live longer than those with a diffuse pattern. Ki67 has also 
been found to correlate with tumour grade and poor survival in vulval squamous cell 
carcinoma. Cases with negative or weak Ki67 expression were associated with a 
better prognosis than those where Ki67 overexpression was high. The mean staining 
index for Ki67 in normal vulva has been shown to be 3.4% (Rolfe et al. in ppn.). The 
mean staining index in the cases in this study of PDV with and without invasive 
disease was 19% and 16% respectively. It is unlikely, on the evidence so far, that 
Ki67 can therefore be used as a prognostic marker in PDV.
Very few studies have examined the correlation between p53 positivity and Ki67 
expression in premalignant vulval lesions. Rolfe et al., (2001) found increased 
expression of p53 and Ki67 in areas of squamous hyperplasia and VIN which 
correlated with subsequent development of invasive squamous cell carcinoma of the 
vulva. In the current study I found no correlation in p53 and Ki67 expression (Table
2.6) in PDV without invasive disease as compared to those cases with invasive 
disease.
2.4.2. pRb and cyclin Dl expression in PDV 
pRb
As discussed earlier, the loss or inactivation of many tumour suppressor genes may 
be an important aetiological or prognostic factor in cancer. Absent or decreased pRb 
expression has been demonstrated in lung cancer (Habour et al., 1988), glioblastomas 
(Venter et al., 1991) and breast carcinomas (Lee et al., 1988). Inactivation of the pRb
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gene by the E7 protein of HPV 16/18 has been demonstrated, and has been associated 
with the development of cervical cancers (Howley et al., 1991). In other studies, pRb 
expression has been the same in normal cervical epithelium, CIN and cervical 
carcinoma (Parker et al., 1997; Sano et al., 1998; Skomedal et al., 1999). pRb 
inactivation has been shown to be involved in the progression of vulval cancer, and 
premalignant VIN and lichen sclerosus (Rolfe et al., 2001). The study also 
demonstrated that loss of pRb expression was associated with poor tumour grade. 
Similarly, Chan et al., (1998) also demonstrated that inactivation of pRb in SCC of 
the vulva increases from stage I to stage IV disease suggesting a role for this protein 
in SCC.
There have been no studies analysing the expression of pRb in Paget cells. In this 
study 70% (7/10) of invasive PDV did not express the protein as compared to 40% 
(25/62) of the cases of PDV without invasive disease. The difference may suggest 
that pRb inactivation is involved in the malignant progression of PDV. Those cases 
of PDV without invasive disease that expressed abnormal pRb may require closer 
clinical surveillance. It is not yet known if such inactivation of pRb is loss or if there 
is a mutation present. Long term clinical follow up of these patients may lead to the 
early identification of disease progression and therefore improve the prognosis.
Cyclin Dl
Cyclin D l has been implicated in a number of cancers and over expression of the 
cyclin Dl gene has been reported in bladder (Proctor et al.1991), head and neck 
(Schuuring et al., 1992), and lung cancers (Berenson et al., 1990).
Rolfe et al., (2001) demonstrated that abnormal expression of cyclin Dl in SCC of 
the vulva was statistically significant as compared to VIN, lichen sclerosus and
104
adjacent normal epithelium, (the group also found that abnormal expression of cyclin 
Dl was associated with a greater depth of invasion). There have been no studies 
analysing cyclin Dl expression in Paget cells of the vulva. It was found in this work 
that 61% (36/59) of cases of PDV over expressed the cyclin Dl protein and 
50 % (5/10) of the cases of PDV with invasive disease. It is not known whether this 
over expression of the cyclin D l protein is due to amplification of the gene or loss of 
gene regulation. This could suggest a role for cyclin Dl in the pathogenesis of PDV 
but not malignant progression.
pRb regulates cyclin Dl expression and both are involved in the regulation of the G1 
phase of the cell cycle. Several studies have sought to address the nature and 
significance of the interaction between cyclin Dl and pRb (Bates et al., 1994; Nielsen 
et al., 1997; Kourakalis et al., 2006). It has been shown that mutation of RBI leads to 
the absence of cyclin Dl function (Bates et al, 1994). Jiang et al. (1993) also 
demonstrated the occurrence of cyclin Dl amplification/over expression and the 
presence of RBI aberrations in a distinct subset of oesophageal tumours. In this 
study, 16 PDV cases without invasive disease (26%) and five cases of PDV cases 
with invasive disease (50%) were positive for cyclin Dl and negative for pRb (Table
2.6). The abnormal expression of cyclin Dl and pRb in these cases, in particular the 
PDV cases with invasive disease may represent significant events in the disease 
process of PDV. There was a significant difference (p=0.048) in the combined 
positive expression of cyclin Dl and pRb in PDV without invasive disease as 
compared with those cases with invasive disease (Table 2.6).
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2.4.3. p53 and Ki67 expression in PDB 
p 53
There have been very few studies (Table 2.8B) examining p53 expression in PDB. 
Kanitakis et al. (1993) reported that four of 12 cases (33%) of PDB over expressed 
the protein and in the study by Nakamura et al. (1995) three of six cases (50%) were 
positive for p53. p53 expression has been well documented in breast carcinomas 
themselves (Thor et al., 1992; Allred et al., 1993; Silvestrini et al., 1993; Jacquemier 
et al., 1994; Rosen et al., 1995). The range of p53 positivity has been shown to vary 
between the different histological types of breast tumour. In one study (Thor et al., 
1992) 68% of medullary carcinomas expressed p53 as compared to 9% of lobular and 
23% of ductal carcinomas. It was not expressed in certain low grade carcinomas 
(tubular or papillary). PDB is usually associated with ductal carcinoma.
Five of the PDB cases (13%) in this current study over expressed p53. p53 protein 
changes may therefore only have a role to play in a minority of PDB cases.
Table 2.8B p53 expression in Paget*s disease of the breast
Study No positive for p53
Uranoetal., (1992) 0/2 (0%)
Kanitakis et al., (1993) 4/12 (33%)
Nakamura et al., (1995) 3/6 (50%)
Fu et al., (2001) 6/14 (43%)
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Ki67
Several studies (Walker et al., 1988; Bouzubar et al., 1989; Isola et al., 1990; Ioachim 
et al., 1996 Fu et al., 2001) have demonstrated that a high Ki67 score is associated 
with high histological grade in breast tumours. In this current study there was no 
correlation between Ki67 score and histological grade of breast tumour associated 
with PDB. In addition, the proliferation rate in PDB itself was generally low.
2.4.4. pRb and Cvclin Dl expression in PDB 
pRb
From the literature there appears to be no study examining the expression of pRb in 
PDB. Several authors have implicated that pRb has a role to play in the pathogenesis 
of breast cancer. (Lee et al., 1988; T’ Ang et al., 1988). Bieche and Lidereau (2000) 
quantified retinoblastoma mRNA by reverse transcriptase- polymerase chain reaction 
in 129 primary breast tumours. From their results they suggested that the RBI gene 
promoted breast tumour aggressiveness and rapid tumour cell proliferation. This 
current study demonstrated similar findings; sixty seven percent of the PDB cases did 
not express the pRb protein which may suggest a role in the pathogenesis of PDB.
Cvclin Dl
Eight percent of PDB cases in this study over expressed cyclin D l. The only other 
study examining cyclin Dl expression in PDB found a much higher figure (Fui et al., 
2001). They found all 14 cases (100%) of their PDB over expressed cyclin D l. The 
discrepancy between this and the study by Fui et al. may be due to differences in the 
methodology e.g. a cocktail of 2 antibodies (clone P2D11F11, Novocastra and clone 
DCS-6, Dako) were used.
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Gredts and Ingram (2000) examined cyclin Dl expression in 81 invasive breast 
carcinomas. They found that 28/81 (35%) of their cases expressed the protein. 
Bartkova et al., (1994) found that half of the 170 primary breast carcinomas over 
expressed cyclin D l. Over expression of cyclin Dl protein or mRNA has been 
demonstrated in high grade DCIS, which shows more frequent recurrences than low 
grade tumours (Weinstat-Saslow et al., 1995; Simpson et al., 1997) However, Van 
Diest et al.,(1997) reported that over expression of cyclin Dl is not by itself an 
indicator of prognosis. The variations in these results could be as a result of the fact 
that over expression of the cyclin Dl protein is linked to the oestrogen receptor (Hui 
et al., 1996) and is up-requlated by activated oestrogen receptor. Overexpression of 
cyclin Dl protein in breast cancer may result in“normal” stimulation by oestradiol.
2.4.5. C-erbB-2 expression in PDB
It has been shown that the c-erbB-2 protein is over expressed in 20 % of all breast 
cancers and 25% of invasive ductal cell carcinomas (De Potter and Schelfhout 1995); 
however, it appears not to be expressed in lobular carcinomas ( Portem et al, 1999).
It has also been shown to be expressed in PDB. Lammie et al., (1989) found that 
41/45 (91%) of their PDB cases over expressed the c-erbB-2 protein. Similarly, Fu et 
al., (2001) found a high percentage of their cases (93%) expressing the protein and 
Brummer et al (2004) demonstrated all five cases of PDB over expressed c-erbB-2 
protein.
The c-erbB-2 protein act as an intermediary between the chemotactic factor secreted 
by epidermal keratinocytes. This chemotactic factor attracts the Paget cells to spread 
into the epidermis and acts via the c-erbB-2 protein. In this study it was found that 
66% of PDB cases over expressed the c-erbB-2 protein. Similarly, those underlying 
ductal carcinomas that were available for assessment had similar scores to the PDB
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section. There was no significant difference in those cases of DCIS and invasive 
carcinomas compared to those that did not express the protein. This study suggests c- 
erbB-2 protein may be important in the pathogenesis of PDB.
There have been reports that c-erbB-2 overexpression may be involved in cell cyle 
regulation through p27, D cyclins, pRb and c-myc (Loden et al., 2003). In this study 
no correlation was found between the cell cycle proteins and c-erbB-2 overexpression 
in PDB.
This is the largest immunohistochemical study on cases of PDV and PDB. These 
lesions are very uncommon and, even after collecting cases from multiple centres, it 
was difficult at times to obtain numbers to allow for statistical significance. A PDV 
register for PDV in the UK has now been established (chapter 6) to gain access to 
more cases. However, with current data, p53, Ki67 and c-erbB-2 
immunohistochemistry does not provide information on prognosis or management. 
pRb may be involved in the pathogenesis of PDV and PDB, and cyclin Dl in the 
pathogenesis of PDV. An even larger series of well documented cases is required if a 
firm conclusion is to be made regarding the role of these cell cycle markers in the 
pathogenesis and prognosis of Paget’s disease of the vulva and of the breast. The 
collaboration with societies such as the British Society for the Study of Vulval 
Disease or the International Society for the Study of Vulval Disease may be able to 
provide more cases that are required.
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CHAPTER 3
MUTATION ANALYSIS OF THE P53 GENE IN 
PAGET’S DISEASE OF THE VULVA AND THE
BREAST
no
3.1. INTRODUCTION
3.1.1. P53 gene
The P53 gene has been described as the most commonly mutated gene in human 
cancers (Hollstein et al., 1999). Located on the short arm of chromosome 17p 13.1., 
it encodes a nuclear phosphoprotein involved in cell proliferation and apoptosis and 
is classified as a TSG. Loss of its function by mutation, deletion or binding of 
proteins (e.g. Mdm2 or E6 from HPV) has been implicated in a number of cancers 
(Barker et., 1990; Sliutz et al., 1997) and has been shown to be useful as a prognostic 
parameter in some cancers (Hietanen et. al., 1995).
Mutations in the P53 gene were first identified in colon and lung cancer in 1989 
(Barker et al., 1989; Takahasi et al., 1989). It was thought at the time that mutations 
in the P53 gene were predominantly localised in exons 5-8. However further analysis 
of the entire coding region has shown a number of mutations in exons 4, 9 and 10 
(Hasimoto et al., 1999; Skaug et al., 2000).
Immunohistochemical staining and DNA sequencing have been used to assess 
abnormalities in the P53 gene. Most abnormalities are point mutations leading to the 
synthesis of a stable mutated protein that accumulates in the nucleus of the tumour 
cells which can be detected by IHC (Dowell et al.,1994). The correlation between 
p53 accumulation and p53 mutation is approximately 80% as frameshift mutations do 
not lead to p53 accumulation and therefore will not be detected by IHC analysis.
Our study analysed exons 5-8 of the P53 gene for mutations because of the greater 
chance of finding a mutation within this region. Furthermore, exons outside this 
region have a significant greater number of frameshift and nonsense mutations.
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3.1.2. Laser Capture Microdissection (LCM)
Microdissection is a long established method to obtain purified cell populations for 
analysis of genetic alterations at the DNA level from both fresh and fixed tissues and 
cell preparations. Microdissection originally involved manual and/or 
micromanipulator guidance of a needle to scrape off an area of interest (e.g. Paget 
cells) of a thin tissue section (Going et al., 1996). This method is highly operator- 
dependent, tedious and can be inaccurate, owing to the uncertainty of the population 
of cells obtained.
The first technological advance in microdissection was Shibata’s procedure of 
selective ultraviolet radiation fractionation, which relied on negative selection: 
ablation of the unwanted areas of tissue on the slide (Shibata et al., 1992). A pigment 
painted over the areas of interest provides a protective shield from ultraviolet 
radiation, which destroys the unprotected tissue and improves the purity of 
subsequent manual microdissection of the selected areas. Micromanipulators have 
improved the accuracy and reliability of manual dissection which, however, remains 
an intrinsically slow process for procuring pure cell populations from tissues. LCM 
was designed to diminish the uncertainties that remain with other manual, ablation 
and mechanical dissection techniques. Operator contact with the tissue during the 
LCM is almost negligible and targeting and procurement is simple, reliable and rapid. 
Multiple similar targets can be easily accumulated onto the same polymer transfer 
film. Individual single laser shots can be used to procure specific cells or cell clusters. 
In addition, multiple shots can be combined in order to procure complicated tissue 
structures. The morphology of all procured microsamples during the microtransfer is 
retained so that further inspection and archiving of images is easily accomplished. 
LCM was first described by Becker in 1996. It was originally conceived and first
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developed as a prototype research tool at the National Institute of Child Health and 
Human Development and the National Cancer Institute of the National Institutes of 
Health. It has since been commercialised and used in many laboratories.
3.1.2.i. Principles of LCM
LCM provides a method for the selective adherence of visually targeted cells and 
tissue fragments to a thermoplastic membrane activated by a low energy infrared 
laser pulse. The system consists of an inverted microscope, a solid state near infrared 
laser diode, a laser control unit, a joy-stick controlled microscope stage (Figure 3.1) 
with a vacuum chuck for slide immobilisation, a camera, and a colour monitor. The 
thermoplastic membrane used for the transfer of selected cells has a diameter of 
approximately 6mm and is mounted on an optically clear cap, which fits on standard 
0.5ml microcentrifuge tubes for further tissue processing (Figure 3.2). The cap is 
suspended on a mechanical transport arm and placed on the desired area of the 
dehydrated tissue section under standard pressure. After visual selection of the 
desired cells guided by a positioning beam, laser activation leads to focal melting of 
the ethylene vinyl acetate membrane. The melted polymer expands into the section 
and fills the extremely small hollow spaces present in the tissue. The polymer 
resolidifies within milliseconds and forms a composite with the tissue. The adherence 
of the tissue to the activated membrane exceeds the adhesion to the glass slide and 
allows selective removal of the desired cells. Laser impulses, usually between 0.5 and 
5 milliseconds in duration, can be repeated multiple times across the cap surface, 
which allow the rapid isolation of large numbers of cells. The selected tissue 
fragments are harvested by simple lifting of the cap, which is then transferred to a 
microcentrifuge tube containing the buffer solutions required for the isolation of the
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molecules of interest (eg. DNA, proteins). The morphology of the transferred cells is 
preserved and can be readily visualised under the microscope.
housing
M embrane
—  C aptured celtsTissue
section1
Joystick
Objective —
Figure 3.1 Diagram of the LCM tissue transfer process.
Ref. cgap-mf.nih.gov.
An advantage of LCM is its speed and precision. Depending on the chosen laser spot 
size, the architecture features of the tissue and the desired precison of the 
microdissection, thousands of cells can be collected within a few minutes. The 
morphology of both the captured cells as well as the residual tissue is well preserved. 
The isolated cells are attached firmly to the cap, minimising the danger of tissue loss. 
In contrast, most other microdissection techniques require the removal of isolated 
cells with the help of a needle tip or using a microcapillary step, requiring skill and 
practice. Because LCM is very fast and does not destroy adjacent tissues, several 
tissue components can be sampled sequentially from the same slide, such as normal
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and neoplastic cells. A disadvantage of LCM is that the microdissected tissue section 
is not coverslipped. Coverslipping would prevent physical access to the tissue 
surface, which is a requirement of any current microdissection. Without a coverslip, 
and the index matching between the mounting media and the tissue, the dry tissue 
section has a retractile quality, which might obscure cellular detail at high 
magnifications. Consequently, several methods have been devised in order to 
optimise microscopic visualisation of the dry, non-coverslipped tissue under high- 
power magnification. A diffusion filter has been designed to diffract light passing 
through the cap, which allows the clear visualisation of cells before microdissection. 
An alternative method to improve the visualisation is the addition of a drop of xylene 
to the tissue to provide wetting and refractive index -matching. The xylene 
evaporates before microdissection.
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The Laser Capture MkrocMssection Process
1 Place cap on tissue
2  Pulse laser at target cells
3  Remove cap with adhered target cells
4  Extract m olecules from target cells
Figure 3.2 Laser capture microdissection process.
Ref. www.mcg.edu.
3.1.3 DNA Extraction
Techniques for the extraction of DNA from fresh tissue, cell or cultured cells have 
been devised. Similarly, they can be applied to archival material such as paraffin 
wax-embedded tissue. These procedures involve incubating the tissue with proteinase 
K (Jackson et al., 1992), a proteolytic enzyme, for times ranging from minutes up to 
24hl or more. After extraction, the proteinase K is inactivated by heat treatment at
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95°C for 10 min, followed by purification of the DNA by a number of extraction 
steps using phenol and chloroform. Phenol: choloroform is used to remove proteins 
from the nucleic acid solution. The DNA is then resuspended in a buffer such as 
Tris-EDTA (ethylene diaminetetra-acetate) or in sterile water.
More rapid extraction of DNA is achieved by boiling the tissue in sterile distilled 
water for approximately 15 min. This can provide DNA of sufficiently good quality 
although yield and quality of DNA are lower than that using the traditional method. 
Quantification of DNA was performed using the Dot Blot test.
3.1.4. Principles of quantification of DNA
DNA concentration can be determined by spectrophotometric measurement or 
Ethidium Bromide fluorescent quantitation. Spectrophotometric determination, 
which involves measuring the absorbance of ultraviolet light of the sample, is ideally 
used when the sample is without any impurities. Readings of wavelengths at ~ 260nm 
should be used. An optical density of one corresponds to approximately 50pg/ml of 
double stranded DNA. If the sample of DNA is very small or there are significant 
impurities then ethidum bromide can be used. The fluorescence emitted by the 
ethidium bromide is proportional to the total mass of DNA; the quantity of DNA can 
therefore be estimated using a series of standards.
3.1.5. Polymerase Chain Reaction (PCR)
Originally devised by Kary Mullis (1986) the polymerase chain reaction (PCR) is an 
in vitro technique that allows the amplification of a specific DNA region that lies 
between two regions of known DNA sequence. The technique is based on repeated 
cycles of high temperature template denaturation, oligonucleotide primer annealing
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and polymerase -mediated primer extension. The simplicity of the reaction, as well as 
its speed and sensitivity, has made it an important tool in a wide variety of 
applications, including the diagnosis and characterisation of infectious and genetic 
diseases (including cancer), forensic analysis, environmental microbiology and 
evolutionary studies.
3.1.6. Basic principle of the PCR
PCR utilises two primers (short, single-stranded DNAs) complementary to the 
opposite strands of the DNA sequence to be amplified. The extension of each primer 
creates a DNA strand including the sequence complementary to the opposite primer. 
After heat-mediated denaturation of the template DNA, the primers bind to their 
respective sequences (anneal) on the template DNA and a DNA polymerase 
synthesises a complementary strand. It is a cyclical process: denaturation of the 
DNA to become single stranded, annealing of the primers and extension by utilising 
nucleotides. This results in exponential amplification of the specific sequence with 
each cycle doubling the amount of specific DNA sequence being amplified.
However, there will come a point whereby additional cycles do not lead to any 
further increase in the DNA yield. This results from exhaustion of the reagents.
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Figure 3.3 Diagram of a PCR cycle.
3.1.7. Primers
Successful specific amplification of a desired target sequence in the PCR is 
dependent upon design and optimal use of a primer pair. The consensus of opinion 
(Innis et al., 1990; Kocher et al; 1991; Old et al., 1994) has provided a set of rules for 
the design of PCR primers:
1. Primers should range from 15-30 bases in length.
2. Base composition should be 50-60% guanine and cytosine.
3. Long runs with more than three or four of the same base should be avoided.
4. Primers should not have a secondary structure (e.g. hairpin loops).
5. Ideally, primers should not contain sequences that are complementary to each
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other. This will avoid the annealing of such primers.
6. Palindromic sequences should be avoided.
7. Primer melting temperatures (Tms) between 55-80 °C are preferred.
The annealing temperature used in the PCR is dependent on both the length and 
composition of the primers. Ideally, it should be between 1 °C and 5 °C lower than the 
lowest Tm value. (Warford et al.,1988).
3.1.8. DNA polymerase
A DNA polymerase enzyme is required to synthesise the new strands of DNA, thus 
joining the two strands of the target DNA as templates and the two oligonucleotide 
primers as starting points for new strand synthesis. The enzyme Taq is the most 
frequently used DNA polymerase and is isolated from the bacterium Thermus 
aquaticus, which works optimally at 72 °C and over a pH range of 7.0-7.5, adding ~ 
100 nucleotides/s to the primer under these conditions. It is a 94kDa protein with a 
half-life of 40 min at 95 °C. It is heat stable and therefore allows the withstanding of 
denaturation cycles. However, it has a lack of 3’—>-5’ exonuclease activity, this can 
lead to misincorporation of nucleotides.
3.1.9. Deoxvribonucleoside triphosphates (dNTPsf
Deoxyribonucleoside triphosphates (deoxyribonucleotides) are essential for the 
synthesis of new DNA. These are heat resistant and have a half-life o f more than 40 
cycles of PCR (Innis et al., 1988). Usually, each dNTP concentration should be 
between 50 pM and 200 pM. This concentration is sufficient to synthesise 6.5pg and
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25(xg of DNA respectively. Deoxyribonucleotides provide energy and nucleosides for 
the synthesis of the new strands of DNA.
3.1.10. Reaction buffer
The most often used is a lOmM Tris-Hcl buffer with a pH range of 8.5-9.0 at 25 °C. It 
also usually contains 50mM kcl. Detergents such as Tween 20, Triton X-100 and/or 
extra protein, e.g bovine serum albumin (BSA) or gelatin may help to prevent the 
precipitation of the hydrophobic Taq.
3.1.11. MeCh
Taq polymerase is an Mg2+ dependent enzyme. In addition, free Mg2+ may affect 
primer annealing, strand dissociation, product specificity and fidelity. The
^  I
concentration of Mg infuences the efficiency of primer to template annealing. It is 
important therefore to optimise the Mg2+concentration in the reaction. In the current 
study 1.5mM of Mg2+ was optimal for PCR amplification of exons 5-8 of P53.
3.1.12. Principles of electrophoresis
Electrophoresis is a technique used to separate, identify and purify DNA fragments. 
The location of DNA can be determined with the fluorescent intercalating dye 
ethidium bromide by direct examination on a UV transilluminator and the DNA 
directly recovered from the gel if required. The gel itself is composed of either 
agarose or polyacrylamide, each of which have attributes suitable to a particular task. 
Agarose is a polysaccharide extracted from seaweed. Agarose gels have a large range 
of separation, but relatively low resolving power. Fragments of DNA from about 200 
to 50,000bp can be separated using standard electrophoretic techniques. Agarose gels
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are used to check the progression of restriction enzyme digestion, to determine the 
yield and purity of DNA, to identify PCR products and to size fractionate DNA 
molecules, which then can be eluted from the gel. It is easy to prepare and is non 
toxic.
Polyacrylamide is a cross-linked polymer of acrylamide. It is more difficult to 
prepare; oxygen inhibits the polymerisation process and also acrylamide is a potent 
neurotoxin. The polyacrylamide gels have a small range of separation, but very high 
resolving power. In the case of DNA, polyacrylamide is used for separating 
fragments of less than about 500bp. Non denaturing polyacrylamide gel is used for 
the separation and purification of fragments of double-stranded DNA, whereas 
denaturing polyacrylamide gel is used for the separation of single -stranded DNA.
In contrast to agarose, polyacrylamide gels are used for separating and characterising 
mixtures of proteins.
3.1.13. Principles of sequencing
DNA sequencing is the process of determining the nucleotide order of a given DNA 
fragment. In most cases DNA sequencing is performed using the chain terminator 
method developed by Frederick Sanger (Sanger et al., 1977).
3.1.13.i. Sanger sequencing
This method uses sequence-specific termination of a DNA synthesis reaction using 
modified nucleotide substrates. Extension is initiated at a specific site on the template 
DNA using a short oliognucleotide primer complementary to the template at that 
region. The oligonucleotide primer is extended using a DNA polymerase. Included 
with the primer and DNA polymerase are the four deoxynucleotide bases, along with
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a low concentration of a chain terminating nucleotide most commonly a di- 
deoxynucleotide. Limited incorporation of the chain terminating nucleotide by the 
DNA polymerase results in a series of related DNA fragments that are terminated 
only at positions where that particular nucleotide is used. The fragments are then 
size-separated by electrophoresis.
3.1.13..ii. Automated commercial sequencing
A new technology has emerged to replace the Sanger Method. Automated 
commercial sequencing is similar to the chain terminator sequencing except that a 
flouresecent dye is attached to the di-deoxynucleotides (ddNTP’s). The reactions are 
performed in a single tube containing all four ddNTP’s, each labelled with a different 
colour dye (Russell, 2002). These dyes fluoresce at different wavelengths, which are 
read via a machine (Metzenberg). As in the Sanger’s method, the DNA is separated 
on a gel, but they are all run on the same lane as opposed to four different ones. It 
has been developed so that more DNA can be sequenced in a shorter period of time 
Automated commercial sequencing was used in this study.
The aim of this chapter was to identify and confirm any mutations in exons 5 to 8 of 
the P53 gene in immunohistochemically positive sections of PDV and PDB. Such 
confirmation would be important in clinical practice in finding improvements in the 
treatment of PDV and PDB and understanding the molecular mechanisms underlying 
these diseases. If a common mutation is found, P53 genechips could be analysed. 
Also, clonality could be performed to provide further information on the origin of the 
underlying invasive carcinoma.
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3.2. METHODS
3.2.1.Sample preparation
Six immunohistochemical samples, three cases of PDV (including two associated 
with invasive carcinoma) and three cases of PDB (one case associated with invasive 
breast carcinoma, one case with DCIS only and the remaining case not associated 
with either) were selected according to the percentage (25-100%) of cells 
immunohistochemically positive for the p53 antibody . The stained slides were 
immersed in xylene solution to remove the coverslip. Prior to LCM the sections were 
rehydrated in graded ethanol rinses (70%, 90% and 100% for 3 min each) and then 
immersed in xylene for 5 min. The final dehydration and xylene steps are crucial for 
successful LCM. Any moisture present in the sample will impede transfer efficacy. 
The slides were then air dryed ready for LCM.
3.2.2. LCM
A CapSure LCM cap (Arcturus, California) was placed onto an area where the Paget 
cells were stained positive for the p53 protein. To capture the cells, the infrared laser 
was pulsed. The laser activates the transfer film on the CapSure LCM cap which then 
expands down into contact with the tissue. The Paget cells adhered to the CapSure 
LCM cap. The CapSure LCM cap with the Paget cells attached to the film surface 
was removed, the surrounding tissue remaining intact. This was then inserted into a 
microcentrifuge tube ready for the addition of the extraction buffer.
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3.2.3. DNA extraction
50pl of the extraction buffer (5mm Tris- Hcl [pH 8.5], 0.5mM EDTA, 0.5mg/ pi 
proteinase K [Sigma-Aldrich], 0.5%v/v Tween 20) was placed into the sterile 
microcentrifuge Eppendorf tube containing the microdissected Paget cell’s DNA. The 
tubes were placed in a thermomixer overnight at 37 °C. The solution was then 
centrifuged at 3500rpm for 10 min and the supernatant removed, placed in a 0.5ml 
sterile Eppendorf and stored at 4 °C. Prior to PCR, proteinase K was inactivated at 95 
°C for lOminutes.
Quantification of the DNA was performed using standard DNA concentrations (MW 
markers) diluted to varying concentrations with ethidium bromide (based on ethidium 
bromide fluorescence). The concentration of the extracted DNA was then estimated 
on a transilluminator.
3.2.4. PCR
4 pi of DNA solution was added to 46 pi of PCR mix giving a final overall 
composition (50 pi): 200pM dNTPs, 75mM Tris-HCL (pH8.8, RT) 1.5mM Mgcl2, 
0.01%v/v Tween 20, 20mM (N tL^ SO4 . PCR cycling conditions, primer amounts 
and primer concentrations are described in Table 3.1.
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Table 3.1 PCR conditions and primers
Loci Primers Primer
concentration
PCR conditons
p53 exon 5 U-GGAATTCTGTTCACTT
GTGCCCTGACTTTCAAC
D-GCAACCAGCCCTGT
CGTCTCTCCA
14pmoles
Denature-94°C for 5 min. initial cycle; 
94°C for lmin for 35 cycles.
Anneal- 60°C for 1 min. x 35cycles; 
Extend- 72°C for lmin. x 35 cycles. 72°C 
for 10 min. for final cycle.
Enzyme:7a<7 ( 2.5units, Advanced 
Biotechnologies)
p53 exon 6 U-CCTGCTTGCCACAGG
TCT
D-CCGGAAATGTGATGA
GAGGT
15 pmoles Denature-94°C for 5 min. initial cycle; 
94°C for lmin for 35 cycles.
Anneal- 60°C for 1 min. x 35cycles; 
Extend- 72°C for lmin. x 35 cycles. 72°C 
for 10 min. for final cycle.
Enzyme: Taq (2.5units, Advanced 
Biotechnologies)
p53 exon 7 U-CCTGCTTGCCACAGG
TCT
D-CCGGAAATGTGATGA
GAGGT
17 pmoles Denature-94°C for 5 min. initial cycle; 
94°C for lmin for 35 cycles 
Anneal- 60°C for 1 min. x35cycles; 
Extend- 72°C for lmin. x 35 cycles. 72°C 
for 10 min. for final cycle.
Enzyme: Taq (2.5units, Advanced
Biotechnologies)
p53 exon 8 U-AGGT AGGACCTG 
ATTTCCTTACTGCC
D-GGAATTCTGAGGCAT
AACTGCACCCTTGGTCT
17 pmoles
Denature-94°C for 5 min. initial cycle; 
94°C for lmin for 35 cycles 
Anneal- 60°C for 1 min. x 35cycles; 
Extend- 72°C for lmin. x 35 cycles. 72°C 
for 10 min. for final cycle.
Enzyme:Taq (2.5units, Advanced
Biotechnologies)
3.2.5. Polyacrylamide gel analysis
10% non-denaturing polyacrylamide gel electrophoresis in a vertical chamber was 
used (Bio Rad). Running buffer used was lxTBE. The gel was run at 200v for 30min, 
8V/cm. Once completed the PCR product was stained in EtBr (0.5jjig/ml in 0.5xTBE) 
and viewed in the transilluminator. Standard MW markers were used for size 
comparison and were also loaded onto the gel alongside bromophenol blue, which 
was used as the tracking dye. PCR was repeated twice to ensure reproducibility of the 
results.
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3.2.6. Purification of PCR product
DNA was purified from the polyacrylamide gel using Qiagen PCR purification kit. 
Five volumes of PBS buffer to one volume of the PCR mix were added, mixed, and 
placed in a mini centrifuge column. This was then centrifuged for one min. The flow­
through was discarded and 0.75ml of the PE (wash) buffer was added to the tube to 
wash the remaining mix. This mix was then centrifuged for one min. The flow­
through was again removed and the mix was again centrifuged for a further min. to 
ensure all the residual ethanol from the PE buffer was removed. The mix was then 
placed in a sterile centrifuge tube along with 30pl of elution buffer. This mixture was 
then centrifuged for 1 min.
3.2.7 Sequencing
Automated commercial sequencing was performed on the PCR product at the 
Divison of Genomic Medicine, University of Sheffield. Sequencing of both DNA 
strands was visualised using an automated sequencer (ABI-Prism). The sequences 
were analysed using Sequence navigator software (ABI).
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3.3. RESULTS
3.3.1. Photomicrographs
Figure 3.4 p53 expression in PDV (x 200) with a score of 4.
Figure 3.5 Photomicrograph of section of PDV following pulse laser of 
Paget cells (x 200).
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Figure 3.6i p53 expression in PDB (x 400) with a score of 4.
Figure 3.6ii p53 expression in PDB (x 100) with a score of 4.
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Figure 3.7 Photomicrograph of section of PDB following pulse laser 
of Paget cells (x 200).
Figure 3.8 p53 Photomicrograph demonstrating the captured PDB 
cells (x 400).
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Figure 3.9 p53 expression in PDB (x 400) with a score of 4.
Figure 3.10 Section of PDB after removal of Paget cells (x 400) 
following LCM.
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Figure 3.11 Photograph of cap demonstrating adherent Paget cells 
(x 400).
3.3.2. Mutation analysis of exons 5-8 of the P53 gene in PDV and PDB
1 CCTCTTCCTA 
TGCCAACTGG 
5 1  CCAAGACCTG 
CCCGCCCGGC 
1 0 1  ACCCGCGTCC 
ACATGACGGA 
1 5 1  GGTTGTGAGG 
AGCGATGGTG 
2 0 1  AGCAG
CAGTACTCCC CTGCCCTCAA CAAGATGTTT
CCCTGTGCAG CTGTGGGTTG ATTCCACACC
GCGCCATGGC CATCTACAAG CAGTCACAGC
CGCTGCCCCC ACCATGAGCG CTGCTCAGAT
Figure 3.12 Sequence (5’-3') of genes in exon 5 of the P53 gene in PDB associated 
with infiltrating carcinoma.
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1 CCCTCCTCAG CATCTTATCC GAGTGGAAGG AAATTTGCGT
GTGGAGTATT
51 TGGATQACAG AAACACTTTT CGACATAGTG TGGTGGTGCC
CTATGAGCCG
101 CCTGAGGTCT GGTTTGCAAC TGGGGTCTCT GGGAGGAGG
Figure 3.13 Sequence (5'-3') of genes in exon 6 of the P53 gene in PDV associated 
with invasive disease.
1 TTATCTCCTA GGTTGGCTCT GACTGTACCA CCATCCACTA
CAACTACATG
51 TGTAACAGTT CCTGCATGGG CGGCATGAAC CGGAGGCCCA
TCCTCACCAT
101 CATCACACTG GAAGACTCCA GGTCAGGAGC CACTTGCCAC
CCTGCACACT
151 GGCCTGCTGT GCCCCAGCCT CTGCTTGCCG CTGACCCCTG
GGCCCACCTC 
20 1  TTACCGAT
Figure 3.14 Sequence (5’-3') o f genes in exon 7 of the P53 gene in PDV.
1 TCTCTTTTCC TATCCTGAGT AGTGGTAATC TACTGGGACG
GAACAGCTTT
51 GAGGTGCGTG TTTGTGCCTG TCCTGGGAGA GACCGGCGCA
CAGAGGAAGA
101 GAATCTCCGC AAGAAAGGGG AGCCTCACCA CGAGCTGCCC
CCAGGGAGCA
151 CTAAGCGAGG TAAGCAAGCA GGACAAGAAG CGGTGGAGGA
GACCAA
Figure 3.15 Sequence of gene (5'-3!) in exon 8 of the P53 gene in PDB associated 
with DCIS.
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Table 3.2 Analysis of exons 5-8 of the P53 gene in PDV and PDB
Sample Diagnosis p53 IHC positivity P53 sequencing
Case no 42 PDV without 
invasive disease
>75% wt
Case no 28 PDV
with invasive disease
>40% wt
Case no 30 PDV with invasive 
disease
>75% wt
Case no 130 PDB with DCIS >25% wt
Case no 92 PDB with DCIS and 
invasive caricnoma
>50% wt
Case no 131 PDB without DCIS 
or invasive disease
>50% wt
There appeared to be no mutations in exons 5-8 of the P53 gene in any o f 3 cases of 
PDV or the 3 cases of PDB.
3.4. DISCUSSION
3.4.1. LCM vs other microdissection techniques in cancer studies 
The microdissection of cells in premalignant lesions is a requirement for identifying 
molecular genetic-changes occurring during the process of tumouriogenesis. LCM 
has the advantage over other common microdissection techniques such as manual 
tissue dissection, laser microbeam microdissection (LMM) and laser pressure 
catapulting (LPC) in that it is a very rapid method, versatile and very precise. Manual 
dissection has the disadvantage of not being suitable for small lesions (<50cells) and 
the high risk of contamination, and LPC has the danger of destroying the actual cells 
that is required. (Walch et al. 2000). LMM can be more time consuming and requires 
greater skills than LCM however, the smaller laser beam diameter and the high 
precison for 1-10 cells makes LMM more suited for microdissection of tissue at 
single cell level.
134
Because of its speed and it does not destroy adjacent tissues, LCM can be used to 
sample both normal and neoplastic cells together on the same slide and thousands of 
cells can be collected within a few minutes. Combining IHC, LCM and sequencing of 
the P53 gene Ren et al. (1997), identified mutations in the P53 gene within 
synchronous dysplasia, carcinoma in situ and invasive sqamous carcinoma of the 
skin. p53 mutations were also detected in the adjacent normal keratinocytes. LCM 
was also used to evaluate p53 mutations in premalignant oesophageal lesions and 
oesophageal adenocarcinoma (Djaalivand et al., 2004).
LCM was used in this study because of ease and rapidity of the procurement of Paget 
cells and also it allowed the preservation of the morphology of the transferred Paget 
cells, which could be visualised readily under the microscope
3.4.2. Loss of P53 function in tumours
Many studies have shown that there is an important association between activation of 
oncogenes and /or inactivation of tumour suppressor genes and the development of 
most human cancers. Some identified genes and their respective proteins have been 
suggested to be useful as prognostic markers for particular cancers (Duffy et 
al.,1993). Mutation and loss of heterozygosity (LOH) of the P53 gene has been 
reported to be the most common cancer -related genetic change (Hollstein et. al 
1991). As well as loss of function in certain cancers, the function of the p53 protein 
may also be abrogated through binding to viral oncoproteins, and Mdm2. HPV E6 
has been shown to bind the P53 gene product and degrade it. (Wemess et al.1990). 
Mutational analysis of the P53 gene has been well documented in vulva and breast 
cancer. P53 expression has been shown to be a useful prognostic marker in vulvar 
carcinoma, VIN and squamous cell hyperplasia (Hantschmann et al., 2005) and 
Chulvis et al., (2004) have demonstrated mutations in the P53 gene in two of their
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recurrent /progressive cases of VIN. Very few studies have sought to examine 
mutations in the P53 gene in PDV. Takata et al. (1997) examined the LOH at the loci 
17pl3.1 where the P53 gene is located, in 14 cases of extramammary Paget’s disease, 
two of which were cases of PDV, and direct sequencing of exons 5-8 of the P53 gene 
in 8 cases. No LOH or mutations were found in any of the cases. This would be in 
keeping with our results although it does not correlate with the immunohistochemical 
results in the current study which suggested that p53 protein expression may be 
involved in disease progression in PDV.
In breast cancer the P53 gene has been extensively studied and several studies have 
demonstrated mutations in the P53 gene and its role as prognostic marker in breast 
cancer patients (Bems et al., 1998; Falette et. Al.,1998). Wt p53 expression has also 
been demonstrated in primary breast cancers (Nenutil et al., 2005; Marchetti et al., 
2003). As discussed in chapter 2, very few studies have examined p53 expression in 
PDB ( Table 2.8B Page 106) and so far no study have performed mutational analysis 
of the P53 gene in PDB. No mutation was found in any of the three cases of PDB, 
which included a case of DCIS, and DCIS with invasive carcinoma.
3.4.3 Expression of wt p53:
Sequencing results in the current study suggest that wt p53 is being expressed as 
there were no mutations found at exons 5-8 of the P53 gene. Overexpression of the 
p53 protein could be due to the fact that the mutation is in fact located outside of the 
exon 5-8 region. Only exons 5-8 were sequenced in the six cases of PDV and PDB in 
the current study. However, mutational analysis of the whole P53 genome have 
shown that it is uncommon for mutations to lie outside the region of exons 5-8. 
Different cellular and environmental conditions may cause the accumulation of wt
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p53. DNA damage from cytotoxic drugs, smoking and viruses are known to be 
inducers of p53 and hence cause the accumulation of the p53 protein.
PDV and PDB may habour molecular changes that could inactivate the p53 pathway 
and hence the accumulation of wild type p53.
3.4.4. Further work:
More samples need to be analysed to assess P53 mutations in PDV and PDB. 
Applying LCM to this work would be valuable in assessing clonality of PDV and 
PDB. This would allow us to determine the origin of the Paget cells in those cases of 
PDV with invasive/associated adenocarcinoma. DNA chip analysis could be a 
method used to assess the P53 gene as it combines a good sensitivity and a high 
throughput (Ahrendt et al., 1999).
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CHAPTER 4
MARKERS OF ANGIOGENESIS IN PAGET’S DISEASE 
OF THE VULVA AND THE BREAST
Poster Presentations:
VEGF-A and disease progression in Paget’s disease of the vulva and breast.
Ellis P., Wong Te Fong L.F., Rolfe K.J. MacLean A.B Perrett C.W 181st meeting of 
the Pathological Society Nottingham July 2000.
PDECGF/TP expression in Paget’s disease of the vulva. Blair Bell Society 
Meeting. Ellis P., Wong Te Fong L.F., Rolfe K.J. MacLean A.B Perrett C.W London 
Oct 2000. .
Oral presentation:
An examination of the role of VEGF-A and PD-ECGF/TP in Paget’s disease of the 
vulva and breast. Ellis P., Wong Te Fong L.F., Rolfe K.J. MacLean A.B Perrett C.W. 
International institute of Anticancer Research. Athens Greece June 2001
Abstract:
Vascular Endothelial Growth Factor (VEGF) and disease progression in Paget’s 
disease of the vulva and breast. Ellis P., Wong Te Fong L.F., Rolfe K.J. MacLean 
A.B Perrett C.W. Journal of Pathology 192ss:P23A 2000
Full publication:
Ellis P.E., Wong Te Fong L.F., Rolfe K.J., Crow J.C., Reid W.M.N., Davidson T., 
MacLean A.B Perrett C.W (2002). The role of vascular endothelial growth factor-A 
(VEGF-A) and Platelet-derived endothelial cell growth factor/ thymidine 
phosphorylase (PD-ECGF/TP) in Paget’s disease of the vulva and breast. Anticancer 
Res.22: 857-861.
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4.1. INTRODUCTION
4.1.1. Angiogenesis
Angiogenesisis is the formation of new capillary blood vessels from pre-existing 
microvessels. Vasculogenesis is the process whereby the early vascular plexus forms 
from the mesoderm by the differentation of angioblasts (vascular endothelial cells that 
have not yet formed a lumen), which subsequently generate primitive blood vessels. 
Mesoderm-inducing factors of the fibroblast growth factor family are crucial in 
inducing paraxial and lateral plate mesoderm to form angioblasts and haematopoietic 
cells. Angiogenesis precedes and sustains tissue growth and therefore plays a critical 
role in normal tissue physiological processes such as reproduction, wound healing or 
bone remodelling (Philips et al., 1990; Brown et al.,1992 ; Clarke et al.,1996). 
Angiogenesis involves the migration of endothelial cells from the parent vessel 
towards a chemo-attractant. As well as the ability to promote endothelial cell 
migration, angiogenic factors must also degrade the matrix through which the cells 
move. Endothelial cell invasion, as part of the angiogenic process, involves secretion 
of urokinase-type plasminogen activator and its inhibitor (PAI-1). Fine maintenance 
of the proteolytic balance seems to be crucial for the correct development of new 
blood vessels. Having migrated, the endothelial cells must proliferate, lay down their 
own basement membrane and form a lumen, which is the basis of the new capillary. 
This sequence of events-cell migration, matrix degradation and proliferation is the 
basis of angiogenesis. Many different factors have been identified which promote the 
proliferation, migration and morphogenesis of new blood vessels, both in embryonic 
development and in diseases such as cancer. The most extensively studied is vascular 
endothelial growth factor (VEGF).
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4.1.l.i. Tumour Angiogenesis
Angiogenesis is an important process in tumour growth and metastasis (Figure 4.1) 
and allows tumours to facilitate their expansion beyond a certain volume (Folkman, 
1990,1995). In theory, the development of tumours is associated with two phases of 
tumour growth (Brem et al., 1977; Adcock et al.,1982; Burke et al., 1987; Folkman et 
al., 1987;). First is the “pre-vascular phase”, which is seen with various intraepithelial 
neoplasias, can persist for many years, and is not capable of metastasis (Weidner et 
al., 1991). In contrast, the “vascular phase” is characterised by rapid tumour growth 
and the potential for metastasis (Weidner et al., 1991). The vascular phase, otherwise 
termed the “angiogenic phase’, occurs when a tumour possesses the innate ability to 
potentiate its own growth. Oncogenesis of this type, whereby the extent of 
neovascularisation is directly correlated with metastasis, has been demonstrated in 
several cancers e.g. breast carcinoma (Weidner et al., 1991) and in cutaneous 
melanoma (Brem et al., 1977; Adcock et al., 1982; Burke et al., 1987). In situ 
carcinomas may exist for a long time without neovascularisation and, as a 
consequence, they remain limited to a small ~ few mm3. Some tumour cells then 
switch to the angiogenic phenotype and recruit new capillary blood vessels that 
support the growth of both the angiogenic and non-angiogenic cells (Folkman et 
al.,1989; Kandel et al., 1991; Weidner et al., 1991; Folkman, 1994). Expansion of the 
tumour mass is made possible, not only because of perfusion of blood throughout the 
tumour, but also because of the paracrine stimulation of tumour cells by numerous 
growth factors and matrix proteins that are produced by the new capillary 
endothelium (Nicosia et al., 1986; Hamada et al., 1992; Rak et al., 1994). The switch 
to the angiogenic phenotype itself depends on a net balance of positive angiogenic 
factors released by the tumour (Sinevad et al.,1989; Bouck et al., 1990; Dameron et
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al., 1994). The positive factors include a fibroblast growth factor (FGF) (Maciag et 
al., 1984), pFGF (Shing et al.,1984), VEGF (Ferrara et al., 1989), angiogenin (Fett et 
al.,1985) and angiopoietin -1. (Folkman and Shing, 1992). They can be exported from 
tumour cells, mobilised from the extracellular matrix, or released by macrophages 
attracted to the tumour. Although this increased production of positive angiogenic 
factors (Table 4.1) is necessary, it is not sufficient for the angiogenic phenotype. 
Negative regulators of angiogenesis must also be decreased. Of several naturally 
occurring negative regulators of angiogenesis thrombospondin-1 was the first for 
which it was demonstrated that the inhibitor is produced constitutively by normal cells 
but down-regulated during tumourigenesis. Thus, by the time tumour cells have 
become angiogenic, they are producing only 4-6% of the thrombospondin originally 
generated by their normal precursor cells (Folkman and Shing, 1992).
Table 4.1 Some endogenous regulators of angiogenesis
Stimulators of angiogenesis Inhibitors of angiogenesis
VEGF Thrombospondin-1
PDECGF/TP Vascular endothelial growth factor inhibitor
Angiopoietin -1 and Angiopoietin-2 Angiostatin
Insulin -like growth factor Endostatin
Fibroblast growth factor Vasostatin
Epidermal growth factor Fragment of platelet factor 4
Placental growth factor Derivative of prolactin
Tumour necrosis factor Interleukin-1,12
Matrix metalloproteinase Restin
Ephrin family Placental proliferin-related protein
Transforming growth factor Anti-thrombin III
Granulocyte macrophage colony 
stimulating factor 
Interleukin-8
Meth-land Meth-2 
Interferon a and Interferon p
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Figure 4.1 An example of tumour angiogenesis.
Ref www.itb.cnr.it
4.1.2. VEGF
Vascular endothelial growth factor (VEGF), a heparin binding glycoprotein, was 
originally identified in the media conditioned by normal bovine pituitary folliculo- 
stellate cells ; Ferrara and Henzel ,1989) and by a variety of transformed cell lines 
(Levy et al.,1989;Tisher et al., 1989; Conn et al.,1990) It is a multifunctional 
cytokine with potent angiogenic activity. VEGF stimulates angiogenesis through its 
action as an endothelial mitogen and its ability to increase vascular permeability. 
There are several members o f the VEGF family (Table 4.2): VEGF, VEGF-B, 
VEGF-C (Andre et al.2000), VEGF-D (Olofson et al.,1998), VEGF-E, and the 
structurally-related placenta growth factors (PIGFs 1-3). VEGF, VEGF B, VEGF E 
and P1GF stimulate angiogenesis as well migration and proliferation of endothelial 
cells. VEGF C and VEGF D have been shown to stimulate lymphangiogenesis and
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act as lymphangiogenic growth factors (McColl et al., 2004). The five isoforms of the 
VEGF transcripts encode polypepetides consisting of 121,145,165,189 and 206 
amino acids and they are generated by alternative splicing (Neufeld et al., 1999). The 
variation in size suggests different roles. VEGF 121 and 165 are secreted soluble 
forms, (VEGF 165 can also remain bound to the plasma cell memebrane) whereas 
VEGF 145,189 and 206 remain associated with cell plasma membrane surface 
because of their interaction with proteoglycans. The biological effects of VEGF are 
mediated through the activation of specific tyrosine kinase receptors expressed 
mainly on angioblasts and endothelial cells (Neufeld et al., 1999). VEGF acts 
selectively on endothelial cells by binding to specific class III receptor tyrosine 
kinases. The receptor VEGFR-2 binds VEGF, VEGF-C and VEGF-D and promotes 
the proliferation and motility of endothelial cells. VEGF-R1 shows 10-fold lower 
kinase activity than VEGF-R2, and has been proposed to act as a negative regulator 
of VEGF-induced endothelial -cell proliferation (Hiratsuka et al., 1998). VEGF-R3, 
which in adults is exclusively expressed in lymph node endothelial cells, binds 
VEGF-C and VEGF-D (Neufeld et al., 1999). VEGF is distributed widely in different 
tissues. Several studies have demonstrated its over expression in a variety of tumours 
including those of the breast (Toi et al.,1994) and vulva (MacLean et al.,2000). Anti 
VEGF therapy has been used in clinical trials to inhibit angiogenesis and is showing 
promising results in cancer treatment therapies. Bevacizumab, a recombinant 
humanized monoclonal antibody to VEGF has been shown to induce apoptosis of 
breast cancer cells and is currently been used in combination with 5-FU for the first- 
line treatment of metastatic colorectal cancer (Wedham et al., 2006). Figure 4.2 
demonstrate VEGF involvement in the angiogenesis signalling cascade.
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Table 4.2 Roles of VEGF receptors and respective ligands
VEGF receptor Ligands Function
VEGFR-1 VEGF, VEGF-B, P1GF Essential for vascular development, 
VEGF signalling, 
release of growth factors
VEGFR-2 VEGF, VEGF-C, VEGF-D 
VEGF-E
Essential for vascular development, 
proliferation, migration, 
angiogenesis
VEGFR-3 VEGF-C, VEGF-D Proliferation, migration, role in 
vascular development, 
signals for lymphangiogenesis
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Figure 4.2 The Angiogenesis signalling cascade.
Ref: rex.nci.nih.gov/behind the news/uangio/13uangio/l 3uangio.htm
4.1.3. Platelet derived- endothelial growth factor/Thymidine phosphorylase
Originally isolated from platelets in 1987, platelet-derived endothelial growth factor 
(PD-ECGF) is a 47 kilo Dalton (kDa) protein that promotes cell growth and 
chemotaxis in endothelial cells in vitro and angiogenesis in vivo (Ishikawa et al, 
1998). It is a non-glycosylated intracellular protein, with no heparin binding activity, 
found in various tissues such as placenta, lung and endometrium (Fox et al., 1995) as 
well as in certain cancers e.g vulva (Wong Te-Fong et al.,2000), breast (Yonenga et
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al., 1998) bladder and colorectal tumours (O’Brien et al., 1996). The enzyme 
thymidine phosphorylase (TP), which catalyses the reversible phosphorylitic 
breakdown of thymidine to thymine and 2- deoxyribose-1-phosphate, has been 
identified as being homologous to PD-ECGF (Furukawa et al., 1992). The by-product, 
2-deoxy-D-ribose, has been shown to have angiogenic activity (Haraguchi et al.,
1994). The role of PD-ECGF/TP is primarily metabolic, controlling the thymidine 
levels in the cell. Accumulation of thymidine is toxic to the cells and causes errors in 
DNA replication, integrity, and repair. However, high levels of TP have been 
identified in macrophages (Fox et al., 1995) suggesting that it provides other functions 
such as angiogenic activity.
4.1.4. Microvessel density (MVD)
MVD is a measure of tumour angiogenesis. Several studies have demonstrated an 
association between increasing tumour MVD and prognosis in solid tumours 
(Weidner, 1995,1997 Weidner and Folkman, 1996). MVD has been shown to be a 
prognostic indicator in breast cancer (Tsutsui et al., 2003) and vulva cancer (Obermair 
et al.,1996), and is increased in cases of VIN 3 as compared to cases of VIN1 and 
VIN 2 (Saravanamuthu et al., 2003). It is considered the gold standard in estimating 
angiogenesis.
4.1.5. Endothelial cell markers
A variety of endothelial cell markers have been used to identify microvessels for the 
purpose of counting. The most commonly used include factor VIII related antigen 
(F8RA)/ von Willebrand factor (vWF), CD31/PECAM-1, and CD34 (Fina et al.,
1990; Johnson et al., 1993). F8RA forms part of the vWF complex and plays a critical
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role in the process of haemostasis (Franchini et al. 2006). CD31(PECAM-1) a 
platelet- endothelial cell adhesion molecule is a transmembrane glycoprotein involved 
in cell adhesion (DeLiser et al., 1994) and CD34 is a surface glycoprotein of unknown 
function (Krause et al., 1996). Tissue sections are stained with antibodies specific for 
the endothelial cell marker expressed by the vascular endothelial cells. Ideally the 
markers should be specific, only being expressed by endothelial cells and not other 
cell types, and occur on endothelial cells.
In our group three endothelial markers have been used, vWF, CD31 andCD34 to 
measure tumour vascularity. vWF was chosen as the endothelial cell marker to be 
used in this study due to its consistent staining and good contrast between 
microvessels and other components.
The objective of this study was to determine whether the expression of angiogenic 
growth factors VEGF, PD-ECGF/TP, and MVD differed between intra-epithelial 
PDV and those cases of Paget’s disease associated with an invasive adenocarcinoma, 
and their expression in PDB, in order to investigate their role as potential prognostic 
marker and indicate some of the molecular mechanisms underlying PDV and PDB 
angiogenesis. I also investigated whether growth factors worked synergistically.
4.2. METHODS
4.2.1. Sample collection and preparation
Table 4.3 Number of PDV archival cases available for IHC
Marker PDV without invasive 
disease
PDV with invasive 
disease
VEGF 44 10
PD-ECGF/TP 44 10
VWF 60 8
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Table 4.4 Number of PDB archival cases available for IHC
Marker PDB PDB with 
DICS alone
PDB with 
DCIS and 
invasive 
carcinoma
PDB with
invasive
carcinoma
VEGF 38 14 6 6
PD-ECGF/TP 38 14 6 6
VWF 33 13 6 6
Preparation and collection was as per section 2.2.1, chapter 2, Pages 85.
4.2.2.Immunohistochemical staining with the VEGF-A. PD-ECGF/TP and vWF 
(F8RA) antibodies
Sections were deparaffmised in xylene and rehydrated in different percentages of 
ethanol up to distilled water for 10 min. 3% hydrogen peroxide was placed on the 
sections to block endogenous peroxidase for 10 min. They were then placed in 
distilled water for 10 min at 37°C.
Optimisation of the protocol was performed for all primary antibodies as per section
2.2.2, chapter 2, Pages 86. Optimisation of the antigen retrieval method was 
performed using 3 different methods for each protein; microwaving in sodium citrate 
buffer (pH 6.0) for 10 mins at 750 watts; protease digestion (bacterial protease Type 
24, Sigma) using 12.5mg in 100ml of PBS at 37°C for lOmins, and finally using no 
antigen retrieval. Different protease digestion times (using different time intervals of 
5, 7.5,10 and 15mins.) and protease concentrations (6, 10,12.5, and 15mg) as well as 
different incubation times and temperatures were also tried. The optimal incubation 
time and temperature was identified when specific staining was achieved with the 
lowest concentration of antibody but still providing intense staining. The optimal 
protease concentration used wasl2.5mg and the digestion time was lOmins. The
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endothelial cell markers were each assessed in terms of specificity and staining. 
CD31/PECAM-l and CD34 cross reacted with other tissue components such as 
macrophages. vWF gave the most consistent staining pattern. Table 4.5 summarises 
the optimal conditions used for IHC.
Table 4.5 Antibodies and optimum conditions used for immunohistochemistry
Antigen Source Clone
Working
dilution
Antigen
retrieval
Positive
Control
Negative
control
Incubation
Time
Incubation
temp.
Human
VEGF
R&D
Systems
Abingdon,
UK
26503.11,
IgG2B
1:40 Protease
digestion
Placenta IgG2B overnight 4°C
Human
PD-
ECGF/TP
John 
Radcliffe 
Hospital, 
Oxford,UK
P-GF.44C 1:10 Microwave Placenta TBS 1 hr RT
vWF Dako,Ely, 
Cambs,UK
F8/86 1:40 Protease
digestion
Placenta PBS 1 hr RT
CD34 Serotec,
Oxfordshire,
UK
QBEN
D/10
1:300 Microwave Placenta PBS 1 hr RT
CD31 Dako,Ely, 
Cambs,UK
JC/70A 1:50 Microwave Placenta PBS 1 hr RT
Biotinylated rabbit anti-mouse serum (Dako, Cambs. UK) dilution 1:400 inTBS, PBS 
(vWF) was used as the secondary antibody in all cases.
4.2.3 MVP counting
Any brown staining endothelial cell or endothelial cell cluster that was clearly 
separate from adjacent microvessels, tumour cells, and other connective tissue 
elements was considered as a single countable microvessel. Large vessels with lumina 
greater than approximately seven red blood cells were excluded from the count.
Blood vessels were detected by a method similar to Bosari et al. (1992).
Areas of highest neovascularisation, i.e containing the highest number of capillaries 
and small venules per area (“ hot spots”) were found by scanning the whole tissue 
section at low power (x 40 and xlOO) using a light microscope. Five fields in each 
section with the highest number of hot spots were selected. The highest vessel density
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(HVD) of five fields at x 200 field (0.74mm2 under the light microscope) and x 400 
field (0.17mm2 under the light microscope) was recorded and the average vessel 
density (AVD) was also recorded in these five fields at x200 and x400. This was 
repeated using the HVD and AVD of three fields. The area of HVD and AVD using 
five fields did not differ significantly from the values obtained using three fields and 
therefore the analysis was performed using three fields. Individual MVD were made 
at both x200 and x400 magnification within each hot spot. The MVD is confined to an 
area within 500pm of dermal tissue just beneath the basement membrane of the 
epidermis and expressed as HVD/AVD per mm2.
Sections were stained on 3 separate occasions to ensure reproducibility. Results were 
analysed by three independent observers (PEE, ACWTF and JCC). In all cases there 
was <5% variation in results between sections and observers.
4.2.4. Scoring
4.2.4-i. VEGF quantification
The slides were viewed under a light microscope at a magnification of xlOO. The 
presence of VEGF was quantified by counting the number of positive (brown) focal 
areas representing VEGF per cm 2 of tissue section and scoring them accordingly. 
VEGF imunostaining was examined for in both the cytoplasm and nucleus of the 
cells. A section was scored positive if 10 or more focal areas were present in the 
dermis and epidermis combined. A focal area consisted of 10 or more stained cells. 
The number of focal areas in the epidermis and dermis were also recorded. The blood 
vessels of the placenta express VEGF and were used as the positive control. When 
scoring the sections for VEGF, the positive control is checked alongside the PDV or 
PDB section to determine whether VEGF is expressed in the section.
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4.2.4.ii. PD-ECGF/TP quantification
A section was scored positive for PD-ECGF/TP if 10% or more Paget cells were 
stained brown at x 100 magnification. Samples were assessed to the nearest 5% of 
cells showing positivity. Both nuclear and cytoplasmic positivity was counted. 
PD-ECGF/TP expression was noted in the epidermal and dermal cells. The intensity 
of staining was also recorded; 1= mild intensity; 2 =moderate intensity and 3=strong 
intensity.
4.2.5. Statistical analysis
Statistical analysis was performed using the Fisher exact test for PD-ECGF/TP and 
VEGF expression. The Mann-Whitney U test was used to compare MVD expression 
between invasive and non invasive cases of PDV and cases of PDB with DCIS and 
invasive carcinoma. The McNemar’s chi squared test was used for analysing double 
marker expression of VEGF and PD-ECGF/TP. A p value of <0.05 was considered 
significant.
4.3. RESULTS
4.3.1. VEGF expression in PDV and PDB
None of the Paget cells present in PDV or PDB expressed VEGF. Positive focal areas 
of VEGF expression (Figure 4.3) were found within the epidermal and dermal cells in 
14 cases of PDV. Of the fourteen cases 5 were PDV with invasive disease. VEGF 
expression (Figures 4.5 and 4.6) was also seen in the epidermal and dermal cells in 
23 cases of PDB, seventeen of these cases were associated with an underlying 
tumour. VEGF expression was found to be significantly higher (p=0.001) in the 
breast epidermal and dermal cells compared to the vulval epidermal and dermal cells.
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Table 4.6 and 4.7 summarises the results.
Figure 4.3 VEGF expression in PDV (x 200).
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Figure 4.4 Negative control for VEGF expression in PDV 
(x 200).
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Figure 4.5 Two VEGF focal areas in PDB (x 50).
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Figure 4.6 A VEGF focal area within stromal cells of the dermis in PDB (x 400).
4.3.2. PD-ECGF/TP expression in PDV and PDB.
Twenty-two of the 54 vulval cases (41%) expressed PD-ECGF/TP with both nuclear 
and cytoplasmic staining present in 50% or more of the Paget cells. Figure 4.7 
demonstrates PD-ECGF/TP expression in PDV. Of the vulval cases associated with 
invasive adenocarcinoma four (40%) expressed PD-ECGF/TP. Table 4.8 demonstrate 
the results. Seventy-five percent of Paget cells were positive in one case, 50% of the 
cells positive in two cases and 20% in the remaining case. There was no difference in 
the intensity of staining of the epidermal and dermal cells between those cases of 
PDV without invasive disease and those with invasive disease. In PDB 21/38 (55%) 
cases expressed PD-ECGF/TP. The staining intensity was moderate and the range of 
positivity was 10-75% of cells. PD-ECGF/TP expression in the underlying breast 
DCIS and invasive carcinoma is demonstrated in Table 4.9. PD-ECGF/TP expression
was noted to be significantly higher in the breast epidermal and dermal cells 
(p<0.0005) compared to the vulval epidermal and dermal cells.
PDV and PDB cases that expressed both VEGF and PDECGF/TP are shown in 
Table 4.6. PD-ECGF/TP expression was also found to be significantly different 
compared to VEGF in the vulval Paget cells and in the vulval epidermal and dermal 
cells with p <0.001. Similiarly, a significant difference was also found between 
VEGF and PD-ECGF/TP expression in breast Paget cells, p <0.001. No significant 
difference was found between VEGF and PD-ECGF/TP expression in breast 
epidermal and dermal cells.
Table 4.6 VEGF and PD-ECGF/TP expression in PDV and PDB.
Location VEGF
expression
PDECGF/TP
expression
VEGF/ 
PD-ECGF/TP 
double marker 
expression
Vulval Paget cells 0/54 22/54 (41%) -
Vulval epidermal 
and dermal cells 14/ 54 (26%) 29/54 (54%) 12/14(85%)
Breast Paget cells 0/38 21/38(55%) -
Breast epidermal and 
dermal cells 23/38(61%) 36/38 (95%) 19/38 (50%)
Table 4.7 VEGF expression and associated underlying breast tumour
Cases VEGF expression in epidermal/dermal 
cells and underlying tumour
PDB with DCIS 11/13(85%)
PDB with DCIS and carcinoma 2/6 (33%)
PDB with carcinoma alone 4/6 (67%)
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Table 4.8 Immunoreactivity for PD-ECGF/TP expression in relation to 
invasive carcinoma
Location
Without invasive 
adenoncarcinoma
With invasive 
adenocarcinoma
Vulva 18/44 (41%) 4/10 (40%)
Table 4.9 PD-ECGF/TP expression in breast Paget cells and underlying DCIS 
and invasive carcinoma
Cases %Paget cells 
stained
Underlying 
tumour and % 
positive
Case 90 20% Carcinoma 75%
Case 91 75% Carcinoma 75%
Case 96 50% DCIS/Carcinoma
10%
Case 98 0% DCIS 0%
Case 99 50% DCIS 75%
Case 102 0% DCIS 50%
Case 103 75% Carcinoma 75%
Case 113 40% Carcinoma 10%
Case 116 5% DCIS/Carcinoma
5%
Case 143 0% Carcinoma 50%
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Figure 4.7 PD-ECGF/TP expression in PDV (x200).
4.3.3. Microvessel Density in PDV and PDB
There appeared to be no significant difference in the MVD in intraepidermal PDV as 
compared with PDV associated with invasive disease. Figures 4.8 and 4.9 
demonstrate microvessels in PDV. MVD was also found to be similar in PDB 
associated with DCIS, invasive disease and PDB alone. Figure 4.10 demonstrates 
micro vessels in PDB. The mean HVD and AVD values are summarised in Tables 
4.10 and 4.11.
Correlation with VEGF and MVD, PD-ECGF/TP and MVD expression in 
intraepidermal PDV and PDV with invasive disease x200 field are shown in Tables 
4.12A and 4.12B. There appeared to be a trend towards higher HVD and AVD in 
VEGF and PD-ECGF/TP positive cases of invasive PDV compared to those cases that 
did not express VEGF or PD-ECGF/TP. However, the numbers were too small to 
perform statistical analysis. Similar results were demonstrated at x 400 field. There
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was no significant difference between the MVD in those cases positive or negative for 
VEGF or PD-ECGF/TP in PDV without invasive disease. Similar analysis was 
performed on PDB. There was no significant difference between PDB cases with 
DCIS, PDB with DCIS and carcinoma, and PDB with carcinoma.
Table 4.10 Mean values of the MVD in PDV with and without invasive disease
Cases n HVD(x200) AVD(x200) HVD(x400) AVD(x400)
PDV without 
invasive disease
60 39 (22.7) 27(19.3) 60.5 (35.3) 40.1 (22.3)
PDV with invasive 
disease 8 27.6 (26.3) 19.1 (17.97) 71.2 (55) 51.2 (31.8)
«, number of cases. The SDs of the mean are given in brackets.
Table 4.11 Mean values of the MVD in PDB
Cases n HVD(x200) AVD(x200) HVD(x400) AVD(x400)
PDB with DCIS 13 34.1 (17.7) 23 (16.1) 68(18.4) 50.9(18.2)
PDB with DCIS/ 
invasive carcinoma
6 19.7(13.5) 15.8(12.0) 53 (27.1) 43.7 (22.3)
PDB with invasive 31.1 (5.4) 22.8 (4.3) 114.7 (82.3) 95 (71.8)carcinoma 6
«, number of cases.r"he SDs of the mean are given in brackets.
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Table 4.12A. MVD in correlation to VEGF and PD-ECGF/TP in PDV 
cases without invasive disease
PDV without 
invasive 
disease
it Mean HVD 
(x200)
Mean AVD 
(x200)
VEGF positive 19 44.6 (27.9) 32.4 (27.7)
VEGF negative 17 33.4 (22.7) 23.24(16.9)
PD-ECGF/TP
positive
25 41.2 (27.7) 29.3 (25.9)
PD-ECGF/TP
negative
21 41.4(19.9) 29.1 (13.9)
n, number of cases. The SDs of the mean are given in brackets.
Table 4.12B. MVD in correlation to VEGF and PD-ECGF/TP in PDV
cases with invasive disease
PDV with 
invasive 
disease
it Mean HVD 
(x 200)
Mean AVD 
(x 200)
VEGF positive 4 40.5 (27.2) 28.04(16.9)
VEGF negative 3 4.1 (0) 2.2 (0.78)
PD-ECGF/TP
positive
4 34.1 (32.9) 23.5(21.67)
PD-ECGF/TP
negative
2 16.9(18.1) 11.5(11.9)
n, number of cases. The SDs of the mean are given in brackets.
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Figure 4.8 vWF expression demonstrating microvessels in PDV (x200). 
Arrows = Paget cells.
Figure 4.9 vWF expression demonstrating microvessels in PDV (x200).
Arrows = Paget cells.
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Figure 4.10 vWF expression demonstrating microvessels in PDB (x200).
Arrows = Paget cells.
4.4. DISCUSSION
4.4.1 .VEGF expression in PDV
4.4. l.i VEGF in general pre-malignant lesions
It is becoming increasingly apparent that angiogenesis may be acquired early in 
tumour development and increased angiogenic activity has been reported in several 
pre-malignant lesions. Guidi et al. (1995) examined the association between 
angiogenesis and the expression of VEGF mRNA in cervical intraepithelial neoplasia 
and invasive cervical carcinoma by in situ hybridisation. From their results they 
demonstrated that VEGF expression and MVD were significantly increased in high- 
grade intraepithelial lesions and invasive cervical carcinoma compared to low-grade 
cervical lesions and benign squamous epithelium. Dobbs et al., (1997) demonstrating 
VEGF expression using immunohistochemistry found similar results; a significant
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increase in VEGF and MVD expression from normal cervix through CIN I to CIN III 
to invasive squamous cell carcinoma. VEGF expression has also been found to be 
significantly upregulated in oesophageal metaplasia, dysplasia and adenocarcinoma 
of the oesophagus (Kitadai et al., 2004; Vallbohmer et al., 2006) and benign, 
premalignant and malignant prostate tissue (Kollermann et al., 2001)
4.4.1 .ii VEGF in vulval lesions
Several studies have demonstrated VEGF expression in pre-malignant and malignant 
vulval disease (Obermair et al., 1996; Bancher-Todesca et al., 1997; MacLean et al. 
2000). Bancher-Todesca et al., using immunohistochemistry, examined the 
expression of VEGF and micro vessel density (MVD) in vulval intraepithelial 
neoplasia (VIN). They demonstrated that for both VEGF expression and MVD the 
differences between VIN I and VIN III and between VIN II and VIN III were 
statistically significant and the highest values were found in VIN III. In addition, it 
has been reported that patients with vulval tumours with a high MVD and moderate 
to strong VEGF expression had a poorer survival rate compared to those patients with 
low MVD or weak VEGF expression (Obermair et al., 1996). In contrast, Doldi et al. 
demonstrated that VEGF mRNA expression was high in VIN, with no difference 
between VIN I and VIN III, but low in vulval cancer. Work from our group 
(MacLean et al., 2000) has shown that VEGF is not expressed in normal vulval tissue 
but is expressed in 6% of VIN lesions and 92% of vulval cancers. Wong Te-Fong, et 
al (2000) has demonstrated similar results. Such data suggest that VEGF in both 
invasive and potentially invasive (VIN) lesions of the vulva may be involved in 
malignant progression and may be a valuable marker of vulval lesions which go on to 
become invasive.
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To my knowledge there has been no previous study that has examined VEGF 
expression in Paget’s disease of the vulva. VEGF was not expressed by Paget cells, 
even in those cases associated with invasive disease. However, VEGF expression was 
found in the epidermal and dermal cells in 26% cases of PDV, five of these were 
cases with invasive disease. The significance of this is not clear. As stated earlier, 
VEGF is not expressed in normal vulval lesions (MacLean et al., 2000). It is 
therefore possible that in some cases of PDV the presence of Paget cells stimulate 
epidermal and dermal cells to release VEGF and instigate angiogenesis.
4.4.2. PD-ECGF/TP expression in PDV
4.4.2.i PD-ECGF/TP in pre-malignant and malignant lesions
Very few studies have examined PD-ECGF/TP expression in precancerous lesions.
Increased expression has been demonstrated in dysplastic oesophageal tissue as
compared to normal oesophageal mucosa (Kitadai et al, 2004). It has also been
examined in cervical intraepithelial neoplasia and invasive cervical carcinoma (Isaka
et al., 2002) and vulva intraepithelial neoplasia (Wong-Te-Fong et al., 2000;
MacLean et al., 2000) These studies demonstrate an increase in the expression or 
intensity of PD-ECGF/TP in invasive cervical carcinoma and vulvar cancer relative 
to the premalignant lesions and suggest that PD-ECGF/TP may have a prognostic 
value.
Because of the relative rarity of PDV, my numbers are small; however, 40% of the 
PDV cases with invasive disease expressed PD-ECGF/TP compared to 41% of cases 
without invasive disease. Epidermal and dermal cells were positive in 54% of cases. 
There was a signifcant difference in expression of PD-ECGF/TP and VEGF in the 
vulval Paget cells and the vulval epidermal and dermal cells. The data suggest that
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PD-ECGF/TP maybe involved in PDV pathogenesis, but it is not a marker of 
malignant progression of PDV.
4.4.3. Double marker expression in PDV
One of the questions that remained to be answered was whether VEGF and PD­
ECGF/TP acts synergistically. Wong-Te-Fong et al., (2000) and MacLean et al., 
(2000) have both assessed these angiogenic factors in VIN and vulval cancers. There 
appeared to be no relationship between VEGF and PD-ECGF/TP expression in VIN 
and vulva cancers. In the current study I found a good correlation between VEGF in 
the epidermal and dermal cells, and PD- ECGF/TP. Eighty five percent of cases 
coexpressed both markers in PDV. This suggests a possible synergistic effect but 
whether this effect plays a role in the angiogenesis and the malignant transformation 
of PDV remains to be elucidated.
4.4.4. MVD in PDV
The method of MVD has been used in many studies to investigate the role of 
angiogenesis in patients with cancer. The role of angiogenesis as determined by 
MVD has been examined in vulvar lichen scleorosus, VIN and vulvar cancer 
(Bancher-Todesca et al., 1997; Saravanamuthu et al., 2003) MVD is not a useful 
parameter in determining potential malignant progression in vulvar lichen sclerosis 
but could be valuable in VIN 3 in determing progression to invasive disease 
(Saravanamuthu et al., 2003). Other techniques have been used to measure tumour 
angiogenesis. The Chalkey method measures the relative area of vessel profile in a 
high-density region of the tumour as compared to MVD, which measures the density
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of the vessels (Hansen et al., 2004). Hollingsworth et al. (1995) described a method 
using vascular volume. Determination of vessel density by vascular volume 
represents an average of the entire section rather than focusing on areas of most 
intense neovascularisation and therefore does not reflect the angiogenic activity of 
tumour cells or metastatic potential.
vWF was used as the endothelial cell marker of choice because of its consistent 
staining and it was less likely to react with other tissue components as compared to 
CD31 and CD34 endothelial cell markers. However, vWF does have its limitations; it 
is unable to distinguish between new and pre-exisitng blood vessels; the monoclonal 
antibody E-9 is the only endothelial marker capable of distinguishing between the 
two but can only be used on frozen sections (Wang et al.,1994). vWF can also be 
identified in lymphatic endothelial cells and platelets (Mietten et al., 1994). From the 
results obtained in my study, MVD appears not to be a useful parameter in 
determining which cases of PDV will develop invasive disease. There did appear to 
be a trend towards higher MVD in VEGFand PD-ECGF/TP positive cases in PDV 
with invasive disease as compared to those cases that did not express VEGF or PD­
ECGF/TP.
4.4.5 VEGF expression in PDB
4.4.5.i VEGF in preinvasive breast disease
Angiogenesis in preinvasive lesions may differ from that seen in invasive tumours. 
The increase in vessels is seen in the normal stroma around or beneath the in situ 
tumour rather than between clusters of tumour cells, as in invasive disease.
Therefore, in in situ tumours, angiogenic factors produced by inflammatory and
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stromal cells may play a greater role than those derived from the tumour cell 
themselves (Rice et al., 2002)
Up-regulation of VEGF protein and mRNA expression has been reported in DCIS 
and other preinvasive lesions of the breast. (Yoshiji et al., 1996; Guidi et al.,1997 
Heffelfinger et al., 1999; Viacara et al., 2004). VEGF mRNA expression by tumour 
cells in DCIS was greater than that observed in adjacent benign ductal or lobular 
epithelial cells in 96% of the cases (Guidi et al., 1997). In another study, VEGF 
protein expression was increased in carcinoma in situ relative to atypical hyperplasia 
of the breast (Heffelfinger et al., 1999). However, they did not find any difference in 
VEGF expression between carcinoma in situ and invasive disease. We found that 
VEGF was not expressed in the Paget cells of PDB but was found to be expressed in 
the dermal and epidermal cells in 61 % of PDB cases. The presence of Paget cells in 
some cases of PDB may stimulate epidermal and dermal cells to release VEGF and 
promote angiogenesis. However, other angiogenic factors may be involved.
4.4.5.ii VEGF in invasive breast disease
VEGF expression is well documented in invasive breast cancer (Lawerence et al., 
1995; Locopo et al., 1998; Rajesh et al., 2004; Choi et al., 2005). It has been 
suggested that VEGF is an independent prognostic indicator for invasive breast 
cancer; increased expression correlated with poorer prognosis in node positive and 
node negative patients (Gasparini et al., 1997). There was no correlation between 
grade of underlying tumour and VEGF expression. In the current study VEGF 
expression was highest in the epidermal and dermal cells associated with PDB with
166
DCIS (85%; Table 4.7) followed by PDB with carcinoma alone (67%) and then PDB 
with both DCIS and carcinoma (33%).
4.4.6. PD-ECGF/TP expression in PDB
PD-ECGF/TP expression has been shown to be increased in breast carcinomas as 
compared to benign breast disorders (Yonenga et al., 1998). In Toi et al., (1995) 
study, 39% (39/100) of their invasive ductal carcinoma cases were positive for PD­
ECGF/TP expression. Nagaoka et al., (1998) examined PD-ECGF/TP expression in 
117 invasive breast carcinomas. They assessed PD-ECGF/TP in the cancer and 
stromal cells separately. Ffity two percent of cases were classified as PD-ECGF/TP 
positive in cancer cells and 37.6% of cases were classified as positive for PD­
ECGF/TP in stromal cells. They demonstrated that PD-ECGF/TP expression in 
stromal cells correlated with both tumour size and microvessel count. They also 
found that relapse free survival and overall survival were significantly worse in 
patients with PD-ECGF/TP -positive stromal cells than in patients with negative 
cells. They concluded that PD-ECGF/TP expression in stromal cells correlated with 
tumour angiogenesis and can be used to predict the prognosis of patients with 
invasive breast cancer. In my study, Paget cells in 55% of PDB cases expressed PD­
ECGF/TP and in 95% of cases it was positive in the epidermal and dermal cells. 
There was concordance in the expression of PD-ECGF/TP in the underlying tumour 
and Paget cells in 80% of the cases. These results suggest that PD-ECGF/TP may 
play an important role in the promotion of angiogenesis in PDB, and it may be that 
the PD-ECGF/TP produced from the epidermal and dermal cells may play a greater 
role in the angiogenic process than the PD-ECGF/TP derived form the Paget cells 
themselves.
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4.4.7. Double marker expression in PDB
Toi et al., (1995) suggested that both VEGF and PD-ECGF/TP may be involved in 
the neovascularisation of human breast cancers. They found a significant correlation 
in the expression between the two markers, and were frequently coexpressed in the 
highly vascularised breast tumours with a high microvessel count. Sixty three percent 
of the tumours expressed both markers. In the current study, epidermal and dermal 
cells and Paget cells coexpressed VEGF and PDECGF/TP in 50% of PDB cases.
However, there were no differences in the expression of the markers and the type of 
tumour. These results suggest there is an unlikely to be a synergistic effect from the 
coexpression of these markers, and it plays no role in the disease progression in PDB.
4.4.8. MVD in PDB
Several studies have shown that MVD is a prognostic factor for several solid tumours 
(Bosari et al. 1992; Horak et al. 1992; Macchiarini et al. 1992.; Weidner et al., 1993) 
Weidner and co workers demonstrated that intratumour MVD is an independent 
factor for breast carcinoma (Weidner et al., 1992). They found a correlation between 
MVD and overall and relapse free survival in patients with early-stage breast 
carcinoma. Hall et al. (1992) were unable to find a relationship between MVD and 
breast metastasis. Another study, demonstrated no correlation between VEGF and 
MVD in 34 node negative breast carcinoma. (Rajesh et al., 2004)^Similarly, Viacara 
et al., 2004) did not find any correlation between VEGF expression and MVD in their 
preinvasive lesion of the breast. In my study there appeared to be no correlation 
between MVD and VEGF or PD-ECGF/TP in PDB associated with PDB with DCIS 
or DCIS+ carcinoma. In conclusion my data suggest that VEGF and PD-ECGF/TP
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may have a role to play in the angiogenesis of PDV and PDB but not their malignant 
progression. In Paget’s disease of the breast, the angiogenic process may continue 
even after migration of Paget cells from the underlying tumour and that angiogenic 
factors released from the epidermal and dermal cells may have an important role in 
the angiogenesis of PDV and PDB. MVD does not appear to be a useful parameter in 
determining disease progression in PDV or PDB.
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CHAPTER 5: CELL ADHESION MOLECULE 
EXPRESSION IN PAGET’S DISEASE 
OF THE VULVA ANDTHE BREAST
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5.1. INTRODUCTION
5.1.1. Cell Adhesion
The evolution of specific mechanisms for cell adhesion was one of the crucial steps 
in the development of metazoan organisms. During embryonic development adhesive 
interactions play a major role in triggering a variety of morphogenetic processes 
including cell motility, growth, differentiation and survival. Such interactions may 
involve either direct cell-cell contact or adhesion to extracellular matrix (ECM) 
networks. These processes involve two critical and distinct stages, namely a binding 
event mediated through cell-surface receptors, which specifically and directly interact 
with the external ligand, and a morphogenetic event, which depends on the activity of 
force-generating cytoskeletal systems within the cells. Studies have shown that these 
transmembrane structural linkages are also involved in signal transduction 
(Bershadsky et. al.1995; Gumbiner, 1996). Malignant transformation is characterised 
by disruption of cytoskeletal organisation and altered adhesion dependent responses. 
The growth of many cancer cells is ‘anchorage independent’, and such cells have 
often lost the negative regulation of cell proliferation conferred by excessive cell-cell 
adhesion (i.e. have lost the ‘contact inhibition of growth’; Ben-Ze’ev,1997). The 
reduction or lack of cell-cell adhesion molecules have been demonstrated in various 
carcinomas and have been implicated in the invasion and metastatic process 
(Shiozaki et al., 1991). Abnormal expression of cell-cell adhesion molecules has been 
reported in various skin carcinomas and has been implicated in the process of 
invasion and metastasis (Tada, 1996). Loss of expression of these molecules in PDV 
and PDB may determine which cases may have appeared in the epidermis secondary 
to an underlying adenocarcinoma, or which go on to develop invasive disease.
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Figure 5.1 Schematic diagram of cell-cell adhesion.
5.1.2 Cellular Junctions
Historically, cellular junctions have been placed into two major categories on the 
basis of their morphological appearance: the occludens junctions, which display a 
sealing o f the intracellular space, and regulate the permeability characteristics o f the 
paracellular space between adjacent cells (Gumbiner, 1987), and the adherens 
junctions, which have a widened intracellular space and are associated with various 
forms of submembranous densities termed plaques (Farquhar and Palade 1963).
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These submembrane plaques of cell-cell and cell-ECM junctions are contacts that 
link the adhesion receptors to the cytoskeleton (Gumbiner, 1997). These structures 
consist of protein complexes that are specific either to cell- ECM junctions (i.e. talin 
and paxillin) or to cell-cell junctions (a- and p-catenin and plakoglobin) or that are 
shared by both types of adhesion (i.e vinculin, a-actinin, zyxin and tensin). These 
submembrane plaques contain, in addition, a wide array of signalling molecules 
(kinases and phosphatases), suggesting that the structure and composistion of these 
plaques may have an important role in adhesion-mediated signalling (Gumbiner, 
1996). The adherens (adhering) junctions (AJs) can again be divided into two 
distinct morphological groups. One is represented by the intermediate junctions 
(zonula, fascia or punctum adherens), which have a ~ 20nm intracellular space and 
loosely woven submembranous mats associated with actin microfilaments. The other 
type is the desmosome (macula adherens), which has a wider (~30nm) intracellular 
space bisected by a midplate and a pair of dense, rigid and parallel cytoplasmic 
plaques associated with bundles of intermediate filaments (Farquhar and 
Palade,1963; Drochmans et al., 1978; Cowin et al., 1985a).
5.1.3. Zonula Adherens Junctions
The zonula AJ’s are required for both the establishment and maintenance of epithelial 
layers (Geiger et al., 1989). In addition, these junctions have been identified in 
several other cell types including cardiac myocytes and fibroblasts. Zonula AJ 
subserve several important functions including mediating intercellular adhesion, 
sensing the presence of neighbouring cells, and anchoring the actin cytoskeleton. 
Zonula AJs are multiprotein complexes that are assembled around cell adhesion 
molecules called cadherins. Cadherins are a multifunctional family of calcium-
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dependent, transmembrane, glycoproteins which promote cell-cell adhesion 
(Takeichi, 1991). The cadherin extracellular domain mediates homophilic 
interactions between like cadherin molecules on neighbouring cells, while the 
intracellular domain interacts with several cytoplasmic proteins which include: a- 
catenin, B-catenin, y -catenin (plakoglobin) and the tyrosine kinase substrate pl20cas 
(Ozawa, 1990 ; McCrea, 1991; Knudsen, 1992). Cadherin-catenin interactions are 
required for complete cadherin activity to regulate the interaction between cadherins 
and the actin-based cytoskeleton (Ozawa,1990; McCrea, 1991; Takeichi, 1991).
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Figure 5.2 Cellular junctions.
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5.1.4. Plakoglobin
Plakoglobin, also known as y -catenin, is an 83kDa protein that localises to the 
cytoplasmic face of both desmosomal and adherens junctions (Cowin et al., 1986). 
Plakoglobin was first demonstrated to associate with the desmosomal cadherins,
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desmoglein and desmocolin, and was subsequently shown to associate with the 
classical cadherins E- and N- cadherin (Knudsen et al.,1994). 
plakoglobin is highly homologous to p-catenin, and both possess dual roles in cell 
adhesion and in the Wnt /Wingless signalling pathways. Within AJs, plakoglobin 
links the cell adhesion molecule E-cadherin to the actin cytoskeleton via a-catenin. It 
also has an additional role to play in cell adhesion as an integral component of 
desmosomes (Cowin et al.,1996; Smith et al., 1998). Catenin-mediated cell adhesion 
and Wnt signalling both play multiple roles in various developmental processes and 
also in the adult organism. In contrast to frequent mutations in p-catenin in tumours 
of various types (Morin, 1999; Polakis, 1999) only one case of a plakoglobin 
mutation has been reported, and that was in gastric cancer (Caca et al.,1999). 
Moreover, plakoglobin expression is often lost during cancer progression (Aberle et 
al., 1995) and restoration of plakoglobin expression in several highly tumourigenic 
cells lacking plakoglobin can suppress their tumourigenicity (Simcha et al.,1996; 
Ben-Ze’ev,1997).
5.1.5. E-cadherin
E-cadherin is a member of the multifunctional family of calcium ion-dependent 
transmembrane glycoproteins with molecular masses ranging between 120-140 kDa. 
They promote and maintain cell adhesion in virtually all multicellular organisms. The 
cadherin superfamily comprises over fourty proteins which are, on average, 50-60% 
homologous. Cadherin expression is required for the assembly of cells into solid 
tissues and, importantly, cadherins are expressed in a tissue-specific fashion 
(Takeichi, 1991). E-cadherin (also known as a ‘classic’ cadherin along with N- and P- 
cadherin) interacts in a homophilic manner, i.e. cadherins of the same type bind to
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each other. Other members of the cadherin superfamily include the desmosomal 
cadherins (desmogleins and desmocollins), which are associated with the keratin 
filament network, and the proto-cadherins which are distantly related to the classical 
cadherins in their extracellular domains and differ completely in their cytoplasmic 
tail (Suzuki,1996). E- cadherin consists of an extracellular domain, a transmembrane 
segment, and a cytoplasmic domain. The most direct effect of cell-cell adhesion is on 
morphogenesis, i.e on the assembly of individual cells into highly ordered tissues and 
organs through cell-cell adhesion junctions (Gumbiner, 1996). These interactions 
between cells involve transmembrane cell adhesion receptors of the cadherin family 
(Takeichi, 1995).
Levels of E-cadherin, which is expressed in epithelial cells, are often reduced in 
many carcinomas, including carcinomas of the head and neck, oesophagus, skin, 
thyroid, lung, breast, stomach, liver, kidney, pancreas, colon, bladder, prostate and 
female genital tract (Vleminckx et al.,1991). E-cadherin downregulation also usually 
correlates with lower survival rates (Vleminckx et al.,1991). In vitro studies have 
demonstrated that in cultured cells restoration of E-cadherin levels by cDNA 
transfection leads to suppression of invasiveness and of the tumourigenic capability 
of cells (Frixen et al., 1991; Vleminckx et al. ,1991) and can decrease protease 
secretion by the tumour cells (Miyake et al., 1995). In addition to downmodulation of 
E-cadherin levels, studies have demonstrated that mutations/deletions in the E- 
cadherin gene can correlate with malignancy in tumour cells. For example, 50% of 
diffuse-type gastric carcinomas harbour a mutation that affects the calcium ion- 
binding site of E-cadherin (Becker et al., 1994) and deletions in the extracellular 
domain of E-cadherin were reported in infiltrative lobular breast carcinoma (Berx et 
al. 1995).
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5.1.6. 0- catenin
P-catenin is a 92kDa protein which shares 70% amino acid identity with both 
plakoglobin (y-catenin) and the product of the Drosophila segment polarity gene 
armadillo (Peifer, 1990; McCrea, 1991; Takeichi, 199). The armadillo protein is part 
of a multiprotein junctional complex and is a required component of the Drosophila 
wingless wnt signal transduction pathway (Peifer, 1990; McCrea, 1991). B-catenin, 
plakoglobin and pl20cas are homologous but distinct proteins which contain 
between 10-13 copies of a 42-44 amino acid motif first identified in the armadillo 
protein and referred to as armadillo repeats. These armadillo repeats mediate the 
interaction between P-and y-catenin and the cadherin cytoplasmic domain. In addition 
they mediate p-catenin’s interaction with the tumour suppressor protein 
Adenomatous Polyposis Coli (APC; Rubinfeld, 1993; Peifer, 1994). Regulation of p- 
catenin levels by the Wnt pathway is essential for ensuring proper development and 
differentiation of many tissues. Wnt signalling elicits a very broad range of catenin- 
dependent and independent responses (Peifer and Polakis, 2000), including 
specification of cell fate at different stages of development (Wodarz and 
Nusse,1998), regulation of cell proliferation (Gat et al.,1998; Kolligs et al., Orford et 
al.,1999) and survival (Orford et al.,1999), cytoskeletal remodelling to define cell 
polarity (Peifer and Polakis, 2000) and cell motility (Wallingford et al., 2000).
In the absence of a Wnt signal, cytosolic p-catenin is rapidly eliminated by the 
ubiquitin -proteasome pathway (Aberle et al., 1997). This is initiated by the action of 
a multi-component destruction complex containing glycogen synthase kinase3p 
(GSK 3p ), axin and APC protein; which promotes the phosphorylation of P- 
catenin at its N terminus.
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Several studies have demonstrated elevated P- catenin levels in various cancers (Ben- 
Ze’ev, 1997; Ben-Ze’ev and Geiger, 1998; Morin 1999; Polakis, 1999). These 
increases in p- catenin levels result mostly from mutations in p- catenin itself that 
affect residues in the GSK 3p phosphorylation site critical for p-catenin degradation. 
In addition, mutations in key components of the degradation machinery, such as APC 
or axin, have also been detected in some tumours, e.g. colorectal carcinomas (Morin 
et al., 1997; Satol et al., 2000). The result of such mutations is an elevation in p- 
catenin content and activation of P-catenin lymphoid enhancer factor/T-cell factor 
(LEF/TCF)- dependent transcription. This could contribute to uncontrolled cell 
proliferation and tumour progression (Gumbiner, 1997; Korinek et al., 1997). Several 
target genes of the p- catenin -LEF/TCF-binding sites might provide the molecular 
basis for growth regulation by P- catenin signalling. Induction of the genes that 
encode c-Myc and cyclin D l, whose promoters contain LEF/TCF-binding sites, 
might provide the molecular basis for growth regulation by p-catenin signalling 
( Shtutma et al., 1999; Tetsu and McCormick, 1999), whereas the induction of 
matrilysin expression could promote cell invasion (Crawford et al., 1999). In 
addition, PPAR5, a transcription factor involved in colon cancer, is also a target for 
the P- catenin- LEF/TCF complex (He et al., 1999).
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Figure 5.3 Mechanisms of inactivation of plakoglobin, E-cadherin and B-catenin 
in cell mediated adhesion system in human cancers.
5.1.7. Principles of In situ hybridisation (ISH)
5.1.7.i. Introduction
ISH is a method of localising either mRNA within the cytoplasm or DNA within the 
chromosomes of the nucleus, whereas IHC is a method of detecting the presence of 
specific proteins in cells or tissues. The method uses hybridisation of the sequence of 
interest to a complementary strand of a nucleotide probe. ISH takes advantage of the 
specific annealing of complementary nucleic acid molecules, which can be DNA and 
/or RNA, through hydrogen bonds formed between bases attached to the sugar- 
phosphate backbone. Any nucleic acid sequence can therefore be specifically 
detected by use o f a probe that is the ‘antisense’, complementary sequence. ISH 
involves the:
(a) Generation of a nucleic acid probe, labelled to enable subsequent detection.
(b) Preparation of chromosome spreads or fixation of tissues.
(c) Pre-treatment of tissues to increase accessibility o f target nucleic acid.
(d) Hybridisation of labelled probe to chromosomes or tissues.
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(e) Washing under conditions that remove non-hybridised probe.
(f) Detection of the labelled probe, revealing the location of the target cellular 
nucleic acid.
5.1.7.ii. Preparation of material
In general material used for ISH is treated in a number of ways:
a) It is fixed in formalin, as one would normally fix tissues for histology, and 
embedded in paraffin wax.
b) It is snap frozen, and embedded in a special support medium for 
cryosectioning. The sections are subsequently lightly and rapidly fixed in 
paraformaldehyde, just prior to processing for hybridisation.
c) Cells in suspension can be cytospun onto glass slides and fixed with ethanol 
or methanol
d) Preparation of metaphase chromosomal spreads, normally fixed with a 
mixture of methanol and acetic acid.
5.1.8. Choice of Probes
Probes can be as small as 20-40 bases or up to 1000 bases. Optimisation of 
conditions used is very important. The strength of the bonds between the probe 
and the target plays an important role. The strength decreases in the order RNA- 
RNA, DNA-RNA, DNA-DNA. This stability is in turn influenced by the 
temperature, pH, guanine (G) and cytosine (C) content of probe, concentration of 
Na+ and the amount of formamide in the reaction mixture.
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5.1.9. Probe types
A number of different types of nucleic acid probes can be prepared for use in 
ISH:
5.1.9.i. Oligonucleotide probes:
These are produced synthetically by an automated chemical process. The method 
utilises readily available deoxynucleotides, which are economical but requires the 
specific nucleotide sequence to be known. These probes are resistant to RNAase 
and are small, generally from 20-40 bases. This is ideal for ISH because their 
small size allows for easy penetration into the cells or tissue of interest. In 
addition, because they are synthetically designed, it is possible to make a series of 
probes that have the same GC content. Since G/C base pairs bond more strongly 
than A/U base pairs, differences in GC content would require different 
hybridisation conditions. Another advantage of the oligonucleotide probes is that 
they are single stranded therefore excluding the possibility of renaturation. The 
disadvantages are that because they are so small they cover less of the target than 
conventional DNA/RNA probes. One way of getting around this shortcoming is 
to prepare non-overlapping oligonucleotides to effectively hybridise to a larger 
area of the target.
5.1.9..ii. Single-stranded DNA probes
These have similar advantages to the oligonucleotide probes except they are 
much larger, in the 200-500 bp size range. They can be produced by reverse 
transcription of RNA or by amplified primer extension of a PCR-generated 
fragment in the presence of a single antisense primer. That is, having amplified
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the sequence of interest, a subsequent round of PCR is carried out using the first 
PCR product as template, but only using the anti-sense primer, thus producing 
single-stranded DNA.
5.1.9.iii. Double-stranded DNA probes
These can be produced by the inclusion of the sequence of interest in a vector and 
then introduced into bacteria which are allowed to replicate. After lysing the 
vector DNA is then extracted and purified. The sequence of interest is excised 
with restriction enzymes. On the other hand, if the sequence is known then by 
designing the appropriate primers one can produce the relevant sequence very 
rapidly by PCR, potentially obtaining a very clean sample. Because the probe is 
double stranded, it means that denaturation or melting has to be carried out prior 
to hybridisation in order for one strand to hybridise with the mRNA or DNA of 
interest. Double- stranded DNA probes are generally less sensitive because of the 
tendency of the DNA strands to re-hybridise to each other. However, bacterial 
preparation has the advantage of obtaining large quantities of the probe and was 
the method preferred for this thesis.
5.1.9.iv. RNA probes or riboprobes
RNA probes have the advantage that RNA-RNA hybrids are very thermostable 
and are resistant to digestion by RNAases. This allows the possibility of post­
hybridisation digestion with RNAase to remove non-hybridised RNA and 
therefore reduces the possibility of background staining.
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There is one method o f preparing RNA probes:
In vitro transcription of linearised plasmid DNA with RNA polymerase can 
be used to produce the RNA probes. In this thesis plasmid vectors containing RNA 
polymerase promoters from bacteriophages T7 and SP6 were used.
These probes are very difficult to prepare as they are very sensitive to RNAases and 
can easily be destroyed; therefore, scrupulous sterile techniques must be observed. 
However, an advantage is that antisense RNA can be synthesised as the probe and 
sense RNA synthesised as the negative control.
5.1.10. Choice of labelling
Traditionally, probes were radiolabelled with 32P, 35S or 3H but more recently non­
radioactive labels have been developed which, in general, are more versatile, have 
equal or greater sensitivity, produce quicker results and also, of importance, avoid the 
handling of hazardous materials. Radiolabelled probes are still the choice for many
'X'J if #
workers, however. P and S are the most commonly used radioisotopes because 
their high activity is necessary to detect transcripts present in low amounts. 
Non-radioactive labels, such as biotin and digoxigenin, require an additional step for 
colour development, but other labels such as fluorescein and rhodamine can be linked 
directly to the nucleotide.
Digoxigenin (DIG) is a steroid isolated from the digitalis plant and, as blossoms and 
leaves are the only known source of digoxigenin, the anti-DIG antibodies are not 
likely to bind to other biological material. The digoxigenin is linked by a spacer arm 
containing 11 carbon atoms attached to the C-5 position of the uridine nucleotide and 
can be incorporated into the sequence in a number of ways. The advantage of this
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probe is that it can be detected with antibodies conjugated to a number of different 
labels such as alkaline phosphatase, which results in a blue precipitate when the 
enzyme is incubated in the presence o f the substrate NBT/BCIP (4- nitroblue 
tetrazolium chloride/ 5-bromo-4-chloro- 3-idolyl-phosphate) or becomes a 
fluorescent label when incubated with HNPP (2-hydroxy-3 napthoic acid- 2’ 
phenylanilide phosphate) and fast Red. The anti-DIG antibodies can also be 
conjugated to other labels that require no development, such as fluorescein. DIG- 
labelled probes were used in this study as they are more sensitive than biotin and 
have comparable sensitivity to 35S labelled probes.
X a lk a lin e  p h o sp h a ta se  co n ju g a ted  a n tib o d y
•  d igoxigen in
S u b stra te
NBT Blue 
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Digotigcnbt labelled 
UN A probe
mRNA hybridises with probe
niRNA of interest in cell
AAP
Figure 5.4 In situ hybridisation labelling process.
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5.2 METHODS
5.2.1. Immunohistochemical staining with plakoglobin, E-cadherin and p- 
catenin antibodies
Sixty-three cases of PDV, including eight associated with invasive disease and 23 
cases of PDB, which included 10 cases with DCIS only, 4 cases had both DCIS and 
invasive carcinoma, 5 cases had an underlying invasive carcinoma and 4 cases had no 
underlying DCIS or invasive carcinoma, were analysed for the expression of 
plakoglobin, E-cadherin and P-catenin. These cases were retrieved from the 
Histopathology Department at the Royal Free Hospital and collaborators as listed in 
the appendix. The cases were diagnosed and treated between 1984 and 2000.
The archival cases had all been formalin fixed and paraffin wax-embedded. Dr 
Salvador Diaz-Cano (SDC) and JCC (collaborating histopathologists) reviewed all 
H&E stained slides of the cases to confirm the original diagnosis.
Optimisation of protocol
Optimisation of the protocol was performed and refined. Initially antigen retrieval 
was performed using the method of microwaving for plakoglobin and p-catenin and 
protease digestion for E cadherin. However, using both microwaving and pressure 
cooking was found to be more effective for E-cadherin and plakoglobin. P -catenin 
was just as effective without antigen retrieval. Optimising of antibody dilutions was 
performed for all primary antibodies, starting with the recommended manufacture’s 
dilution and then using a range either side. The sections from the control tissue were 
then assessed for intensity of staining with the presence and absence of non-specific 
staining. Incubation time was also optimised for all antibodies, along with incubation
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temperature, allowing for specific staining with the lowest concentration of antibody 
but still providing intense specific staining.
Paraffin wax-embedded sections of Paget’s tissue, 5pm thick, were cut and mounted 
on APES-coated glass slide. The sections were deparaffinised in xylene (2x5 min) 
and rehydrated in graded solutions of alcohol (100%, 90% and 70% for 3 min each). 
To block endogenous peroxidase sections were immersed in 3% H2O2 in methanol for 
10 min. The sections were then left in running water for two min. Conditions for 
antigen retrieval, incubation times and the primary antibodies used are described in 
Table 5.1. Sections were incubated with the secondary antibody rabbit anti mouse 
IgG (1:50 dilution in PBS) for 30 min and washed in PBS (3x5 min) Addition of 
streptavidin HRP complex (Dako, Cambridge, UK ) to the sections (1:500 dilution) 
for 30 min was followed by a further wash in PBS (1x3 m in). Antibody binding was 
visualised with a solution containing the chromogen 3,3’- diaminobenzidine (Sigma- 
Aldrich, Poole, UK). The sections were counterstained with Mayer’s haematoxylin 
(Merck, Lutterworth, UK). Finally, the slides were rehydrated in graded alcohol 
rinses, cleared in xylene and mounted in DPX.
Normal vulval skin was used as the positive control for PDV cases and normal breast 
skin for PDB cases and were used in each staining procedure to ensure optimal 
quality of reagents and methods, and to ensure that the staining was successful. 
Apocrine and eccrine glands were used as internal controls. Due to the limited 
amount of specimens, sections were stained on two separate occasions. They were 
also scored by two individuals (SDC, PEE) to ensure reproducibility. There was 
<5% variation between sections and observers.
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Scoring
The location of the pattern of staining of the protein was recorded as one of the 
following: membranous, diffuse cytoplasmic, paranuclear, and nuclear. The 
percentage of Paget cells expressing each protein had a score of <5%, <25%, <50% 
<75% and <100%. The intensity of the staining was also recorded as either nil, mild 
or strong.
Statistical analysis
Statistical analysis was performed using the Chi Square for trends and Fisher exact 
test when appropriate. A p value of <0.05 was considered significant.
Table 5.1 Conditions, antigen retrieval, incubation times and antibodies used for 
Immunhistochemistry
Antigen Source Clone Working dilution* Antigen
retrieval
Incubation
time
Positive
controls
Plakoglobin Zymed 15 
Laboratories 
Cat no. 13-8500
1:00 microwave
pressure
cooking
VAh vulval skin 
(PDV) 
breast skin 
(PDB)
E-cadherin Zymed 36 
Laboratories 
Cat no.33-4000
1:250 microwave
pressure
cooking
1 Vih vulval skin 
(PDV) 
breast skin 
(PDB)
B-catenin Zymed 14 
Laboratories 
Cat no. 138400
1:50 none 1 l/2 h vulval skin 
(PDV) 
breast skin 
(PDB)
* Diluted in PBS
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5.2.2 In-situ hybridisation for plakoglobin, E-cadherin and p-catenin
To evaluate the mRNA for plakoglobin, E-cadherin and p-catenin selected cases of 
PDV and PDB were subjected to in situ hybridisation. DIG- labelled RNA probes, 
both sense and antisense, were prepared as described in detail in Appendix I.
All materials and solutions (except Tris based solutions) used for in situ 
hyubridisation were pretreated with 2% diethylpyrocarbonate (DEPC) to inactivate 
RNAses and autoclaved. Tris reacts with DEPC and therefore Tris-based solutions 
were made with water pretreated with DEPC and autoclaved.
Preparation of PDV and PDB tissue sections
Paraffin waxed-embedded 4pm sections were cut using a sterile blade and mounted 
on RNAase free APES-treated slides. Sections were dewaxed (xylene 2x5min) and 
rehydrated in graded ethanol rinses (100% for lOmin, 70% for 5 min) and then in 
water containing 1% DEPC. The following procedures were performed to prepare 
the sections for pre-hybridisation. This preparation was done to make the RNA 
within the cell more accessible to the probe. For antigen retrieval two methods were 
tried.
Method 1: Sections were microwaved in pre-warmed 10% citrate buffer for 10 min 
and then left to cool in DEPC-treated water for 10 min. This was followed by 
incubating sections for 10 min in 0.25% acetic anhydride to acetylate the sections. 
The slides were then rinsed in PBS in DEPC water (2x5 min).
Method 2: Sections were incubated in 100 pi of Poteinase K solution at 37°C for 
15min. Proteinase K was inactivated by submerging sections in 0.2% Glycine (in 
PBS) for lOmin and rinsing twice in DEPC PBS. This was followed by incubating 
the sections with 0.25% acetic anhydride for lOmin and then again rinsing twice in
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DEPC PBS. This method was found to be less effective and therefore the first method 
was used.
Pre-hybridisation
Sections were dried partially to remove excess PBS and encircled using a wax pen to 
restrict pre-hybridisation solution to the area of the section. Following this, sections 
were incubated in the pre-hybridisation solution for 4 h at 42°C.
Hybridisation
The probe was heated to 100°C for 1 min to remove secondary structure and stored 
on ice. The pre-hybridisation solution was discarded and sections were then 
hybridised overnight with 40ng of RNA probe at 42°C in hybridisation solution. 
Sections were covered with Parafilm to prevent evaporation.
Post-hvbridsation
The parafilm coverslip were removed and slides rinsed twice in 2xSSC (composition 
detailed in Appendix I) at room temperature (2x5min). The sections were washed 
with increasing stringency in SSC at different concentrations ( 2x SSC,lx SSC, 
0.5xSSC and O.lx SSC) with 50% formamide at 42°C for 30 min each time, at each 
concentration and then incubated for 30 min with blocking solution (prepared using 
3 pi of normal sheep serum and 20pl of Triton X-100 per ml of buffer 1 solution). This 
was followed by incubating the sections with the anti-DIG alkaline phosphatase 
conjugated sheep Fab fragments (diluted 1:400 in buffer 1) containing 1% normal 
sheep serum to reduce non specific binding of the antibody, for 90 min at room 
temperature. The sections were washed in buffer 1 (2x5 min) and then in buffer 2 
(1x5 min). To visualise antibody binding of the probes NBT /BCIP chromogen 
solution (Sigma) was added to the sections and left overnight at 4°C. To stop the
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colour reaction sections were washed in buffer 3 (lOmM Tris HCL, 0.5 molar EDTA 
and distilled water) for 30 min. The slides were air-dried and mounted using aqueous 
mount. Composistion of solutions are described in Appendix I page 244.
Stained sections were scored for the intensity of the mRNA signal of the intracellular 
junctions. Nuclear and cytoplasmic staining was also recorded. Sections were stained 
on two separate occasions and the results analysed by two independent observers 
(PEE and Dr Lucy Ghalia). There was <5% variation between sections and observers. 
The surrounding apocrine/eccrineglands and epidermal cells were used as positive 
controls. The sense probe of each section was used as the negative controls.
5.3 RESULTS 
5.3.1 Immunhistochemistry results
5.3.1 .i Evaluation of plakoglobin. E-cadherin and 3- catenin expression in PDV
20 cases (34%) of PDV were grouped histologically in a nested pattern compared to 
40 cases (68 %) that found the Paget cells to be lying in a single pattern. There 
appeared to be no significant differences in the expression of the adhesion molecules 
between the two groups (the Paget cells in two cases were found to have neither a 
single or growth pattern and had an infiltrative and solid growth pattern respectively, 
and in another case the Paget cells were arranged in both a single and nested pattern; 
these cases were not included in the final count). Four of the PDV cases with 
invasion had a nested pattern, two were arranged in a singular pattern, and two were 
neither but had an infiltrative pattern. The cases were further divided as to whether 
there was any lichenoid inflammation reaction surrounded the cells. Twenty-three 
cases (39%) had lichenoid inflammation reaction surrounding the Paget cells as 
compared to 36 cases (61%) that did not. Three of the PDV cases with invasive
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disease had a lichenoid inflammatory reaction surrounding the Paget cells; five did 
not. Tables 5.2, 5.3, and 5.4 demonstrate the histological pattern and percentage score 
for each protein marker.
Table 5.2 Plakoglobin score and associated histological pattern in PDV
Histological
pattern
<5% <25% <50% <75% <100%
Nested 7 4 3 4 2
Single 18 8 5 7 2
Nested + 
lichenoid
0 2 1 3 0
Single + 
lichenoid
5 4 3 2 0
Table 5.3 E-cadherin score and associated histological pattern in PDV
Histological
pattern
<5% <25% <50% <75% <100%
Nested 0 3 2 7 8
Single 2 3 5 14 13
Nested + 
lichenoid
0 1 0 2 4
Single + 
lichenoid
1 2 1 7 4
Table 5.4 p-catenin score and associated histological pattern in PDV
Histological
pattern
<5% <25% <50% <75% <100%
Nested 9 4 5 2 0
Single 12 18 6 2 2
Nested + 
lichenoid
3 2 1 1 0
Single + 
lichenoid
3 1 2 1 1
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Plakoglobin
Thirty six (57%) of the 63 cases of PDV had a score of greater than 5% or more; in 4 
cases (6%) >75% expressed plakoglobin; in 11 cases (17%) it was >50% of the 
Paget cells ; 8 cases had a score of >25% and 13 cases a score of >5% but < 25%. 
This was compared to 27 cases (43%) that had a score of <5%. In most cases the 
staining was membranous; 34 cases (58%) had membranous staining, 9 (15%) had 
diffuse cytoplasmic staining and 4 had nuclear staining (6%). In the 41% of cases the 
staining intensity was mild and in 37% it was strong.
Sixty percent (33/55) of the intraepidermal PDV cases had >5% of Paget cells 
expressing the Plakoglobin protein compared to 37% (3/8) of cases of PDV with 
invasive disease. Table 5.5 demonstrate the results. Figure 5.5a and Figure 5.5b 
demonstrate plakoglobin protein expression in non invasive PDV with a score of 
<5%. The staining was membranous and mild in intensity.
Table 5.5 Plakoglobin expression in PDV
Samples <100% <75% <50% <25% <5%
PDV
without
invasive
disease
(n=55)
3 11 8 11 22
PDV with 
invasive 
disesase 
(n=8)
1 0 0 2 5
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E-cadherin
Fifty eight of the 61 cases (95%) had a score of greater than 5% with 22 cases having 
a score of >75%. Only 3 cases had a score of <5%. Again the staining pattern was 
mostly membranous (58 cases out of 59), the remaining case was nuclear. The 
intensity of staining was mostly strong (49 cases).
Ninety-eight percent (53/54) of PDV cases had > 5% of Paget cells expressing the E- 
cadherin protein compared to 71% (5/7) of PDV with invasive disease. This result 
was significant, p value = 0.005. Table 5.6 demonstrate the results.
Figure 5.6 demonstrate E-cadherin protein expression in non invasive PDV with a 
score of <100%. The staining was membranous and cytoplasmic, and the intensity 
was strong. The Paget cells were in a nested pattern and lichenoid inflammatory 
reaction was present.
Table 5.6 E cadherin expression in PDV
Samples <100% <75% <50% <25% <5%
PDV
without
invasive
disease
(n=54)
20 21 8 4 1
PDV with 
invasive 
disesase 
(n=7)
2 0 1 2 2
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B catenin
P catenin expression in PDV was similar to plakoglobin expression with 41 (65%) 
cases had a score of between 100 and 5%. Twenty-two cases (37%) had a score of 
<5%. As before, the staining pattern was mostly membranous (34 cases), 13 cases 
had nuclear staining, 11 cases had diffuse cytoplasmic staining pattern and 4 had 
paranuclear staining. The intensity of the staining was mild.
Sixty-nine percent (38/55) of PDV had >5% of Paget cells expressing p -catenin 
compared to 37% (3/8) of PDV cases with invasive disease. Table 5.7 demonstrate 
the results. Figure 5.7 show p -catenin protein expression in non invasive PDV with a 
score of <50%. The staining was membranous and the intensity was strong.
Table 5.7 p-catenin expression in PDV
Samples <100% <75% <50% <25% <5%
PDV
without
invasive
disease
(n=55)
2 3 11 22 17
PDV with 
invasive 
disesase 
(n=8)
0 1 0 2 5
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Figure 5.5a Plakoglobin protein expression in non invasive PDV (xlOO) 
with a score of < 5%.
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Figure 5.5b Plakoglobin expression in Paget cells in PDV (x400) 
with a score o f < 5%.
Figure 5.6 E cadherin protein expression in non invasive 
PDV (x200) with a score o f <100%.
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Figure 5.7 6- catenin protein expression in non invasive PDV (x200) 
with a score o f <50%.
5.3.1 .ii. Evaluation of plakoglobin. E-cadherin and B- catenin proteins in PDB 
Twelve of the 24 (50%) PDB cases had a single pattern compared to nine PDB cases 
that shared a nested pattern. Three cases had an infiltrative pattern. Five of the 24 
(21%) PDB cases had a lichenoid inflammatory reaction surrounding the Paget cells. 
Tables 5.8, 5.9 and 5.10 demonstrate the histological pattern with the percentage 
score for each marker.
Table 5.8 Plakoglobin score and associated histological pattern in PDB
Histological
pattern
<5% <25% <50% <75% <100%
Nested 6 1 0 2 0
Single 10 2 0 0 0
Nested + 
lichenoid
1 0 0 0 0
Single + 
lichenoid
2 2 0 0 0
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Table 5.9 E-cadherin score and associated histological pattern in PDB
Histological
pattern
<5% <25% <50% <75% <100%
Nested 1 2 1 1 4
Single 3 1 0 4 4
Nested + 
lichenoid
0 0 0 1 0
Single + 
lichenoid
0 0 0 2 2
Table 5.10 (3-catenm score and associated histological pattern in PDB
Histological
pattern
<5% <25% <50% <75% <100%
Nested 4 1 1 2 0
Single 7 2 0 2 0
Nested + 
lichenoid
0 0 0 1 0
Single + 
lichenoid
1 1 0 1 0
Plakoglobin
Six of the twenty three cases (26%) had a score of >5% with 17 cases (74%) with a 
score of < 5%. Expression of the protein was found in the membranes in 78% of 
cases (two cases were nuclear and three cases were paranuclear). In most cases (70%) 
the intensity of the staining was strong. Table 5.11 demonstrate the results. Table 
5.12 show plakoglobin protein expression in PDB with/without DCIS or underlying 
carcinoma. Figure 5.8 demonstrate plakoglobin protein expression in PDB with DCIS 
and invasive carcinoma with a score of <75%.
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E-cadherin
E-cadherin expression in PDB was similar to its expression in PDV with 19 (83%) of 
the cases having a score greater than 5% (97% in PDV). Similarly, the protein 
expression was found mainly (78%) in the membranes and the intensity of the 
staining was strong in 70% of cases. Table 5.11 demonstrate the results. Table 5.13 
show E-cadherin protein expression in PDB with/without DCIS or underlying 
carcinoma.
Figure 5.9 demonstrate E-cadherin protein expression in PDB with a score of 
<100%. The staining is membranous and the intensity is strong.
B-catenin
Eleven cases (52%) had a score of >5% and 10 cases (48%) had a score of <5%. In 
two cases the tissue was unsuitable for scoring. The staining was membranous in 11 
cases (52%), 8 cases (38%) were nuclear and 2 cases (9%) were paranuclear. The 
intensity of the staining was mild in 57% of the cases and strong in 33%. Table 5.11 
demonstrate the results. Table 5.14 shows P-catenin protein expression in PDB 
with/without DCIS or underlying carcinoma. Figure 5.10 demonstrate P- catenin 
protein expression in PDB only with a score of <100%. The staining is membraneous 
and the intensity is strong.
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Table 5.11 Plakoglobin, E-cadherin and p- catenin protein expression in PDB
Protein <100% <75% <50% <25% <5%
Plakoglobin
n=23
1 3 0 2 17
E-cadherin
n=23 9 6 1 3 4
P- catenin 
n=21 0 6 2 3 10
Table 5.12 Plakoglobin protein expression in PDB with/without DCIS or 
underlying carcinoma
Sample <100% <75% <50% <25% <5%
PDB only 
n=4 0 0 0 0 4
PDB
+DCIS
n=10
1 0 0 2 7
PDB with
DICS
+invasive
carcinoma
n=4
0 2 0 0 2
PDB
+invasive
carcinoma
n=5
0 1 0 0 4
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Table 5.13 E- cadherin protein expression in PDB with/without DCIS or 
underlying carcinoma
Sample <100% <75% <50% <25% <5%
PDB only 
n=4 1 1 0 1 1
PDB
+DCIS
n=10
3 2 1 2 2
PDB with
DICS
+invasive
carcinoma
n=4
2 2 0 0 0
PDB
+invasive
carcinoma
n=5
3 1 0 0 1
Table 5.14 p-catenin protein expression in PDB with/without DCIS or 
underlying carcinoma
Sample <100% <75% <50% <25% <5%
PDB only 
n=4 0 0 0 1 3
PDB
+DCIS
N=9
0 2 1 2 4
PDB with
DICS
+invasive
carcinoma
n=4
0 2 0 0 2
PDB
+invasive
carcinoma
n=4
0 2 0 0 2
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Figure 5.8 Plakoglobin expression in PDB with DCIS and invasive 
carcinoma (x200) with a score of <75%.
Figure 5.9 E-cadherin protein expression in PDB only (x200) 
with a score of <100%.
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Figure 5.10 6- catenin protein expression in PDB only (x200) with a score of 
< 100%.
5.3.2. In situ Hybridisation results
5.3.2.i. Evaluation of Plakoglobin. E-cadherin and 13- catenin mRNAs in PDV 
Plakoglobin
Ten PDV cases were analysed for mRNA but only eight including one case of 
invasive PDV were suitable for scoring. All cases had decreased mRNA signal in the 
Paget cells compared to the apocrine and epidermal cells. Apart from two cases 
where there was no difference in the mRNA signal in the antisense and sense slides, 
the mRNA signal was absent in the sense slides. Table 5.15 reveal the six cases 
available for comparison of plakoglobin protein expression and mRNA signal in 
PDV.
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Table 5.15 Plakoglobin mRNA and protein expression in PDV
Case no. mRNA Protein
10 decreased <5%
15 decreased <5%
16 decreased <50%
45 decreased <100%
59 decreased <25%
79 decreased <5%
E-cadherin
Seven cases including one case o f invasive PDV were suitable for scoring which 
revealed decreased mRNA signal in the Paget cells as compared to the surrounding 
apocrine glands and epidermal cells. Figures 5.11 reveal E-cadherin mRNA signal in 
Paget cells in PDV (antisense probe ;x200) and Figure 5.12 reveal the negative 
control. Table 5.16 demonstrate seven cases available for comparison of E-cadherin 
protein expression and mRNA signal in PDV.
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Table 5.16 E-cadherin mRNA and protein expression in PDV
Case no. mRNA Protein
1 decreased <100%
16 decreased <100%
45 no decrease <100%
52 decreased <100%
59 decreased <75%
72 decreased <75%
82 decreased <50%
B -catenin
Fifteen were cases were analysed but only nine were suitable for scoring. Eight cases 
revealed decreased mRNA signal in the Paget cells compared to the surrounding 
apocrine glands and epidermal cells. One case revealed no difference in the signal in 
the antisense and sense slides. Table 5.17 reveal the eight cases available for 
comparison of p-catenin protein expression and mRNA signal in PDV.
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Table 5.17 fi-catenin mRNA and protein expression in PDV
Case no. mRNA Protein
1 decreased <5%
16 decreased <5%
48 absent <5%
54 absent <5%
55 decreased <25%
79 decreased <25%
72 decreased <50%
82 absent <25%
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Figure 5.12. Negative control. E-cadherin mRNA signal in Paget cells 
in PDV (sense probe; x200).
E-cadherin mRNA signal in Paget cells in PDV (antisense) (x200).
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5.3.2-ii Evaluation of Plakoglobin .E-cadherin and B-catenin mRNAs in PDB 
Plakoglobin
Eight of 11 PDB cases which included 5 with associated DCIS, 4 with invasive 
carcinoma and 2 cases with PDB only, were suitable for scoring. mRNA signal was 
noted to be decreased or absent in the Paget cells as compared to the surrounding 
apocrine glands and epidermal cells. Table 5.18 demonstrate the seven cases 
available for comparison between plakoglobin mRNA signal and protein expression 
in PDB.
Table 5.18 Plakoglobin mRNA and protein expression in PDB
Case no. mRNA Protein
100 decreased <5%
103 decreased <5%
105 decreased <5%
120 decreased <5%
122 decreased <5%
124 decreased <25%
136 decreased <50%
E-cadherin
Nine of the fourteen PDB cases which included 4 with associated DCIS, 4 with 
invasive carcinoma, and one case of PDB only, analysed were suitable for scoring. In 
all cases mRNA signal was found to be reduced in the Paget cells as compared to the 
surrounding apocrine glands and epidermal cells. Table 5.19 demonstrate the five
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cases available for comparison between E-cadherin protein expression and mRNA
signal in PDB.
Table 5.19 E-cadherin mRNA and protein expression in PDB
Case no. mRNA Protein
89 decreased <5%
98 decreased <5%
100 decreased <75%
103 decreased <100%
124 decreased <5%
B-catenin
Thirteen PDB cases were analysed which included 6 with associated DCIS, 4 with 
invasive carcinoma and 2 cases with PDB only. In the twelve that were suitable for 
scoring, mRNA signal was noted to be decreased in 10 cases as compared to the 
surrounding apocrine glands and epidermal cells. The signal was found to be similar 
in intensity in both the antisense and sense slides in two cases. Table 5.20 
demonstrates the six cases available for comparison between P-catenin protein 
expression and mRNA signal in PDB.
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Table 5.20 B-catenin mRNA and protein expression in PDB
Case no. mRNA Protein
94 decreased <5%
100 decreased <75%
105 decreased <5%
122 decreased <5%
124 decreased <5%
136 decreased <5%
Figure 5.13 B-catenin mRNA signal in Paget cells in PDB (antisense; xlOO).
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Figure 5.14 Negative control. B-catenin mRNA signal in Paget cells 
in PDB (sense probe; xlOO).
5.4. DISCUSSION
5.4.1. Plakoglobin, E-cadherin and B- catenin protein and mRNA expression in PDV
5.4.1 .i Plakoglobin expression in PDV
This is the largest study of plakoglobin, E-cadherin and B- catenin expression in PDV 
and PDB. The reduced expression of cell adhesion molecules has been implicated in 
promoting invasion and metastasis (Oka et. al., 1992; Miyata et. al, 1994). The 
paucity o f information regarding the expression of plakoglobin, E-cadherin and B- 
catenin in PDV is evident (Tada et.al 1996, 2000; Shirahama et al.,1996; Takata et 
al., 1999) and, as such, the role o f these molecules have not been clearly established 
in PDV. To my knowledge, only one study has examined the expression of 
plakoglobin in PDV. Tada et al. (2000) examined the expression of desmoglein I and
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plakoglobin in skin carcinomas, which included 11 cases of extramamary Paget’s 
disease, only one case, was from a female of which the location was documented as 
the pudendum. This case was negative for plakoglobin. In the current study fewer 
Paget cells expressed plakoglobin in the intraepidermal compartment of the PDV 
cases with invasive disease when compared with the intraepidermal compartment of 
PDV cases without invasive disease, although this did not reach statistical 
significance (p=0.27). Plakoglobin mRNA signal was also decreased as compared to 
the surrounding apocrine glands. These findings may suggest a possible dysfunction 
in the regulation of plakoglobin in PDV with invasive disease as compared to those 
without invasion. Nuclear and diffuse cytoplasmic staining of the plakoglobin protein 
was noted in 13 of the cases with only one case being associated with invasive 
disease. Plakoglobin has been reported to be involved in the Wnt signalling pathway 
(Kamovsky et al. 1997; Merriam et al. 1996), however this remains controversial. 
Whether extramembranous expression of the protein is significant in these cases 
remains uncertain.
5.4-l.ii. E-cadherin expression in PDV
Since loss of expression of E-cadherin has been suggested as one of the mechanisms 
contributing to the development of invasion and metastasis of cancer cells, its 
expression has been investigated in several cancers with a view to correlating lack of 
expression with invasive disease. Searching the literature only two studies have 
examined this role in PDV (Shirahama et al., 1996; Tada et al., 1996). Both studies 
three and eight cases of PDV respectively (Table 5.21) demonstrated decreased 
expression of the E-cadherin protein.
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In the current study we found similar results. E-cadherin expression was significantly 
reduced (p= 0.005) in the intraepidermal compartment of the PDV cases with 
invasive disease when compared with the intraepidermal compartment of PDV cases 
without invasive disease. Loss of E-cadherin expression may lead to reduced cell 
adhesiveness and therefore detachment of Paget cells from the intraepidermal lesion 
with the result being invasive disease. There appeared to be no significant difference 
in the cellular localisation of the proteins
Loss of mRNA signal was also noted to decrease from surrounding apocrine glands 
and epidermal cells to in situ PDV, and to invasive PDV cases. However when 
comparing mRNA signal and protein expression the results do not correlate in some 
cases. One possible reason could be due to the mRNA degrading at a faster rate than 
the protein.
5.4.1.iii. B- catenin expression in PDV
The transcriptional activity of (3- catenin and its degradation is regulated by the Wnt 
pathway. In normal epithelial cells, p- catenin is localised at the cell membrane. The 
unbound p- catenin is degraded by the ubiquitin-proteosome system which involves 
the kinase GSK-3 p. Stabilisation of the cytoplasmic P- catenin by the aberrant 
activation of the Wnt signalling leads to its accumulation, complexing with LEF/TCF 
transcription factors and transactivation of LEF/TCF target genes. Activation of these 
genes can lead to cell proliferation or inhibition of apoptosis. Nuclear accumulation 
of P- catenin can be the result of gene mutations (Sparks et al., 1997). In colon 
cancers, disruption of the Wnt signalling pathway by mutations of either the APC or 
the p-catenin gene plays a crucial part in the early stage of tumourigenesis (Morin et 
al., 1997). In the current study diffuse cytoplasmic and paranuclear staining of the P-
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catenin protein was found in 11 and four cases of PDV respectively. Three of these 
cases were in invasive PDV. These results may suggest involvement of aberrant 
activation of the Wnt signalling pathway in some cases of PDV.
5.4.2. Plakoglobin. E-cadherin and B catenin protein and mRNA expression in PDB
5.4.2.i. Plakoglobin expression in PDB
Plakoglobin has not been examined in PDB. Very few studies have sought to 
examine the role of plakoglobin in breast carcinomas (Bukholm et al., 1995 : 
Zschiesche et al., 1997). Loss of heterozygosity and reduced expression of 
plakoglobin associated with disease progression has been demonstrated in breast 
cancers (Sommers et al., 1994; Aberle et al., 1995). In the current study only 26% of 
the PDB cases had >5% of Paget cells expressing plakoglobin. This implicates a 
possible role for plakoglobin in the formation of PDB. There was good correlation 
between plakoglobin mRNA and protein expression.
5.4.2.ii. E-cadherin expression in PDB
The role of E-cadherin in breast cancers is debatable. Reduced expression of E- 
cadherin has been reported to be associated with a poor outcome (Oka et al.,1999; 
Charpin et al.,1997) where as other investigators have demonstrated no independent 
prognostic value for E-cadherin in breast carcinomas (Lipponen et. al., 1998; Soler et. 
al, 1999). To my knowledge only one study (Shirahama et al.,1996) has examined the 
expression of E-cadherin in PDB and both cases were negative fo the protein. 
Eighty-three percent of the PDB cases in my study had >5% of Paget cells expressing
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E-cadherin. It is therefore unlikely that reduced E-cadherin mediated cell-cell 
adhesion is an important factor in PDB carcinogenesis. In two cases mRNA and 
protein expression did not correlate, which as previously discussed, could be due to 
mRNA degradation at a faster rate than the protein.
5.4.2.iii B- catenin expression in PDB
Few studies have sought to examine the role of p- catenin in breast carcinomas 
(Bukholm et al., 1995: Zschiesche et al., 1997) and no one has examined the role of 
P-catenin in PDB. Forty- eight percent of my PDB cases had nuclear and paranuclear 
staining of p-catenin protein. The extramembranous accumulation could be due to 
mutation in the p-catenin gene or due to lack of its degradation by the GSK3 p/ 
proteasome/ APC system as a result of abnormal disruption of the Wnt signalling 
pathway. Except in one case, there was good correlation between 
mRNA signal and protein expression.
The adhesive function of cadherins is dependent on its interaction with catenins. 
Some reports have revealed reduced expression of both cadherins and catenins in 
certain tumours (Muzio et al., 1999). In the current study there appeared to be no 
correlation between reduced expression of E-cadherin and p-catenin.
In summary reduced expression of E-cadherin may a have a role to play in the 
pathogenesis of invasive PDV, unlike PDB where in the majority of cases normal 
expression of the protein was demonstrated. Abnormal plakoglobin and wnt 
signalling pathway may be involved in the formation of some cases of PDV and 
PDB.
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Table 5.21 review of studies on the expression of plakoglobin, E-cadherin and P-
catenin in PDV and PDB
Authors Title of study Results
Shirahama et al. 
(1996)
E-cadherin and P-cadherin expression 
in tumour tissues and soluble 
E-cadherin levels in sera of patients 
with skin cancer
Five cases 
(3 cases of PDV and 
2 cases of PDB) 
negative for E- and 
P-cadherin
Tada et al.(1996) Expression of E-cadherin in skin 
Carcinomas.
Eight cases of PDV. 
Decreased 
expression in the 
invasive (4cases) 
compared to in situ 
(4 cases)
Takata et al. 
(1999)
ErbB-2 overexpression but no 
activation of p- catenin gene in 
EMPD
Positive
membraneous p- 
catenin protein 
expression in all 6 
female cases
Tada et al. 
(2000)
Expression of desmoglein I and 
plakoglobin in skin carcinomas
11 cases of EMPD 
only 1 case from 
female pudendum. 
Negative for 
plakoglobin
216
CHAPTER 6: PAGET’S DISEASE OF THE VULVA 
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6.1 PDV national register and database
6.1.1 Introduction
PDV is a rare disease. Few clinicians have seen cases of Paget’s disease of the vulva, 
with less than 1% seeing five cases or more (Tidy et. al. 1996). At the Royal Free 
Hospital, only four cases of PDV were diagnosed among 1000 women seen in the 
vulval clinic (MacLean et al., 1998). The paucity of information regarding the 
treatment and management of this disease has led to a number of treatment options 
being offered to the patient. A survey in 1996 in the management of preinvasive 
vulval lesions by gynaecologist and dermatologists in the UK revealed that 
dermatologists referred 66% of their Paget cases to gynaecologists; gynaecologists 
managed more than 80% of their cases of Pagets themselves, but referred 10% to 
other gynaecologists and 5% was referred to dermatologists. Dermatologists used 
excision, cryotherapy, topical 5-fluorouracil and retinoids, while 73% of 
gynaecologists advocated wide local excision, vulvectomy or radical vulvectomy 
(MacLean et al., 2004). Because of the few numbers of PDV cases any one clinician 
may have, the information regarding management, recurrence rate and prognosis is 
limited. With this in mind, the British Society for the Study of Vulval Diseases set 
up a national register and database for PDV in 1997. Forms (Figure 6.1) were sent 
out to clinicians requesting that they would register their cases of PDV. Clinicians 
submitted the completed questionnaire to the University Department of Obstetrics & 
Gynaecology at the Royal Free and University College Medical School. These 
patients have come from various parts of the UK and as far a field as South Africa.
So far 106 cases of PDV have been registered. Seventy-eight (74%) of the cases were
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from gynaecologists, 17 (16%) from dermatologists, 6 (5%) from clinical 
oncologists, and 5 (5%) cases were from plastic surgeons and general practitioners. 
The age range of the women registered was between 47 and 98 years. Average age at 
diagnosis was 68 years old. Twenty five percent of the referrals were women aged 80 
years or more. Where the interval between onset of symptoms and diagnosis was 
recorded, in 27 cases it was less than one year, for 20 cases, it was between one and 
five years and for 11 cases it was more than five years with the longest interval being 
13 years. A biopsy was taken in most cases to confirm the diagnosis.
6.1. 2 Underlying cancer
Thirty of the 106 patients registered had an underlying cancer. Thirteen patients had 
an invasive vulval adenocarcinoma discovered at the time the Paget’s lesion was 
excised. Nine patients were diagnosed with intraepithelial Paget’s disease initially, 
but subsequently developed invasive adenocarcinoma. The initial age of diagnosis of 
PDV was between 56 and 80 years. One patient developed invasion within a year and 
therefore may have had pathology that was missed at initial surgery. Two of these 
patients have died of metastatic disease.
6.1.3 Other cancers
From our register there were 16 patients who had a history of an associated cancer: 
for six there was dermal invasion diagnosed at the time of primary biopsy or 
excision, for nine, progression from intraepithelial to invasive PDV occurred 1-19 
years (mean 7 years) after the original diagnosis. In the 16 cases with associated 
cancers, in three the timing of the diagnosis of cancer is unknown, in five it preceded 
the diagnosis of Paget’s, in four it was synchronous and in two it was subsequent to
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the diagnosis of Paget’s. Figure 6.2 demonstrate year of diagnosis and associated 
cancers. Table 6.1 list the anatomical site of the various associated cancers. Seven of 
these patients have died from their cancers. It was interesting to note that eight cases 
of PDV were associated with breast cancer. Chanda (1985) also found that the 
highest number of cases of internal malignancy at a particular site was the breast. 
There have been reports in the literature of an association between previous PDV and 
breast cancer. Friedrich et al. (1975) reported 14 cases of PDV and breast 
carcinoma, Farrell et al., (1999) also reported two patients with PDV associated with 
invasive adenocarcinoma and a history of breast cancer. There have been cases in the 
literature documenting an association between PDV and PDB (Boehm and Morris, 
1971; Popiolek et al 1998). In the database there was only one case of PDV 
associated with PDB.
All patients with PDV should be screened for associated cancers by mammography, 
ultrasound scan of the pelvis plus vaginal speculum examination, cervical cytology 
and endometrial biopsy. If the lesion involves the anal skin examination for an ano­
rectal or colon cancer could include occult bloods and endoscopy, and similarly urine 
cytology, cystoscopy and intravenous urography considered for urothelial cancers.
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Figure 6.1 Time of diagnosis and associated cancers.
Table 6.1 Anatomical sites of associated cancers
Associated cancer No of cases
Breast 8
Bladder 4
Ovary 1
Cervix 1
Endometrium 1
Colorectal 1
Paget’s disease o f
the vulva
Invasion
Endometrial
adenocarcinoma
Bladder
transitional cell
carcinoma
Melanoma
Breast
Ovary
ColoRectal
Death
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6.2 Management of PDV
6.2.1 Surgical treatment
The majority of patients (84 cases) in our database were treated by surgery and many 
had more than one procedure. Many of the women had co-morbidites such as 
diabetes and ischaemic heart disease which made anaesthesia and surgical 
management more difficult.
Previously, radical vulvectomy was the preferred treatment for PDV but others have 
recommended more conservative surgery (Feuer et al., 1990; MacLean et al., 2000). 
From the database we found that most clinicians preferred treating PDV by a wide 
local excision (Table 6.2), often with closure of the defect by the gynaecologist, but 
sometimes with a plastic and reconstructive surgeon using grafts, or pedicle flaps to 
close the defect. Other gynaecologists opted to treat their patients by a vulvectomy 
usually a simple vulvectomy, but sometimes radical, with the removal of inguinal- 
femoral nodes when there was an associated cancer recognised preoperatively. It is 
not possible from the information we have to comment on lymph node involvement.
6.2.2 Non surgical treatment
Several patients had no treatment, or topical corticosteroid cream only. These patients 
had either advanced or metastatic disease elsewhere or complex medical problems 
and were unsuitable for surgery. Immiquimod was given to 7 patients either as 
primary therapy after biopsy, or for persisting disease after surgery. In two of these 
patients there is no demonstrable disease, but in the others, although Paget’s disease 
remains the symptoms have been controlled. As indicated (Table 6.2), some patients 
underwent lesion ablation with the carbon dioxide laser or photodynamic therapy, or
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by radiotherapy. In most cases these treatments were used for recurrences after 
surgery and the numbers are too few to allow comment on efficacy. One patient 
developed recurrence following wide local excision and was treated with 42Gy over 
10 fractions. The initial symptom relief was good, but her discomfort increased until 
repeat surgery became necessary.
Table 6.2 Management options from PDV database
Treatment No of cases
Wide local excision 55
Vulvectomy 24
Surgery + radiotherapy 3
Surgery + photodynamic therapy 2
CO2 laser 1
Immiquimod 7
Topical corticosteroids 2
No treatment 3
6.3 Follow-up of treated patients
As mentioned previously, the recurrence rate in PDV is high and over a half of all 
treatd patients will develop recurrent disease. Sometimes this will be symptomatic 
and demand further intervention, but symptoms of pruritis and irritation are not 
inevitable and observation may be appropriate. However, there is a small risk that 
apparently in-situ lesions can become invasive. Nine of the registered patients from 
the database showed such progression occurring l-21yrs after a diagnosis of Paget’s,
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and with age at diagnosis of invasion ranging from 63-88 (mean 76.2yrs). Therefore, 
the patients need long term follow-up, at recommended intervals of 6 months if 
symptomatic and yearly if asymptomatic.
We have requested updates (Figure 6.3) on the cases of PDV to follow the outcome 
of these patients and the natural history of the disease. To date follow-up information 
has been received on 88 of the patients. Eleven women have been lost to follow-up 
because they have left the country or left the general practioners surgery or in some 
cases, no longer registered with the surgery and therefore presumed dead. There 
were 22 deaths with at least 14 of them dying of Paget’s disease. Twelve died with 
widespread metastatic disease involving the lungs, liver and bone. Of the remaining 
patients the majority were alive but with evidence (clinical or on repeat biopsy) of 
persisting or recurring disease.
It is our hope that the information gained from the database will increase our 
understanding in the management and clinical outcome. We will continue to gather 
information on this rare but important disease.
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PAGET’S DISEASE OF THE VULVA
REGISTRATION FORM
PATIENT’S NAME:______
DATE OF BIRTH:_______
REFERRING CLINICIAN:
SPECIA LTY:______________
ADDRESS:
POSTCODE_________________________________________
Date of initial diagnosis (year):____________________________
How long were the symptoms present before diagnosis was made?_
(Please circle or tick as appropriate responses)
Has a biopsy been taken for diagnosis? Yes / No
Could this tissue be made available for further research? Yes / No
SITE: Anterior 
Posterior 
Perianal
Both - Anterior and Posterior
Other: please specify______________________________
MANAGEMENT
Date -  year only Previous to 
diagnosis / date
Synchronous to 
diagnosis/ date
Subsequent to 
diagnosis / date
Only Biopsy (please circle)
Topical application specify: Circle or add 
- Dermovate -Betnovate
- 5 Fluorouracil - Synalar
- Trimovate - Nerisone
- Hydrocortisone - Daktacort
Wide Excision
Vulvectomy
Groin nodes
Radiotherapy
Photo DynamicTherapy
Observation
Other (specify)
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Is there an Associated Cancer ?
Please indicate which category it falls into and add the date if known
Type Previous to diagnosis 
/ date
Synchronous to 
diagnosis / date
Subsequent to diagnosis 
/ date
Breast
Genital Tract
-Endometrium
-Vulva
-Ovary
-Cervix
-Vagina
Colo-rectal
Sarcoma
Other (specify)
Date of Diagnosis of Cancer
Current Status o f Pagets -  please circle
Persisting Disease symptomatic asymptomatic
New Disease symptomatic asymptomatic
No Apparent Disease_____________________
Was the Paget’s intraepithelial or invasive? Please circle
Diagnosis of Invasion - within area of Pagets 
at follow up - genital tract
- vulva
- colo-rectal
- elsewhere, please specify________________
Current Status of Patient Alive - and free of Paget’s disease
Alive - with disease
Dead - date of death __________
cause of death__________________________________
Can I write for an update? Yes / No / NA
Please return to: Professor A B MacLean
University Dept of Obstetrics and Gynaecology 
Royal Free and University College Medical School 
Royal Free Campus, University of College London, 
Rowland Hill Street, London NW3 2PF
On behalf of The British Society for the Study of Vulval Disease
Figure 6.2 Registration form.
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For database use only
Patient ID Number__________________Registration Date__________  Ref:pagets/pagetsform2b/4'00
FOLLOW-UP FORM
Date as Postmarked
Dear
We are updating our Paget's Register - we had originally thought we would do this 
annually but that now seems too frequent.
I enclose a form designed for computerising our data, but if you wish to photocopy 
correspondence and clinical notes on your patients, we will do the necessary form 
filling, or contact you for missing data. This exercise is producing some interesting 
UK-based information.
I appreciate your active input into this.
Yours sincerely
Professor A B MacLean
Head of Dept of Obstetrics and Gynaecology
Figure 6.3 follow-up form.
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CHAPTER 7: CONCLUSION
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The aim of the study was to identify any differences in the molecular pathology 
between PDV and PDB, and to investigate whether there were any differences in 
molecular markers in the Paget cells of those cases with invasive disease compared to 
those without invasive disease in PDV. The pathogenesis of PDV and PDB is 
unclear, thus the identification of biological factors involved in PDV and PDB 
carcinogenesis may be useful in clarifying the natural history of these diseases. 
Immunohistochemical, mutation and mRNA analysis was performed on molecular 
markers of cell cycle control and apoptosis (pRb, p53, and cyclin Dl), cell 
proliferation (Ki67), molecular markers of oncogenesis (c-erbB-2), markers of 
angiogenesis (VEGF, PD-ECGF/TP and MVD). Proteins involved in cell adhesion 
(E-cadherin, plakoglobin and p-catenin were also analysed. All these molecular 
markers were chosen because they have been shown to be involved at different stages 
of the carcinogenic process and therefore could be involved in the development of 
PDV and PDB.
Sections that were immunopositive for the tumour marker p53 were then 
microdissected using LCM, the DNA extracted, amplified and sequenced to analyse 
for mutations in the exon 5-8 region of the P53 gene. In situ hybridisation was also 
used to determine mRNA expression levels of the adhesion molecules in PDV and 
PDB.
This thesis attempted to answer the following questions:
1. Is there a difference in the molecular pathology between PDV and PDB?
2. Are there differences in the molecular pathology when PDV is associated with or 
without an underlying invasive adenocarcinoma?
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3. Are there biological molecular markers that can determine the progression of 
intraepidermal PDV to invasive PDV?
4. If there are differences in the molecular pathology between intraepidermal and 
invasive PDV are these reflected in different clinicopathological presentation?
Is there a difference in the molecular pathology between PDV and PDB? 
p53, cyclin D1 and pRb expression were generally higher in PDV compared to PDB. 
There was significant difference in the expression of cyclin D1 (p <0.001) and pRb 
(p =0.03) in PDV compared to PDB. The difference in p53 expression did not reach 
statistical significance (p=0.09). Twenty nine percent (15/52) of all cases of PDV 
expressed p53 compared to 13% (5/37) of all cases of PDB. Fifty nine percent 
(41/69) of PDV cases expressed the cyclin D1 protein compared to only 8% (3/34) of 
PDB, and pRb was expressed in 56% (40/72) of PDV compared to 33%(12/36) of 
PDB cases. There was no difference in the expression of Ki67 between PDV and 
PDB.
VEGF was not expressed by the Paget cells of either PDV or PDB. However, they 
may stimulate the surrounding epidermal and dermal cells to release VEGF. VEGF 
and PD-ECGF/TP were significantly higher (p=0.001 and p<0.0005 respectively) in 
the breast epidermal and dermal cells in PDB (61% and 95% respectively) as 
compared to the vulva cases (26% and 54% respectively). There appeared to be no 
significant differences in MVD between PDV and PDB cases
Abnormal expression levels of the cell adhesion molecules also revealed differences 
between PDV and PDB. Thirty six (57%) of the 63 cases of PDV expressed 
plakoglobin with a score of greater than >5 %; in PDB it was 26%. E cadherin was
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expressed (>5%) in 98% of PDV cases and 83% of PDB, and for p catenin 69% of 
PDV and 52% of PDB expressed the protein.
In almost all cases the expression of the mRNA corresponded with the expression of 
the adhesion molecule proteins.
The results suggest that PDV and PDB demonstrate differences in the 
immunophenotype of various molecular markers. This could be as a result of the 
dysfunction of certain pathways (e.g cyclin D1 for PDV and pRb/ plakoglobin for 
PDB) and the angiogenic factors VEGF and PD-ECGF/TP having a more prominent 
role in the pathogenesis of PDB as compared to PDV.
Are there differences in the molecular pathology when PDV is associated with or 
without an underlying invasive adenocarcinoma?
p53 and pRb, molecular markers involved in cell cycle control were noted to have 
different rates of expression in PDV with invasive adenocarcinoma compared to PDV 
without invasive disease.
Abnormal p53 expression in PDV with invasive disease was 40% (4/10) and without 
invasive disease it was 26% (11/42, p= 0.62). Abnormal pRb expression was 
demonstrated in 70% of PDV with invasive disease compared to 40% of PDV 
without invasion (p= 0.16).
Similarly, E-cadherin, plakoglobin and (3- catenin that are involved in cell-cell 
adhesiveness were found to be reduced in the intrapeidermal compartment of PDV 
with invasive disease as compared to those without invasive disease. E-cadherin was 
found to be significantly different, p =0.005. The p values for plakoglobin and for p- 
catenin were 0.27 and 0.21 respectively.
Disruption of cell cycle regulation at pRb checkpoints as demonstrated by abnormal
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expression of the pRb protein and loss of apoptosis as seen by overexpression of the 
p53 protein may be mechanisms underlying disease progression in PDV.
Reduced cell-cell adhesiveness is one of the underlying mechanisms in the 
development of tissue invasion and metastasis. I have demonstrated reduced cell-cell 
adhesiveness in cases with invasive disease, which could be an underlying 
mechanism, involved in the progression of PDV
Are there biological molecular markers that can determine the progression of 
intraepidermal PDV to invasive PDV?
p53 over expression may be associated with progression of PDV towards invasive 
disease, since higher protein levels were found in PDV cases associated with an 
invasive carcinoma. Similiarly, loss of pRb expression was found in 70% of PDV 
cases with invasive adenocarcinoma and 40% of those without. pRb expression is 
present in normal tissue. Increased loss of pRb expression has been demonstrated in 
stage I to IV vulval cancer suggesting a possible role in tumour progression (Chan et 
al., 1998) The evaluation of pRb could be used as a diagnostic or prognostic marker 
for PDV in determining which patient will go on to develop invasive adenocarcinoma 
and therefore could be a helpful addition to clinicopathological investigations in the 
management of PDV. This could involve monitoring of patients with low pRb levels.
If there are differences in the molecular pathology between intraepidermal and 
invasive PDV are these reflected in different clinicopathological presentation ?
In general those patients with invasive disease have a higher risk of recurrence than
those without invasive disease. However, not all cases of recurrent disease appear to
be correlated with p53 expression and loss of pRb expression. One patient who had
invasive disease had repeated surgery for recurrent disease but biopsies taken were
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noted to be negative for p53. Loss of pRb expression was however noted from the 
tissue specimens. Loss of pRb expression maybe a better marker for determining 
which cases of Paget’s disease would go on to develop recurrent disease and hence a 
useful prognostic marker.
FUTURE WORK
Retinoblastoma activity can be lost through mutations in the RBI gene or prevented 
by binding with the viral oncoprotein high-risk HPV E7 (Zur Hausen 1991). Further 
work can be carried out by assessing the presence of HPV activity in those PDV 
cases that have been demonstrated to have loss of pRb expression and sequencing of 
the RBI gene to identify any mutations. RBI gene chip scanning can then be 
performed if  there is a common mutation.
Performing mutational analysis on the PDV cases with reduced expression of 
Plakoglobin, E-cadherin and p catenin will allow further insight into the involvement 
of these molecules in the mechanism of PDV.
The continuing cooperation between those clinicians with PDV cases and the 
addition of these cases to the PDV database will allow for increased awareness and 
improved management o f this rare disease, along with further detailed 
clinicopathological and molecular comparisons.
This has been the largest study performed on PDV and PDB. The identification and 
characterisation of the genes and pathways involved in the molecular mechanism of 
PDV and PDB will lead to a better understanding of these diseases, generating 
potentially new markers and allow for the development of therapeutic improvements.
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Figure 7.1 Potential pathways for the differences in the molecular pathology between 
PDV and PDB. The blue boxes indicate changes identified in this work.
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Figure 7.2 Potential mechanisms for disease progression in PDV and PDB.
The blue boxes indicate changes identified in this work. The green box indicates 
results from other studies.
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APPENDIX I
REAGENTS AND SOLUTIONS 
TISSUE SPECIMENS
PREPARATION OF DIG- LABELLED RNA PROBES FOR 
PLAKOGLOBIN, E-CADHERIN AND (3-CATENIN MRNAS.
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REAGENTS AND SOLUTIONS
3-Aminopropytriethoxysilane solution (APES)
294 of acetone with 6ml APES. Keep APES in the fridge and dilute in acetone just 
prior to use.
Diaminobenzidine (DAB) Solution
Add 180mg of 3,3’-diaminobenzidine tetrahydrochloride to 270ml of distilled water, 
30ml TBS, 1ml imidazole solution. Add 120-pl hydrogen peroxide.
Hydrogen peroxide solution
Add 10ml 30% hydrogen peroxide to 90ml distilled water.
Phosphate Buffered Saline
Dissolve 5PBS powder satchets in 51 distilled water. pH must be 7.4
Phosphate Buffered Saline- bovine serum albumin (PBS-BSA) 
lOOmg of bovine serum albumin is dissolved in lOOmls of PBS.
0.1% BSA. Store at 4° C.
Sodium Citrate Buffer
2.1g of citric acid monohydrate is added to 950ml of distilled water and 13ml 2M 
NaOH. Make up to 11. Adjust pH to 6.0. Store at 4° C. 0.01M sodium citrate. Store at 
4° C.
Tris-Buffered saline (TBS)
43.83g of NaCl and 30.6g of Tris base is made up to 51 of distilled water. Add ~35ml 
of concentrated HC1, pH must be 7.6, store at 4° C.
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10% formol saline:
40% formaldehyde (100ml)
Sodium chloride (9g)
Tap water (900ml),
10% neutral buffered formaldehyde:
40% formaldehyde (100ml)
Distilled water (900ml)
Sodium dihydrogen phosphate monohydrate (4g) and 
Disodium hydrogen phosphate anhydrous (6.5g)
In aqueous solution formaldehyde exists mostly as its monohydrate, methylene glycol 
[CH2(OH)2] in equilibrium with monomeric formaldehyde.
Pre-hybridisation solution (1ml)
200pl 20XSSC
100 pi 10X Denhardts
500 pi Formamide
50 pi lOmg/ml t-RNA
50 pi lOmg/ml salmon sperm DNA
100 pi DEPC water
Hybridisation solution (1ml)
200pl 20XSSC 
100 pi 10X Denhardts 
500 pi Formamide / 20% Dextran Sulphate 
50 pi lOmg/ml t-RNA 
50 pi lOmg/ml salmon sperm DNA 
100 pi labelled probe
Buffer 1 (1L)
Tris-HCl pH 7.5 100ml (0.1M final concentration)
4M NaCL 37.5ml (150mM final concentration)
H20 862.5ml
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Buffer 2 (1L)
Tris-HCl pH 9.5 100ml (0.1M final concentration)
4M NaCL 25ml (0.1M final concentration)
H20 825ml
Buffer 3(1L)
Tris-HCl pH 8.0 
0.5M EDTA 
H20
10ml (lOmM final concentration) 
2ml (ImM final concentration) 
988ml
TISSUE SPECIMENS
Tissues were processed using an enclosed automatic processing system (VIP 
2000F/300E) programmed with the following processing schedule: 10% neutral 
buffered formalin two hours at 40°C, 70% industrial methylated spirit (IMS) one hour 
at 40°C, 90% IMS one hour at 40°C, absolute IMS three hours at 40°C, xylene four 
hours at 40°C, paraffin wax for three hours at 60°C. Tissues were embedded in 
paraffin wax utilising the Tissue-Tex III.
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Preparation of DIG-labelled cRNA probes for plakoglobin, E-cadherin and p-
catenin mRNAs.
Producing the PCR product
Template cDNA was generated from a two-step reverse transcriptase-PCR using 
GeneAmp RNA PCR core kit (Perkin Elmer). The method was as per manufacturers 
instructions.
The following materials were used to produce a 50 pi PCR reaction:
10-100ng of cDNA template
5pl of 10X PCR buffer
2 pi 50Mm MgCL2
0.5pl of 50mM dNTP’s
lpl of forward and 1 pi reverse primer
Sterile water was added to make up the volume to 49pl. 1 pi of the enzyme Biotaq 
polymerase (Bioline)(l unit/ pi) was then added to the solution to make a final 
volume of 50pl.
All PCRs were carried out using a single block PCRexpress (Hybaid).
PCR products were amplified as described with 0.8 pmoles forward primer and 1.6 
pmoles reverse primer.
After the PCR reaction, 95% formamide containing 1% pararosaniline (sigma) was 
added in equal volume to the PCR product and DNA denatured at 95%C for 2 min. 
Primer sequences and annealing temperature for PCR are described in Table 5.22.
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Gene Forward primer Reverse primer Anneal
Temp/°C
Plakoglobin GCCTGCCTTCTTCTTGTGTC CTGAAGCTTTAGTGGCCAGG 60
P-catenin GGAAGGTCTCCTTGGGACTC ACTAGTCGTGGAATGGCACC 60
E-cadherin TTAGGTT AG AGGGTT AT CGCGT TAACTAAAAATTCACCTACCGAC 60
Table 5.22 Primer sequences and annealing temperature for PCR.
Analysis of the PCR product using agarose gel electrophoresis 
3 pi of PCR product was analysed by alongside 3 pi of DNA marker using agarose gel 
electrophoresis. Agarose gels were made by dissolving 1% agarose (sigma) in lxTBE 
(45mM Tris-borate, 2mM EDTA) and then heating the solution in the microwave. 
After cooling to below 65°C, Et Br (final concentration 20 pg /ml) was added and the 
gel poured into a casting tray. DNA products were loaded onto the gel using 6x 
loading dye and run in a submarine tank (BioRad) containing lxTBE. For size 
comparison the 3 pi of known DNA was used as a marker ladder and loaded onto 
each gel. Products were visualised using a UV transilluminator (Alpha Innotech 
corporation).
Purification of the DNA from the agarose gel was performed using a QIAgen Gel 
Extraction kit and carried out as per manufacturer’s instruction.
Linearisation of the plasmid and ligation of the PCR product 
Approximately 1 pg of DNA was subjected to restriction endonuclease treatment for 
l-2hrs (as specified by the manufacturer (NEB) using 1-5 units of enzyme in a total 
reaction volume of 20 pi containing lx buffer (also specified by manufacturer). The 
product was subsequently phenol-chloroform extracted and ethanol precipitated 
before resuspension in distilled water.
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Ligation of the vector and purified insert DNAs were carried out using T4 DNA 
ligase (NEB {2 units per reaction}) in supplied reaction buffer in total volume of 
15pi. Ligations were carried out overnight at 16°C and 3 pi of the reaction used to 
transform chemically competent bacteria using the TOPO Cloning Reaction 
(Invitrogen).
Growing the bacterial colonies with the DNA sequence required using the TOPO 
Cloning Reaction
This reaction provides the direct insertion of Taq polymerase-amplified PCR product 
in a plasmid vector. The plasmid vector (pCR II-TOPO; (Invitrogen) is linked to 
Topoiosmerase I, which catalyses the insertion of the PCR fragment utilising the A 
overhangs generated by Taq polymerase during PCR amplification.
The following materials and reagents were used to perform the TOPO cloning 
reaction as per manufacturer’s instruction:
3 pi fresh PCR product
1 pi of sterile water
1 pi of TOPO vector (pCR II-TOPO)
1 pi of salt solution (1 .2  M NaCl; 0.06M MgCb) which was added last
The 6 pi mixture was then gently mixed and incubated at room temperature for 5 
min. The reaction was then left on ice and the one shot chemical transformation was 
performed.
One-shot chemical transformation
2 pi of the TOPO cloning reaction from above was mixed in a vial with chemically 
competent E. co li. The mixture was incubated on ice for 5-30 min and then heat 
shocked for 30s at 42 °C . This was followed by immediately transferring the tubes to
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ice. 450 pi of Luria-Bertani (LB) broth was added to the mixture and it was then 
incubated at 37 °C for 1 lAh
3-5 pi of the mixture (100 pi from each transformation) was spread onto a prewarmed 
selective plate (agar gel, 50 pg /ml ampicillin and LB) with a glass rod and incubated 
overnight at 37 °C.
A colony was picked and cultured overnight in LB medium containing 50ng/ml 
ampicillin broth.
Isolating the DNA plasmid using miniprep protocol fOiagen)
This system is based on the alkaline lysis of bacteria and differential precipitation of 
small plasmid DNA. The method is described as per the manufacturer’s (Qiagen) 
instructions.
The plasmid DNA was isolated by spinning the solution of LB ampicillin and culture 
down until pellet of bacteria is seen.
The solution of LB ampicillin and culture was placed in to a microcentrifuge tube and 
centrifuged at a speed of 8,000rpm for 1 minute and excess fluid was removed. The 
pelleted bacterial cells were then resuspended in 250 pi of buffer PI (resuspension 
buffer) and transferred into a microcentrifuge tube. This was followed by the addition 
of 250 pi of buffer P2 (lysis buffer) and mixed and then 350 pi of buffer N3 
(neutralisation buffer). The mixture was then centrifuged at a maximum speed 
(13,000 rpm) for 10 min. The supemant was removed and placed into centrifuge 
columns and spun for 1 min. The supemant fluid was again removed and mixed with 
750 pi of the buffer PE (wash buffer) and spun for 1 min. The supemant removed 
was respun for a further 1 min to remove residual wash buffer. To elute DNA 50 pi
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of water was added and allowed to stand for 1 min and then centrifuged for a further 
1 min.
Linearisation of the template DNA using the restriction enzymes EcoRI and Bam
HI
As previously described, the DNA inserts were cloned into the pCRII-TOPO vector 
which have promoters, T7 and SP6 either side of the cloning site. This enables both 
antisense and sense probes to be synthesised using one transcription vector but two 
different RNA polymerases: T7 RNA polymerase for antisense RNA (cRNA) and 
SP6 RNA polymerase sense RNA (mRNA).
In order to synthesise antisense RNA probes, the DNA was linearised with the 
restriction endonuclease EcoRI to initiate transcription from the T7 promoter. For the 
sense probe, the DNA was linearised with the restriction endonuclease 
Bam HI to initiate transcription from the SP6 promoter.
The following materials were used to for a 50 pi reaction mixture 
5 pi of restriction buffer (lOx)
10 pi DNA template 
34 pi sterile water
1 pi of restriction enzyme (Eco R1 or Bam HI)
The mixture was incubated at 37 °C for 2 h and then the DNA was purified using 200 
pi of phenol :chloroform extraction mix , 80 pi of water and 20 pi of NaOH. This was 
followed by centrifuging for 7-10 min at 13,000rpm.
180 pi of the top phase (aqueous) of the mix was removed and placed into a DEPC- 
treated tube with 500 pi of 100% cold ethanol. This was incubated over night at room 
temperature. The mixture was centrifuged for 10 mins at 13,000rpm and then the
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ethanol was removed. 170 pi of 70% ethanol was added and the mixture was 
centrifuged for 3 min at room temperature. The 70% ethanol was removed and the 
remaining solution was dried at room temperature. This was followed by 
resuspending the mix in 100 pi DEPC water.
Transcription of the RNA probes
This was performed using the DIG RNA labelling kit (Boehringer Mannheim). This 
uses DIG to label RNA transcribed by either T7 or SP6 polymerase from the plasmid 
template. Plasmid templates with specific inserts to hybridise to plakoglobin, E- 
cadherin and (3-catenin mRNAs were constructed.
The following reagents were added to a sterile RNAse- free microfuge tube (on ice): 
4 pi of purified template 
2 pi of NTP labelling mixture 
2 pi transcription buffer 
1 pi of RNAse inhibitor (placental)(20units/ pi)
2pl RNA polymerase (20units/ pi) (SP6 and T7)
The mixture was vortexed and centrifuged briefly for a few seconds and then 
incubated for 2 hr at 37°C. Following this 2pl of 0.2M EDTA solution was used to 
stop the reaction. The mixture was centrifuged for 15 min at 13000 rpm. The 
remaining pellet was washed with 50pl 70% cold ethanol and centrifuge for 2-3 min 
at 13000rpm. Excess alcohol was pipetted off and the remaining pellet was dried 
briefly under vacuum and dissolved in 30pl RNAase-free water.
As the amount of DIG-labelled RNA transcript greatly exceeds the amount of DNA 
template, removal of the DNA template (by DNAase I) was unnecessary in this case.
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Quantification of the probe bv a dot blot test
To ensure an excess of probe and also that an approximately equal amount of label 
was added to both sense and antisense reactions, the labelling of RNA was 
quantified.
Using DIG labelled RNA control (lOOpg/ pi), serial dilution of the sense and 
antisense probes and the control RNA were performed. 1 pi of control RNA was 
placed into a RNase free tube along with 9 pi of DEPC water. From this tube 1 pi of 
the solution was placed into another tube with DEPC water (1/100 dilution). This is 
repeated until a final dilution of 1/10000 is obtained. A spot of probe or control RNA 
was placed onto Hydrobond XL nucleic acid membrane and cross- linked using UV 
radiation (120mJ) for 5 min.This binds the RNA onto the membrane. The membrane 
was placed in 5% milk diluted in Tris-buffered saline-Tween mild detergent (TBS-T) 
and left for lh  on the rotator at room temperature. The milk protein prevents non­
specific binding. The excess milk was removed and the anti- DIG antibody (1:500 
dilution) was added. This was placed into a sealed plastic bag and placed on the 
rotator for 30 min. Colour development was produced by adding 2ml of 
NBT/BCIP into the sealed plastic bag containing the membrane. This was placed on 
the rotator for approximately 30 min until colour developed and washed with TBS-T 
and allowed to dry. Newly-labelled RNA was compared to pre-quantified control 
labelled RNA to estimate the concentration of labelled probe RNA.
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APPENDIX II
MOLECULAR DETAILS FOR EACH PATIENT
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PDV p53 Ki67 Cyclin D1 pRb E- cadherin B-catenin Plakoglobin
CASE 001 10% 0 0 m<100% s n <5% 0 m <100% s Nested
CASE 002 0 0 0 0 m<75%s m<25% mi m<25% s Nested
CASE 003 0 0 50% 75% mc<100%s
nu<100%
m<25* Single cell
CASE 004 0 0 0 0 m <25% s 0 <5% 0 m <75% s
nested
lichenoid
CASE 005 0 10% 20% 0 m <75% s 0 <5%0 m <75% s
nested
lichenoid
CASE 006 0 0 0 <10%
CASE007inv 0 0 0 50% m<100%s n<5%0 m<25%s nested
CASE 008 0 40% 40-50% >75% m <5% 0 mi 0 <5%0 m <5% mi single cell
CASE 009 0 10% <10% 0
CASEOlOinv 0 50% 10% 0 m<25%mi m<75%s n<5% 0 single cell, lichenoid
CASE Oil 10% 10% 0
CASE 012 10% 5% 75% 25%
CASE 013 0 10% 20% 0 m<100% s n <5% 0 m <75% mi nested
CASE014inv 0 0 <10 10%
CASE 015 0 5% 75% <10% m <75% s m <25% s* n <5% 0 single cell
CASE 016 0 50% 0 m <100% s c <5% mi nu <50% mi nested lichen
CASE 017 >75% 5% <10% >75% m <75% s m <50% mi c <5% mi nested
CASE 018 <10% 5 50% 0 m<50 mi c <75mi n<5%0 nested
CASE 019 75% 75% 50-75% >75%
CASE 020 0 0 0 0
CASE 021 0 0 50% <10% m<100%s n<5% 0 m<75%s single cell
CASE022inv 25-40% >75% <10% >50% 0 <5 0 0 <5 0 0 <5 0 licheniod
CASE 023 75% 20% 75% 0 m<100%s m<100%s m<5%mi single cell
CASE024inv 25-40% 5 10% 0 m<50% s c<25% mi c<25% mi infiltrative
CASE 025 0 0 40% 50 m<100%s c <5% mi 0 <5% 0 single cell
CASE 026 0 0 15% >75%
CASE 027 <10% 0 75%
CASE028inv 30-40% 0 50% 0 m<25% mi N<5%0 n<5% 0 nested
CASE 029 <10% 50% 50% 50-75% m<75%s M<50%s c<5% mi single cell
CASE030inv 75% 0 0 0
CASE031 0 0 m<50% s M<5%mi n<5% 0 single cell
CASE 032 10% 5% <10% >1% m<75%s M<50%s m<5%mi nested
CASE 033 50% 50% 75% >75% m<100%s M<75%s m<25%mi nested lichenoid
CASE 034 25-40% 50% 10%
CASE 035 <10% 20% 20-40% 0 m<75%s M<25%mi n<5% 0 single cell lichenoid
CASE 036 10% 0 10% 20-40%
CASE 037 75% 40% 75% 0
CASE 038 <10% 0 m<75%s M<50%s m<25%mi single cell lichenoid
CASE 039 50-75% 0 75% 50% m<75%mi c<25%mi m<50%s nested lichen lichenoid
CASE 040 0 0 0% >75% m<100%s M<50%s m<75%s single cell lichenoid
CASE 041 10% 25% <10%
CASE 042 75% 75% 0 >75% m<100%s M<25%mi m>50%s single cell
lichenoid
tissue
CASE 043 75% 50% 75% m<50%s M<25%s m<100%s single cell
CASE 044 0 50% <10% m<75%s M<25%s m<50%s nested
single
cell
CASE045inv 0 5% 0 0 mlOO%s 0<5% 0 m<100% s nested
248
PDV p53 Ki67 Cyclin D1 pRb E- cadherin B-catenin Plakoglobin
CASE 046 0 0
CASE 047 5% 50% >75% m<75%s M<25%s m<25%s
single
Foll+licen lichenoid
CASE048inv 0 0 10% 0
CASE049inv 0 50% 20-40% 0
CASE 050 >75% 0 20-40%
CASE 051 0 75% 0 0 m<50%s M<5%mi m<25%mi single cell
CASE 052 50% 75% m<100%s c <5% mi m<75% s single cell
CASE 053 0 20% m<100%s c<25% mi n<5% 0 single cell lichenoid
CASE 055 20-40% 0 50-75% 0
CASE056 16/3.0 50% 20-40%
CASE 057 0 10-20% 75% 50-75% m<100%s M<50%s m<25%mi
nested pat. 
Li lichneoid
CASE 058 <10% m<25%mi P<25%s m<25%s single cell lichenoid
CASE 059 0 0 >75% >75%
CASE 060 50% 50% m<100%s M<50smi m<25%mi single cell
CASE 061 0 m<75% s c<50% mi c<25% mi single cell
CASE 062 0 >75% m<100%s
m<25%
mi c <25% mi lichenoid
CASE 063 <10% 50% 10-25% 0 m<50% mi
M<25%
mi c<75% s single cell lichenoid
CASE 064 20-40% 20-40% 0 >75% m<25%mi M<50%s m<50%s single cell
CASE 065 <25% 0 <10% m<75%s M<25%s m<75%s single cell
CASE 066 0 0 0 0 m<75%s M<25%mi c<5%mi single cell
CASE 067 10-20% 0 <10% m<100%s N<5%0 m<75%s single cell
CASE 068 <10% <10% 50% 50%
CASE 069 0 0 m<75%s N<5%0 m<50 mi single cell
CASE 070 5.3/2.3 <10% 0 m<50%s P<25%s m<5%mi single cell
CASE 071 <10% <10% 0 m<75%s P<5%s c<5%0mi singlecell
CASE 072 0 0 <10% 0 m<75%s M<50%m n<5% 0
nested follicular+eccrine 
duct ext
CASE 073 <10% >75% m<75%s M<5%s n<5%0 singlecell lichenoid
CASE 074 0 0 10% 0 no tissue N<5%0 m<5%mi single cell
CASE 075 >75% 0 >50% 20-40% m<75%s M<5%mi m<50% s single cell Lichenoid
CASE 076 0 m<100%s M<25%s m<75%s single cell
CASE 077 75% 50% 75% 75% m<100%s M<25%s m<5%mi single cell
CASE 078 0 m<75%s M<25%mi n<5% 0 single cell Lichenoid
CASE 079 0 0 20-40% m<100%s M<25%mi n<5% 0 single cell
CASE 080 0 0 50% <10% m<50%s P<25%s m<5%mi
nested follicular+eccrine 
duct ext
CASE 081 0 0 0 0 m<75%s M<25%s c<25%mi single cell Lichenoid
CASE 082 0 0 m<50%s M<25%s n<5%0 single cell
CASE 083 0 75% 0
CASE 084 50% 0%
Inv= invasive PDV, m= membraneous, c= cytoplasm, nu= nuclear, n=nil, p= paranulcear, mi= mild, s= 
strong
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PDB p53 Ki67 Cyclin D1 pRb C-erBb-2 E- cadherin P-catenin Plakoglobin
CASE 087 0 0 0 0 >75% m<75% s c<25% mi n<5% 0
CASE 088 DCIS 0 0 n <5% 0 n <5% 0 n <5% 0
CASE 089 CA 0 0 >75% n<5% 0 no staining n<5% 0
CASE 090 0 0 0 0
CASE
091DCIS+CA 20-40% 0 m<100% s c <5% mi m <5% s
CASE 092 CA >50% 0 0 0
CASE 093 0 25-40% 0 >75% m<100%s c<5% mi c<5% mi
CASE 094 DCIS >20% 50% 0 0 m<75% s n <5% 0 c<25% mi
CASE 095 DCIS 0 0 0 0 >75% m<25% mi m<50% mi c<5% mi
CASE 096 
DCIS+CA >10% 10% >20 % 10% 0 m<100%s m<50% s m <75% s
CASE 097 CA 0 0 >75%
CASE 098 0 0 >75%
CASE 099 DCIS 0 0 0 0 0 m<100% s c<5% mi m<75% mi
CASE 100 CA 0 0 0 m <75% s m <75% s n <5% 0
CASE 101 0 0 m <100s 0 c <100% s
CASE 102 DCIS 0 0 >75%
CASE 103 CA 0 0 0 m<100%s m<5% mi n <5%0
CASE 104 DCIS 0 0
CASE 105 0 0 50-75%
CASE 106 <10% 0 0 0 0
CASE 107 0 0 0 10% >75%
CASE 108 DCIS 0 0 0 >50% m<100%s m<25% mi n<5% 0
CASE 109 DCIS 0 0 0 0 75%
CASE 110 <10% 0
CASE 111 0 0 0 <10%
CASE 112 DCIS 0 m<25% mi m<50% mi c<5% mi
CASE 113 
DCIS+CA 0 0 0 M<100%s 0 C<100%s
CASE 114 CA 0 <10% <10% 0 25-40%
CASE 115 0 0 40% 75%
CASE 116 
DCIS+CA 0 0 0 >10% 0 c<75% s c<75% s c<5% mi
CASE 117 <10% 0 0 >75% m<75% s c<25% mi n<5% 0
CASE 118 0 0 0 0 >75%
CASE 119
CASE 120 0 >10% >75%
CASE 121
CASE 122 DCIS 0 0 >75% n <5% 0 n <5%0 N <5%0
CASE 123 
DCIS+CA 0 0 50-75% 0 m<100%s m<75% s M <75% s
CASE 124 DCIS <10% 0 10
CASE 125DCIS 0 0 >75% m<100% s c<25% mi c <5% mi
CASE 126 
DCIS+CA \z>10% >10% >10% m<75% s m<75% s M <5% s
CASE 127 <10% m<100%s m<75% s M <75% s
CASE 128 CA <10% <10% 75% <10% >75% m<25% mi c<5% mi mi<5%mi
CASE 129 DCIS 0 0 0 10% >50% m<50% mi m<75% s C< 25% mi
CASE 130 >10% 0 >75%
CASE 13 1DCIS 0 <10% 0 0 0
CASE 132 DCIS >50% >75% 15% 0 m<75% mi m <75%s c <5% mi
CASE 133 >50% 0 >75% m<100%s c<5% mi c<5% mi
CASE 134 0 0 0 0
CASE 135
CASE 136 >75% n <5% 0 m <5% mi n <5%0
CASE 137 >75%
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PDB p53 Ki67 cyclin D1 pRb C-erBb-2 E- cadherin P-catenin Plakoglobin
CASE 138
CASE 139 0 >75% m<100%s c<5% mi nu<25% mi
CASE 140 m<100%s c<5% mi nu<25% mi
CASE 141 10%
CASE 142 0
CASE 143 0 m<75%s M<75% s n<5% 0
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PDV HVDx200 AVDx200 HVDx400 AVD x400 VEGF PD-ECGF (intensity of staining)
CASE 001 17 13.3 5 3.7 0 >75% 2(e), 1(d)
CASE 002 7(d) 3(b) ,10% 1(e),1(d)
CASE 003 46 30.3 5 3 0 50% 1(e),3(d)
CASE 004 42 32 8 5.7 5(d) 10% 2(e), 2(d)
CASE 005 21 14.3 12 7.3 0 0 3(e), 1(d)
CASE 006 8 6.7 8 5.7 0 0
CASE007inv 3 1.3 17 14 0 50% 2(e), 2(d)
CASE 008 26 20.3 14 9.6 0 <5% 0(e), 2(d)
CASE 009 7 4 9 7.3 2(e) 75% 3(e), 2(d)
CASEOlOinv 1(e),2(d) 75% 3(e), 3(d)
CASE 011 3(e) 75% 3(e), 2(d)
CASE 012 32 26.7 8 6.3 1(d) <10%
CASE 013 22 15.3 9 5.3 0 >75% 2(e), 2(d)
CASE014inv 22 14.7 11 8.7 le) <10%
CASE 015 27 18.3 6 5.3 le) <10%
CASE 016 25 16 16 11.7 2(d) 50% 1(e), 2(d)
CASE 017 26 15.3 6 4.6 1(e),2(d) <10%
CASE 018 100 98.3 12 6.3 3(e) 50%
CASE 019 50 34.7 13 9.3 0
CASE 020 1(e)
CASE 021 14 4.7 7 2.3 Kd)
CASE022inv
CASE023 3 2 2 1.3 0 0
CASE024inv 20 19.7 6 5.7 4(d) 10-25%
CASE 025 16 14.6 13 12.3 2(d) 50-75%
CASE 026 17 13.7 8 6 50-75% 3(e), 2(d)
CASE 027 30 22.3 22 11 5(d) 0
CASE028inv 60 38.6 33 19 7(e+d) 50%
CASE 029 30 24.7 13 6.7 0 0 3(e)
CASE030inv 18 10 11 7 1(d) 10%
CASE 031 24 13 6 4.6 Kd) 3(b) 50%
CASE 032 22 13 5 3.7 40%
CASE 033 31 23 12 10.3 1(d)
CASE 034 30 23.3 13 7.7 2(e)
CASE 035 15 10.7 5 3 0
CASE 036 22 13.7 23 9
CASE 037 17 15 8 6.3
CASE 038 26 13 23 12.3 0 0
CASE 039 32 26.3 20 11 0 0
CASE 040 18 12.7 8 7 0
CASE 041 28 22 15 12.3
CASE 042 3 2 5 3.3
CASE 043 10-25%
CASE 044
CASE045inv 3 2.3 4 2.3 0 <10% Ke), 2(d)
CASE 046 0
CASE 047 68 49.7 15 12.7 0 <10% 2(e), 2(e)
CASE048inv 3 1.3 9 7.7 0
CASE049inv 34 25 6 5 0
CASE 050 47 27.3 20 11.3 0
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PDV HVDx200 AVDx200 HVDx400 AVD x 400 VEGF PD-ECGF (intensity of staining)
CASE 051 34 22.7 18 13.3 0 1(e)
CASE 052 2(e), 0(d) <10%
CASE 053 60 39.3 8 6 <10%
CASE 054 25 22 9 7.3 75%
CASE 055 30 20 20 6.6 75%
CASE 056 16 5.3 3 1 0 75%
CASE 057 57 38.3 10 5 20-40%
CASE 058 22 15 5 4.3 4(d) >75%
CASE 059 29 12 5 3.3 >75%
CASE 060 0
CASE 061 >75%
CASE 062 38 12.7 20 13.7 25-40%
CASE 063 38 26 10 5.3 0 3(e)
CASE 064 22 9.6 26 18.6 10% 3(e)
CASE 065 0 >75% 3(e), 2(d)
CASE 066 20 17.7 4 3.3 <10%
CASE 067 17/ 13.3 5 3.7
CASE 068 3(d) >5% 2(e),1(d)
CASE 069 0
CASE 070 9 5.3 3 2.3 0
CASE 071 11 7 11 8.6 0 >50% 2(e), 3(d)
CASE 072 20 13.7 7 7 0
CASE 073 12 9.7 7 6.3 20-40%
CASE 074 54 43 14 12.7 3(e) 2(d) 20-40%
CASE 075 16 12 5 3 2(e) 5(d)
CASE 076 35 19.6 2 1.3 1(e), 3(d) <10% 1(e), 1(d)
CASE 077 30 24.7 10 4.6 0 2(e)
CASE 078
CASE 079 38 28.3 12 8.3 >75%
CASE 080 32 22.6 2 1.6 0 2(e)
CASE 081 36 24.6 17 12 2(e),0(d) >75% 3(e), (2)d
CASE 082 50 28 4 3 >75% 1(e)
CASE 083 1(d)
CASE 084
CASE 085 24 17 7 5.3
CASE 086
CASE 087 6 3.3 2 1.3 0 75% Ke),2(d)
CASE 088 24 16.7 10 6.7 3(d)
CASE 089 2(d) <5%
Inv = invasive PDV, e=epidermis, d= dermis
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PDB HVDx(200) AVD(200) HVDX(200) AVDXC400) 1 VEGF PD-ECGF/TP
DCIS
CASE 112 1(e) 50% l(e)2(d)
CASE 132 40 24.7 0 50%3(e)2(d)
CASE 129 12 4.3 0 75%2(e)3(d)
CASE124 24 16.7 10 6.7 1(e)1(d) 0
CASE131 1(d) 40% l(e)2(d)
CASE 094 30 11.7 10 6.7 2(e) 75% 2(e)3(d)
CASE 095 30 19.3 7 6 3(e) 01(e) 1(d)
CASE 102 51 46 15 13.6 3(e) 01(e)l(d)
CASE 104 14 11.7 13 10.6 1(d) 0
CASE 108 14 9.3 14 9.7 4(d) 2(e)3(d)
CASE 109 34 26.7 14 11 4(d) 01(e) 1(d)
CASE 122 20 11.6 7 3.6 2(d) 0
CASE 125 9 5.6 14 10 2(d) 0
DCIS +CA
CASE 116 0 01(e) 2(d)
CASE 126 24 18 5 4.3 0
CASE 123 8 6 1(e)1(d) 20%2(e)2(d)
CASE 113 26 23.3 8 6.3 0 01(e) 1(d)
CASE099 3 1.3 Ke) 50%2(e)l(d)
CASE096 12 10 14 11.7 0 50%3(e)3(d)
CA
CASE 097 2(d) 0
CASE 092 21 15.3 40 33.7 1(d) 75%2(e)l(e)
CASE 100 20 14 8 5.6 2(d) 0
CASE 103 22 16.7 4(d) 75% 1(e) 1(d)
CASE 128 30 22.3 15 11.3 75%2(e)3(d)
CASE114 22 16 15 14 50%3(e)3(d)
DCIS = ductal carcinoma in situ , CA= carcinoma
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